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Thomas Edison llegó a fracasar en 2.000 ocasiones antes de lograr el 
filamento de hilo de algodón carbonizado para su bombilla. Y cuando le 
preguntaron dijo: "no fracasé, descubrí 2.000 modos de cómo no se hace 







Novel therapies are needed to overcome the limited efficacy of current 
treatments in pancreatic cancer. Adenoviral gene therapy against 
pancreatic tumors is challenged by the limitation of viruses to reach the 
tumor mass, poorly distribute within the tumor and inefficiently 
transduce tumor cells. We show that intraductal administration of 
adenoviruses into the common bile duct of Ela-myc mice targets 
pancreatic tumors more efficiently than systemic delivery with relevant 
transduction of the bulk of the tumor and restricts expression to 
pancreatic tissue. Moreover, intraductal administration of 
AduPARTat8TK/GCV treatment significantly delayed tumor growth 
ameliorating tumor-associated toxicity. Noticeable the new generated 
MMP-activatable adenovirus AdTATMMP was susceptible to MMP2/9 
activation, restored the transduction capacity of AdYTRGE in vitro, and 
increased 7.3 times tumor pancreas transduction. The multimodal 
treatment AduPARTat8TK/GCV and gemcitabine showed synergistic 
effects in vitro; however, did not enhance the antitumoral efficacy of 
single therapies. Interestingly, IRE treatment exhibited significant 
antitumor effects in BxPC-3-Luc orthotopic tumors and prolonged mice 






Els tractaments actuals pel càncer de pàncreas presenten un eficàcia 
limitada de manera que es necessari el desenvolupament de noves 
teràpies antitumorals. La teràpia gènica pel càncer de pàncreas basada 
en l’ús d’adenovirus es troba limitada per la baixa capacitat dels virus 
d’arribar a les masses tumoral, de distribuir-se pel tumor i d’infectar les 
cèl·lules tumorals. Nosaltres hem observat que l’administració 
intraductal d’adenovirus al ducte biliar de ratolins Ela-myc permet arribar 
als tumors pancreàtics de manera més eficient que per la via sistèmica. A 
més a més permet transduir la majoria de la massa tumoral restringint 
l’expressió adenoviral al teixit pancreàtic. D’altre banda, l’administració 
intraductal del tractament AduPARTat8TK/GCV retarda significativament 
el creixement tumoral i disminueix la toxicitat associada al tumor. El nou 
adenovirus AdTATMMP és activat per les MMP2/9 restaurant la capacitat 
de transducció de l’AdYTGRE in vitro, i incrementant 7,3 vegades la 
infecció del tumor pancreàtic. El tractament combinat de 
l’AduPARTat8TK/GCV amb gemcitabina presenta un efecte sinèrgic in 
vitro, però no millora la eficàcia antitumoral de les teràpies simples. 
D’altre banda el tractament de l’electroporació irreversible presenta 
efectes antitumorals significatius en tumors ortotòpics de la línia cel·lular 








Pancreatic cancer (PC) is one of the most devastating malignancies in 
developed countries. Patients with PC normally present with advanced 
disease and have a very poor prognosis. Due to the absence of early 
diagnosis and its highly invasive and metastatic feature, only 15-20% of 
patients have potentially resectable tumors and, unfortunately many of 
them experience recurrence of disease following surgery. Moreover, 
pancreatic cancer shows strong resistance to the current available 
chemotherapy and/or radiotherapy protocols. This figure has remained 
largely unchanged over the past 25 years, and the development of novel 
therapeutic approaches is urgently needed. 
In this thesis we present novel antitumoral strategies for the treatment 
of pancreatic tumors. They are based on three major principles: i) 
improve adenoviral based therapies by exploring novel delivery routes 
and retargeting strategies, ii) search for synergistic treatments, and iii) 
evaluate novel approaches based on non-thermal ablative techniques. 
Adenoviral vectors have been the most extensively vectors used in gene 
therapy clinical trials. They present a good safety profile and can be 
produced at high titers under GMP conditions, do not integrate and 
present high in vivo transduction efficiency. However, they face with 
several limitations when explored as anti-cancer agents. Following 
systemic administration they are trapped by the liver which limits tumor 
delivery and elicits hepatotoxicity. Moreover, malignant tumor cells 
express very variable levels of its primary receptor CAR, and thus Ad5 
infection is often limited. The presence of a dense stroma and the poor 
vascularization of pancreatic tumors are physical barriers for virus 
delivery and spreading throughout the tumor.  
In this thesis we have studied the potential of the intraductal injection of 
adenovirus into the common bile duct as a novel delivery route to 
efficiently arrive to pancreatic tumors, increase tumor transduction and 
improve adenoviral anti-tumor response in the TgEla-myc mouse model. 
With the aim to improve infectivity and tumor selectivity of adenoviruses 
we have engineered the metalloproteinase (MMP) activatable 
adenovirus AdTATMMP and evaluated its efficacy both in vitro and in 
vivo. 
Multimodal therapies can become a strategy to act against pancreatic 
tumors, but it has to be demonstrated that they are more beneficial 
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when combined that as single agents. In the current work we evaluated 
the potential of the adenoviral therapy AduPARTat8TK/GCV to synergize 
with the first line treatment in pancreatic cancer, the chemotherapeutic 
agent gemcitabine. 
Moreover, we have investigated the antitumoral efficacy of a novel 
technology known as irreversible electroporation (IRE), a loco-regional 
therapy in which high-voltage pulses induce plasma membrane defects 
leading to cellular death. We have studied the feasibility of the IRE 
procedure for the treatment of pancreatic tumors in an orthotopic 
mouse model. 
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“En algún sitio algo increíble espera ser descubierto.” 









1. THE PANCREAS  
The pancreas is an organ of endodermal derivation uniformly lobulated 
of 14 to 20 cm length and weighting, on average, 100 g in adult. It is 
composed of four anatomic areas: the head, which comprises the bulk of 
the pancreas and includes the uncinate process; the neck; the body; and 
the tail. It is situated deep in the retroperitoneum and is enveloped by 
peritoneum and connective tissue. The organ is intimately associated 
with many different anatomic structures (Illustration 1A). Surgical access 
to the pancreas is further complicated because it lies behind the stomach 
and transverse colon. Moreover, the arterial blood supply to the 
pancreas is derived primarily from branches of the celiac trunk and the 
superior mesenteric artery. Within the pancreas, a large branch of the 
splenic artery, known as the great pancreatic artery or pancreatica 
magna, provides left and right branches that course parallel to the main 
pancreatic duct (Hruban et al. 2007b). 
 
Illustration 1. Anatomy of the pancreas. A) Gross anatomy of the pancreas. a: 
artery, v: vein, Sup: superior. B) The exocrine pancreas. C) A single acinus. D) A 
pancreatic islet embedded in exocrine tissue. A panel adapted from (Hruban et 









































The pancreas is composed of two separate functional units, the exocrine 
and endocrine pancreas, arranged in 1-10 mm lobules separated by 
connective tissue septa. It regulates two major physiological processes: 
digestion and glucose metabolism. The exocrine pancreas (80% of the 
tissue mass of the organ) consists of acinar and ductal cells. The acinar 
cells produce digestive enzymes and constitute the bulk of the pancreatic 
tissue. They are organized into grape-like clusters that are at the smallest 
termini of the branching duct system (Illustration 1B,C). The ducts, which 
add mucous and bicarbonate to the enzyme mixture, form a network of 
increasing size, culminating in main and accessory pancreatic ducts that 
empty into the duodenum (Bardeesy and DePinho 2002). The main 
pancreatic duct (of Wirsung) averages 3mm in diameter (range, 1.8 to 9.0 
mm) and drains, along with the common bile duct, into the duodenum 
via the major papilla (ampulla of Vater). The common bile duct lies on the 
posterior-superior surface of the head of the pancreas or is embedded 
within the gland (Hruban et al. 2007b). 
The endocrine pancreas, which regulates metabolism and glucose 
homeostasis through the secretion of hormones into the blood-stream, is 
composed of four specialized endocrine cell types gathered together into 
clusters called Islets of Langerhans (Illustration 1D). The - and -cells 
regulate the usage of glucose through the production of glucagon and 
insulin, respectively. Pancreatic polypeptide and somatostatin, that are 
produced in the PP and -cells, modulate the secretory properties of the 
other pancreatic cell types (Bardeesy and DePinho 2002; Hezel 2006).  
 
2. PANCREATIC CANCER 
With a 5-year survival rate inferior to 5% and a median survival of less 
than 6 months, a diagnosis of pancreatic adenocarcinoma carries one of 
the most dismal prognoses in medicine. Due to a lack of specific 
symptoms and limitations in diagnostic methods, the disease often 
eludes detection during its formative stages. Surgery is the only definitive 
cure as pancreatic cancer responds poorly to both chemotherapy and 






Pancreatic adenocarcinoma, although infrequent, has an exceptionally 
high mortality rate, making it one of the four or five most common 
causes of cancer mortality in developed countries. At the beginning of 
the 21st century, the estimated number of pancreatic cancers throughout 
the world was 110.000, with an estimated global mortality rate of 98% 
(Raimondi et al. 2009).  
Pancreatic cancer is more common in elderly persons than in younger 
persons, in the USA the median age at diagnosis is 72 years and only 
about 5-10% of patients develop it before the age of 50 years (Raimondi 
et al. 2007). The majority of patients present with locally advanced or 
metastatic disease, showing a median survival of 6–10 months and 3–6 
months, respectively.  Although 10–15% of patients have potentially 
localized resectable tumors, many experience recurrence of disease 
following surgery. The overall 5-year survival rate among patients with 
pancreatic cancer is <5% (Wong and Lemoine 2009). 
The causes of pancreatic cancer remain unknown. It is associated with 
only a few known environmental risk factors. Cigarette smoking has been 
associated to cause 20–25% of pancreatic cancer cases (Fuchs et al. 
1996). Chronic pancreatitis and diabetes, two benign diseases, have also 
been linked to the disease (Luo et al. 2007b). High-fat, high-cholesterol 
diet, and previous cholecystectomy are associated with an increased 
incidence (Batty et al. 2009). More recently, an increased risk has been 
observed among patients with blood type A, B, or AB as compared with 
blood type O (Wolpin et al. 2009). 
Approximately 5 to 10% of patients with pancreatic cancer have a family 
history of the disease (Shi et al. 2009). In some patients, pancreatic 
cancer develops as consequence of germline genetic alterations such as 
mutations in the tumor suppressor genes INK4A, BRCA2, LKB1, the DNA 
mis-match repair gene MLH1 and the cationic trypsinogen gene PRSS1. 
The incidence of pancreatic adenocarcinoma due to germline mutation is 
estimated in a 53-fold increase (Hezel 2006). 
The major cause of pancreatic cancer results from the accumulation of 
somatic mutations in genes such as KRAS, CDKN2A, TP53, and SMAD4 
(explained in detail in 2.2.2 section), that cause substantial genomic and 
transcriptional alterations that facilitate cell-cycle deregulation, cell 
survival, invasion, and metastases (Raimondi et al. 2009). 
INTRODUCTION 
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2.2. Biology of pancreatic cancer. 
Pancreatic cancer responds to a histologic classification based on light 
microscopic examination of hematoxylin and eosin-stained sections, with 
recognition of the value of immunohistochemical labeling (Hruban et al. 
2007b). Pancreatic ductal adenocarcinoma (PDAC), whose nomenclature 
derives from its histological resemblance to ductal cells, is the most 
common pancreatic neoplasm and accounts for >85% of pancreatic 
tumor cases (Warshaw and Fernandez-del Castillo 1992; Li et al. 2004). It 
is associated with non-invasive preneoplastic lesions that are thought to 
be precursors to the disease although the overwhelming majority does 
not progress to an invasive carcinoma within the lifespan of the 
individual (Hezel 2006). These precursor lesions are: pancreatic 
intraepithelial neoplasias (PanINs), mucinous cystic neoplasm (MCN), and 
intraductal papillary mucinous neoplasm (IPMN) (Brugge et al. 2004; 
Hruban et al. 2005; Maitra et al. 2005); 
2.2.1. Histopathology 
 Precursor lesions 
Pancreatic intraepithelial neoplasm (PanIN) 
PanIN is the most common and extensively studied precursor lesion. It is 
found in the smaller-caliber pancreatic ducts, the epithelum is columnar, 
in contrast to the usual cuboidal ductal lining cells. It is histologically 
classified into three stages of increasing cellular and nuclear atypia. Stage 
I is characterized by the appearance of a columnar, mucinous epithelium 
and with increasing architectural disorganization and nuclear atypia 
through stages II and III. The high-grade PanINs ultimately transform into 
PDAC with evidence of areas of invasion beyond the basement 
membrane. Molecular studies have shown that the PanIN stage 
correlates with increasing mutation frequency and variety (Hruban et al. 
2004; Feldmann et al. 2007; Hruban et al. 2007a).  
Intraductal papillary mucinous neoplasm (IPMN) 
IPMNs resemble PanINs at the cellular level but grow into larger cystic 
structures. Duct dilatation is accompanied by thick mucinous secretions, 
which can be visualized endoscopically as thick mucin extruding from the 




Mucinous cystic neoplasm (MCN) 
MCNs are large mucin-producing epithelial cystic lesions that harbor a 
distinctive ovarian-type stroma with a variable degree of epithelial 
dysplasia and focal regions of invasion. It occurs predominantly in 
women and is the least common of the precursor lesions (Kern et al. 
2011). 
 Pancreatic adenocarcinoma (advanced stage). 
PDAC commonly arises in the head of the pancreas with infiltration into 
surrounding tissues including lymphatic nodules, spleen, and peritoneal 
cavity, and with metastasis to the liver and lungs. The cancer’s lethal 
nature stems from its propensity to rapidly disseminate to the lymphatic 
system and distant organs.  
PDAC primarily exhibits a glandular pattern with duct-like structures and 
varying degrees of cellular atypia and differentiation. Often within an 
individual tumor, there are regional differences in histology, tumor 
grade, and degree of differentiation. 
The disease is characterized by the presence of a dense stroma of 
fibroblasts and inflammatory cells, termed desmoplasia (further 
explained below). Recently, it was described a hypovascularity of primary 
pancreatic cancers. Both characteristics possessed important clinical 
implications (Hezel 2006; Kern et al. 2011). 
 Microenvironment. Cellular components of pancreatic cancer. 
Heterotypic microenvironmental cellular interactions seem to be 
important in the pathogenesis of pancreatic adenocarcinoma. Pancreatic 
cancers are composed of several distinct elements, including 
pancreatic-cancer cells, pancreatic-cancer stem cells, and the tumor 
stroma (Hidalgo 2010) (Illustration 2). 
Pancreatic cancer stem cells are a subgroup of cancer cells (≤1%) that 
appear to have cancer stem-cell features, such as self-renewal and 
differentiation, enabling them to generate mature cells as well as cancer 
stem cells by asymmetric division. These stem cells may be identified by 
the expression of specific membrane markers, such as CD44, CD24, ESA 
and CD133, and can regenerate into full tumors on implantation in 
immunodeficient animals. Pancreatic-cancer stem cells are resistant to 
conventional treatments, probably due to the expression of multidrug-
INTRODUCTION 
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resistant membrane transporters. They also present an increased 
capability to repair DNA and aberrant activation of developmental 
signaling cascades and antiapoptotic mechanisms (Hermann et al. 2007; 
Li et al. 2007; Sergeant et al. 2009). 
 
Illustration 2. Components of pancreatic cancer. Pancreatic cancers are 
composed of pancreatic-cancer cells, pancreatic- cancer stem cells, and the 
tumor stroma. Pancreatic cancer stem cells (PCSC) generate mature cells 
(pancreatic cancer cells) as well as cancer stem cells by asymmetric division. The 
tumor stroma consists on stromal cells embedded in an extracellular matrix. 
Autocrine and paracrine secretion of growth factors and cytokines results in 
continuous interaction between the stromal and cancer cells.  Adapted from 
(Hidalgo 2010). 
Tumoral stroma constitutes a dynamic and interacting compartment that 
is critically involved in the process of tumor formation, progression, 
invasion, and metastasis (Chu et al. 2007; Mahadevan and Von Hoff 
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consists on invading tumor cells, inflammatory cells, and pancreatic 
stellate cells (PSCs). Pancreatic stellate cells, also known as 
myofibroblasts and characterized by α-smooth muscle actin expression, 
are a key cellular element in the formation and turnover of the stroma: 
they are stimulated by cytokines produced by the tumoral cells to 
synthesize collagen and other components of the extracellular matrix 
that contribute to tumor hypoxia. They also appear to be responsible for 
the poor vascularization that is characteristic of pancreatic cancer 
(Masamune and Shimosegawa 2009). Stromal cells express multiple 
proteins such as cyclooxygenase-2, PDGF receptor, vascular endothelial 
growth factor (VEGF), stromal cell–derived factor, chemokines, integrins, 
SPARC (secreted protein, acidic, cysteine-rich), and hedgehog pathway 
elements among others, which have been associated with a poor 
prognosis and resistance to treatment (Infante et al. 2007; Mukherjee et 
al. 2009). The degradation of surrounding matrix components and 
invasion into the nearby tissue is facilitated by upregulation of matrix-
metalloproteases and plasminogen activator, which are highly expressed 
at the stroma-tumor border (Hidalgo 2010; Mihaljevic et al. 2010). 
2.2.2. Molecular pathogenesis. 
It has been proposed that malignant cells must fulfill some of the 
following criteria: i) self-sufficiency in growth signals, ii) insensitivity to 
antigrowth signals, iii) evasion of apoptosis, iv) limitless replicative 
potential, v) angiogenesis, and vi) invasion and metastasis. PDAC cells 
achieve this by accumulating genetic mutations in signaling pathways 
(Hanahan and Weinberg 2000) (Illustration 2). 
A recent landmark paper described a set of core-signaling pathways 
altered in 69 to 100% of all PDACs analyzed (24 tumors) (Jones et al. 
2008). In this study, an average of 63 genetic abnormalities per tumor, 
mainly point mutations, were classified as likely to be relevant. These 
abnormalities can be organized in 12 functional cancer-relevant 
pathways. However, not all tumors have alterations in all pathways, and 
the key mutations in each pathway appear to differ from one tumor to 
another. Some of these pathways are described below (Mihaljevic et al. 
2010). 
 Chromosomic instability. 
PDAC is characterized by genomic complexity and instability. Centrosome 
abnormalities are detected in 85% of PDAC samples, and there is a 
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correlation between levels of such abnormalities and the degree of 
chromosomal aberrations (Sato et al. 1999; Sato et al. 2001). 
Telomere genetics have been implicated in cancer initiation in two ways: 
while telomerase-mediated preservation of telomere function has been 
shown to promote the development of advanced malignancies, the lack 
of telomerase activity and a transient period of telomere shortening and 
dysfunction during early neoplasia drives cancer initiation. Reactivation 
of telomerase activity has been observed later in PDAC progression and 
seems to be a critical step in cancer initiation (Hahn et al. 1999; Artandi 
et al. 2000; Mihaljevic et al. 2010).  
 KRAS. 
K-RAS is a member of the RAS superfamily of GTPases and mediates a 
variety of cellular functions including proliferation, differentiation, and 
survival. 95% of tumors have activating mutations in the KRAS2 
oncogene, frequently a glycine to aspartate mutation at codon 12 (K-
RASG12D). Transcription of the mutant KRAS gene produces an abnormal 
Ras protein that is “locked” in its activated form, resulting in aberrant 
activation of proliferative and survival signaling pathways (Campbell et al. 
1998; Malumbres and Barbacid 2003). 
It is universally accepted a central role for K-RAS mutations in 
tumorigenesis, but some studies indicate that even though mutant KRAS 
is sufficient to initiate the PanIN–PDAC lineage in mice, there is some 
evidence that it may not be necessary (Morris et al. 2010).  
 The 9p21 locus CDKN2A and INK4A and ARF tumor suppressors. 
The 9q21 locus encodes two overlapping tumor suppressors genes: 
INK4A and ARF, and their respective protein products p16INK4A and p19ARF. 
Homozygous deletion of 9p21 is frequent (in ∼40% of tumors). Loss of 
INK4A function occurs in 80%-95% of tumors, with the resultant loss of 
the p16 protein (a regulator of the G1–S transition of the cell cycle) and a 
corresponding increase in cell proliferation (Rozenblum et al. 1997; Sherr 
2001). 
 TP53.  
The TP53 tumour-suppressor gene is mutated, generally by missense 
alterations of the DNA-binding domain, in more than 50% of pancreatic 
adenocarcinomas. Its mutation permits cells to bypass DNA damage 
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control checkpoints and apoptotic signals, contributing to genomic 
instability (Rozenblum et al. 1997; Hidalgo 2010). 
 The TGF-β/SMAD4 pathway. 
TGF-β is a cytokine that mediates a wide range of physiological 
processes, such as embryonic development, tissue repair, angiogenesis 
and immunosuppression. TGF-β also has a complex role in tumorigenesis: 
it acts as tumor-suppressor in epithelial cells, while promotes invasion 
and metastasis during the late stages of cancer progression. Mutations of 
the TGFBR1, TGFBR2 and SMAD4 genes are found in about 1%, 4% and 
50% of patients with pancreatic cancers, respectively (Goggins et al. 
1998). Inactivation of SMAD4, a transcriptional regulator that serves as a 
central component in the TGF-signaling cascade (Massague et al. 2000), 
abolishes TGF-β-mediated tumor-suppressive functions while it 
maintains some tumor-promoting TGF-β responses, such as epithelial–
mesenchymal transition, which makes cells migratory and invasive (Levy 
and Hill 2005; Wong and Lemoine 2009).  
 Embryonic development signaling pathways. 
PDAC is characterized by frequent reactivation of the embryonic signaling 
pathways Notch, Hedgehog (Hh), and Wnt–β-catenin, that are essential 
for embryonic development and tissue homeostasis. Not only do such 
pathways contribute to the ability of tumor cells to proliferate and evade 
cell death, but they also alter cell plasticity. Recent evidence points to 
temporal and spatial control of these pathways in PDAC development 
and maintenance (Morris et al. 2010). 
 miRNA. 
miRNAs are small, endogenous, noncoding RNA molecules that 
negatively regulate gene expression post-transcriptionally and can be 
either oncogenic or tumor-suppressive, depending on their target 
mRNAs. Expression profiling showed that at least 100 miRNA precursors 
are aberrantly expressed in pancreatic cancer (Lee et al. 2007; Wong and 
Lemoine 2009). For example, miR-200a and miR-200b have been found 
overexpressed in the sera of patients with pancreatic cancer or chronic 




2.2.3. Tumoral progression model. 
As previously mentioned, various genetic risk factors predispose 
individuals to the development of pancreatic cancer. A new study has 
suggested that it takes at least 10 years from initiation of the tumor to 
the development of the parental clone and a further 5 years to the 
development of metastatic subclones, with patients dying an average of 
2 years later (Illustration 3) (Yachida et al. 2010; Costello and 
Neoptolemos 2011)  
 
Illustration 3. Development and progression of pancreatic cancer. Various 
genetic risk factors predispose individuals to the development of pancreatic 
cancer. It takes at least 10 years from initiation of the tumor to the development 
of the parental clone and a further 5 years to the development of metastatic 
subclones, with patients dying an average of 2 years later. Adapted from 
(Costello and Neoptolemos 2011). 
Similar to adenoma to carcinoma sequence seen in other types of 
tumors, a PanIN-to-PDAC progression model has been proposed (Hruban 
et al. 2000; Real et al. 2008): PanINs acquire increasing numbers of 
genetic alterations as they progress from early to late stages and finally 
to PDAC (Illustration 4). The normal pancreas is an organ with a low rate 
of cell proliferation. However, tissue damage, such as that originated by 
pancreatitis, results in a prominent proliferative response. This response 
might involve proliferation of the duct cells that are associated with 
disruptions in the basement membrane, inflammatory responses due to 
cytokine release and reactive oxygen species (ROS) production, and 
autocrine/paracrine release of growth factors (for example, TGF-, HGF 
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and KGF). The proliferative response might result in regeneration of 
pancreatic tissue and return to quiescence when the stimulus is 
attenuated. This proliferative arrest is likely to involve INK4A and TGF-
/SMAD4 pathways. If the proliferative stimulus is maintained, there is a 
selective pressure for subsequent mutations in growth-inhibitory 
pathways that leads to PanIN and metastasis development (Bardeesy and 
DePinho 2002). 
An initial genetic alteration is KRAS mutation. When KRAS activity is 
above a crucial threshold, differentiated pancreatic cells de-differentiate 
into a ductal state that persists in PanINs and PDAC. -catenin signaling is 
maintained below a crucial low level, but once the PanIN state is 
established, -catenin signaling is reactivated in parallel with increasing 
expression of Hedgehog (Hh) ligand, that activates target genes in 
stromal cells of the developing desmoplastic response (Morris et al. 
2010). Most human somatic cells lack telomerase activity, hence 
telomeres are eroded as cells proliferate. Progressive telomere 
shortening activates DNA-damage responses, resulting in growth arrest. 
Loss of checkpoint responses, by TP53 mutations, allows cells to continue 
proliferating, leading to telomere dysfunction and genomic instability. 
Chromosome breakage–fusion cycles produce severe aneuploidy and 
chromosomal translocations that contribute to tumour progression. 
Telomerase reactivation subsequently stabilizes the genome and 
facilitates the immortal growth of the tumour cells development 
(Bardeesy and DePinho 2002). 
Even after decades of research, the cell of origin of PDAC is still a topic of 
debate. Traditionally, pancreatic ductal cells have been viewed as the cell 
of origin since PDAC cells morphologically resemble ductal cells. 
However, nowadays is proposed that PDAC might originate from a 
number of different cells or cells in different conditions that reprogram 
into a ‘ductal’ cell type. This means that rather than having a common 
cellular origin, certain genetic alterations may lead to development of 
PDAC, independent of the cell type they occur in (Mihaljevic et al. 2010). 
Another proposed origin/model is the cancer stem cell model, in which 
growth, regrowth and metastatic reconstitution of tumors is driven by a 
subpopulation of tumor cells (the cancer stem cells) that have self-
renewal and multipotent capacity to generate progeny of various 
differentiation states that constitute the bulk of the tumor. Cancer stem 
cells originate from the tissue’s normal stem cells by the accumulation of 
oncogenic mutations. In pancreas, centroacinar cells (CAC) are 
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considered a “stem cell”-like subpopulation, as express developmental 
markers and may differentiate into acinar as well as ductal cells. The 
oncogenic mutations alter the mechanisms that control normal stem-cell 
expansion in response to stimuli from the microenvironment, whereby 
stem cells become independent of their niche. Another theory implies 
that mutations in more differentiated cells affect genes responsible for 
stem-cell features and cell-cycle control, taking the more differentiated 
cells back to a stem-cell state. As a result, some subpopulations of the 
tumor bulk may adopt a cancer stem cell phenotype. The term cancer 
stem cell, therefore, does not refer to the cell of origin, but to the cell 
that sustains the tumor (Reya et al. 2001; Clarke and Fuller 2006; 
Sergeant et al. 2009). 
 
Illustration 4. Tumoral progression model of pancreatic cancer. Normal epithelium 
progress to infiltrating cancer (left to right) through a series of histologically defined 
precursors (PanINs). Changes in the epithelium are matched by desmoplastic changes 
in the stroma. Constitutively active KRAS is sufficient to initiate the development of 
PanIN and pancreatic ductal adenocarcinoma (PDAC). Acini, insulin-positive cells, 
centroacinar cells and ducts can give rise to PanINs after reprogramming into a ductal 
phenotype. PanINs are classified into three stages of increasing cellular atypia and, in 
humans, have been found to possess increasing numbers of mutations. Common 
mutations: initial point mutations in KRAS, reactivation of β-catenin signaling and 
Hedgehog (Hh) when PanIN are stablished, inactivation of p16 gene at an intermediate 
stage, late inactivation of TP53, SMAD4 and activation of telomerase. Adapted from 
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2.2.4. Proteases in pancreatic cancer. 
The ability of cancer cells to migrate and invade surrounding tissues is 
mediated by molecular interactions of receptors with ligands and various 
proteases. The most common of these proteases are matrix 
metalloproteases (MMP) and serine proteases, such as Urokinase 
plasminogen activator (uPA). Moreover, MMP-2 and MMP-9 activation as 
well as uPA /uPAR (uPA Receptor) expression are significantly increased 
in metastatic pancreatic cancers compared with nonmetastatics (He et al. 
2007; Gondi and Rao 2009). 
 uPA-uPAR system. 
The uPA-uPAR system is involved in the regulation of several 
physiological and pathological conditions that exploit cell adhesion and 
migration including wound healing, neutrophil recruitment during 
inflammation as well as tumor invasion and metastasis. Importantly, 
uPAR expression in tumors can occur in tumor cells and/or tumor-
associated stromal cells such as fibroblasts and macrophages (Gondi and 
Rao 2009; Smith and Marshall 2010).  
The uPA-uPAR system consists of the serine protease uPA, its cell 
membrane-associated receptor (uPAR), the substrate plasminogen and 
the plasminogen activator inhibitors (PAI-1 and PAI-2) (Illustration 5). 
uPA is produced and secreted as an inactive enzyme, called pro-uPA, that 
is activated by binding to uPAR. uPA cleaves plasminogen, generating the 
active protease plasmin, that is involved in the degradation of the 
extracellular matrix (ECM) and basement membranes through direct 
proteolytic digestion, or the activation of other proteases including 
metalloproteases and collagenases. Binding of uPA with its receptor 
uPAR can activate downstream signaling pathways leading to cell 
proliferation, migration, and invasion (Mazar et al. 1999; Rao 2003; 
Gondi and Rao 2009). 
 MMPs 
Matrix metalloproteinases (MMPs) are a highly conserved family of zinc-
dependent endopeptidases able to degrade most components of the 
basement membrane and ECM. There are more than 21 human MMPs, 
the majority of them secreted, although a group of them are anchored to 
the cell membrane (MT-MMPs). They play a crucial role in various 
physiologic processes such as embryonic development, bone resorption, 
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angiogenesis and wound healing; as well as in pathologic processes such 
as rheumatoid arthritis, multiple sclerosis, periodontal disease and tumor 
growth and metastasis (Egeblad and Werb 2002; Gondi and Rao 2009). 
 
Illustration 5. Function and regulation of uPA/uPAR system and interaction 
with MMPs. Urokinase-type plasminogen activator receptor (uPAR) binds the 
protease urokinase-type plasminogen activator (uPA) in its active and zymogen 
(pro-uPA) forms. uPA cleaves plasminogen, generating the active protease 
plasmin. Plasmin can reciprocally activate pro-uPA. Plasmin cleaves and activates 
matrix metalloproteases (MMPs). Both plasmin and MMPs degrade many 
extracellular matrix (ECM) components and activate growth factors or liberate 
them from ECM sequestration. The proteolytic activities of uPA and plasmin are 
antagonized by the serine protease inhibitors plasminogen activator inhibitor 1 
and 2 (PAI1 and PAI2) and α2-antiplasmin. uPA–uPAR binding promotes 
clustering of uPAR in the plasma membrane, and increases its ability to bind the 
ECM protein vitronectin. Complexes of full-length uPAR and its ligands interact 
with integrin co-receptors for intracellular signal transduction. Adapted from 
(Smith and Marshall 2010). 
MMPs are secreted in an enzimatically inactive state (pro-MMPs), being 
activated by sequential cleavage steps which involve the removal of pro-
peptide domains. Different proteinases such as other MMPs, plasmin, 
trypsin, chymotrypsin and cathepsins are implicated in MMP activation. 
MMP expression and proteolytic activity are tightly regulated at three 
stages: gene transcription, proenzyme activation and activity of natural 
inhibitors (tissue inhibitors of metalloproteinase: TIMPs) (Sternlicht and 




In cancer, the major source of MMPs and TIMPs is from the different 
types of stromal cells infiltrating the tumor (Egeblad and Werb 2002). 
MMPs have been shown to regulate tumor cell invasion through 
extracellular matrix remodeling and downregulating cellular adhesion. 
Moreover they also affect multiple signaling pathways, such as cancer-
cell growth, differentiation, apoptosis, migration and invasion, and the 
regulation of tumour angiogenesis and immune surveillance. The most 
important of these metalloproteases are MMP-9 and MMP-2, which have 
shown to be involved in invasion and angiogenesis (Itoh et al. 1998; 
Kessenbrock et al. 2010).  
2.3. Diagnosis. 
Pancreatic cancer, unfortunately, usually presents with nonspecific 
symptoms, and many patients are not correctly diagnosed until months 
or even years after tumor development. The symptoms of pancreatic 
cancer depend on the location of the tumor within the gland, as well as 
on the stage of the disease. The majority of tumors develop in the head 
of the pancreas and cause obstructive cholestasis (condition where bile 
cannot flow from the liver to the duodenum). The most common 
symptom is epigastric pain that radiates to the back. Other associated 
complications are the development of diabetes mellitus and pancreatitis. 
Anorexia, weight loss, gastric outlet obstruction and ascites are usually 
manifestations of more-advanced disease. Other less common 
manifestations include deep and superficial venous thrombosis, liver-
function abnormalities and depression (Li et al. 2004; Hruban et al. 
2007b; Maitra and Hruban 2008; Hidalgo 2010; Stathis and Moore 2010).  
Currently, helical computed tomography (CT) with intravenous 
administration of contrast material is the imaging procedure of choice for 
the initial evaluation of pancreatic masses (Miura et al. 2006). This 
technique allows visualization of the primary tumor in relation to the 
superior mesenteric artery, celiac axis, superior mesenteric vein and 
portal vein, and also in relation to distant organs. In general, contrast-
enhanced CT is sufficient to confirm a suspected pancreatic mass, and 
predicts surgical resectability with 80 to 90% accuracy (Karmazanovsky et 
al. 2005).  
Some patients require additional diagnostic studies. Endoscopic 
ultrasonography (EUS) is useful in patients in whom pancreatic cancer is 
suspected although there is no visible mass identifiable on CT. Fine 
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needle aspiration biopsy can be used in conjuction with EUS (EUS-FNA) to 
obtain tissue for diagnostic purposes (Mizuno et al. 2011). 
Magnetic resonance imaging (MRI) demonstrates the location of any 
duct lesion. It can be used to visualize the vascular anatomy and 
determine the resectability of pancreatic neoplasms (Hruban et al. 
2007b). 
Endoscopic retrograde cholangiopancreatography (ERCP) shows the 
pancreatic and bile-duct anatomy and can be used to guide ductal 
brushing and lavage, which provides tissue for diagnosis. ERCP is more 
invasive than the previously mentioned techniques, and is associated 
with a 2% complication rate, making it a less attractive first-line modality 
for the evaluation of pancreatic neoplasms. It is especially useful in 
patients with jaundice in whom an endoscopic stent is required to relieve 
obstruction (Dumonceau and Vonlaufen 2007). 
The central problem with pancreatic cancer remains the lack of an 
effective screening test for early asymptomatic disease. There are many 
potential serum biomarkers for diagnosis, stratification of a prognosis, 
and monitoring of therapy; however, only a few have demonstrated 
clinical usefulness (Harsha et al. 2009). Serum carcinoembrionic antigen 
(CEA) and carbohydrate antigen (CA) 19-9 levels have proven to be 
ineffective screening tests for pancreatic cancer due to the lack of 
sufficient sensitivity and specificity (Ritts and Pitt 1998; Buxbaum and 
Eloubeidi 2010). Nonetheless, CA 19-9 levels have been used to 
prognosticate and to monitor the effectiveness of therapy, and are useful 
in conjunction with other diagnostic tests (Nishida et al. 1999).  
Analysis of pancreatic biopsies is used for cancer evaluation and 
determination of the type of pancreatic neoplasm. Analysis of molecular 
markers in FNA tissue shows promise and is likely to be the strategy of 
the future (Buxbaum and Eloubeidi 2010). 
Recently, Hoheisel and colleagues have described an extensive antibody 
microarray platform, including 810 antibodies, specifically selected 
against 741 cancer-related proteins. Dual-color measurements of 
proteins in blood and urine were achieved with excellent accuracy and 
reproducibility. Importantly, the antibody microarray platform could 
distinguish between urine samples from patients with pancreatic cancer 
and healthy individuals. This approach is promising and has the 
advantage that it could be readily converted into an immunodiagnostic 
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assay for routine use (Schroder et al. 2010; Costello and Neoptolemos 
2011).  
2.4. Treatment.  
The management of patients with pancreatic carcinoma depends on the 
extent of the disease at diagnosis. Surgical resection followed by 
adjuvant therapy is the standard of care for patients diagnosed with 
early-stage disease. However, the majority of patients have locally 
advanced unresectable disease due to local vascular invasion; or present 
with advanced-stage disease or metastatic disease, which precludes 
surgery. Prognosis for these patients is extremely poor and the impact of 
standard therapy is minimal (Stathis and Moore 2010).  
2.4.1. Early disease. 
It is estimated that only 10–15% of patients present with early-stage 
disease that permits curative surgery (Heinemann and Boeck 2008). 
Depending on the location of the tumor, the operative procedures may 
involve cephalic pancreatoduodenectomy (the Whipple procedure), 
distal pancreatectomy, or total pancreatectomy. These patients also 
receive post-operative therapy, although no universal consensus exists as 
to the type of adjuvant therapy. Gemcitabine or 5-fluorouracil (5-Fu) 
chemotherapy without radiation are the most common treatments 
outside North America, while chemoradiation plus systemic 
chemotherapy is still widely used in the USA (Neoptolemos et al. 2004; 
Regine et al. 2008; Stathis and Moore 2010). 
2.4.2. Locally-advanced and systemically advanced disease. 
Patients with locally advanced disease represent almost 30% of newly 
diagnosed pancreatic carcinoma cases. These patients have a better 
outcome (median survival of 8–12 months) than patients with metastatic 
disease. The optimum treatment for patients with locally advanced 
disease has not yet been defined as data are limited; however, radiation 
combined with chemotherapy is often considered the standard 
treatment for these patients (Sharma et al. 2011).  
The first line treatment for patients with systemically advanced 
pancreatic adenocarcinoma is gemcitabine. At present, there is no 
standard second-line treatment. The median overall survival is 5.65 
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months and the 1-year survival rate is 18%. Over the past decade, major 
efforts have been made to improve treatment outcomes in patients with 
metastatic disease, more than a dozen large randomized trials worldwide 
have been conducted (Burris et al. 1997). The most common approach 
has been to use gemcitabine as the control arm and gemcitabine 
combined with a second cytotoxic agent or, more recently, with a 
targeted agent, as the experimental arm (Stathis and Moore 2010). 
Large randomized phase III trials were performed to evaluate the 
combination of gemcitabine with the cytotoxic agents cisplatin, 
oxaliplatin, 5-FU, capecitabine, irinotecan, exatecan and pemetrexed 
(Illustration 6A). The primary end point of overall survival was not 
improved in any of these trials. Combination chemotherapy resulted in 
an improved response rate and had some impact on progression-free 
survival in some of these trials; however, there was an absence of an 
overall survival benefit (Welch and Moore 2007; Merl et al. 2010b; 
Stathis and Moore 2010).  
In the age of molecular targeted therapy, several drugs developed to 
specifically target those pathways/components altered in pancreatic 
cancer, such as RAS (Tipifarnib), MMPs (Marimastat, BAY 12-9566) 
angiogenesis (Bevacizumab, humanized anti-VEGF antibody), EGFR 
(Erlotonib, EFGR inhibitor; Cetuximab, anti-EGFR antibody) have been 
tested in phase II and randomized phase III trials (Illustration 6B). With 
the exception of erlotinib and gemcitabine, none of the targeted agents 
tested improved overall survival of patients. Gemcitabine plus erlotinib 
improved the median overall survival compared with those who received 
gemcitabine alone (6.24 months versus 5.91 months), and the respective 
1-year survival rates (23% versus 17%, p=0.023) (Moore et al. 2007; 
Stathis and Moore 2010).  
Recently, in the 2010 ASCO Annual Meeting, the phase III trial PRODIGE 
4/ACCORD and the phase II trial TARGET were presented with a primary 
end point of overall survival (Merl et al. 2010a). The PRODIGE 4/ACCORD 
trial consisted on the administration of FOLFIRINOX (oxaliplatin, 
irinotecan, leucoviron and 5-FU) vs gemcitabine. The combined 
treatment showed statiscally significant longer median overall survival 
(10.5 months vs 6.9 months, p<0.001) and 1-year survival (48.8% vs 
20.6%). However, it presented a higher incidence of toxicity, which would 
limit its use to patients with good performance status (Conroy et al. 
2011). The phase II trial TARGET consisted on the combined inhibition of 
VEGF and EGFR pathway (bevacizumab and erlotinib) plus gemcitabine 
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and capecitabine. Patients with metastatic disease had an improved 
overall survival (11.1 months) and 1-year survival (49%) compared with 
historical data of standard therapy. These results may represent a start of 
a paradigm shift in the management of advanced pancreatic cancer. 
 
Illustration 6. Phase III clinical trials in advanced pancreatic adenocarcinoma. 
Adapted from (Stathis and Moore 2010). 
Phase III trials of targeted agents in advanced pancreatic carcinoma
Abbrevations: FT, farnesyltransferase: MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Phase III trials of chemotherapy in advanced pancreatic cancer patients





3. MODELING PANCREATIC CANCER IN MICE. 
In the last 10 years, there has been a relative explosion of new rodent 
systems that recapitulate both genetic and cellular lesions that lead to 
the development of pancreatic cancer. These mice models have been 
used to study causal signaling pathways and to evaluate novel detection, 
chemopreventative, and therapeutic measures. There are three primary 
groups of rodent models: carcinogen-induced, xenograft implanted and 
genetically engineered models. 
3.1.1. Carcinogen-induced models. 
Carcinogen-induced models rely on the administration of certain 
chemicals to generate cellular changes that rapidly lead to pancreatic 
cancer. The most widely used and studied model is Syrian gold hamster 
intraperitoneally injected with BOP (N-nitrosobis(2-oxopropyl)amine). 
These tumors are very similar to those in humans since they have a 
ductal phenotype with pronounced desmoplasia and predilection for 
perineural invasion; and at the molecular level, K-RAS and p53 mutations 
have been reported. Tumors in rats can be induced using a wide range of 
carcinogens, such as azaserine and DMBA. However, tumors in rats are 
biologically and phenotypically distinct from those in humans, grow 
relatively slow, infrequently metastasize and have different molecular 
changes. Carcinogens in mouse have rarely been used to model 
pancreatic neoplasia because they mostly induce cancers of acinar origin 
(Wei et al. 2003). 
Carcinogens induced models resemble the human disease in their use of 
environmental factors to induce progressive tissue changes leading to 
cancer. However, the cancers that form are not of human origin and they 
lack a genetic definition; moreover, the administration of these 
compounds has broad effects in other tissues (Bardeesy et al. 2001; Ding 
et al. 2010).  
3.1.2. Xenograft Models.  
In general, nude and SCID mice are used to generate xenograft tumors as 
they are incapable of rejecting foreign tissues and cells. Nude mice 
display defective development of thymus and hair follicles, thus lack T 
lymphocytes and hair (Fidler 1986). Severe combined immunodeficient 
(SCID) mice lack mature B- and T lymphocytes because they carry a gene 
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mutation that impairs rearrangements of immunoglobulin and T-cell 
receptor genes (Bosma and Carroll 1991). Xenograft models develop by 
the inoculation of well-characterized pancreatic cancer cell lines (mostly 
of human origin) or from the implantation of primary or metastatic 
cancer tissue (Fogh et al. 1980; Kim et al. 2009). 
 Subcutaneous xenograft tumors. 
Subcutaneous xenograft tumors are generated by implantation of tissue 
or cells in the subcutaneous pocket under the mouse skin, usually along 
the back or upper portion of the hind legs. This cancer model is relatively 
reliable, inexpensive, fast, and technically simple when establishing 
tumors to reach a defined end point for evaluation. The most notable 
limitation is that these cancer cells are forced to grow under the skin of 
immunocompromised mice, which ignores the contribution of the host’s 
immune system in tumor growth modulation (Kim et al. 2009). 
Moreover, subcutaneous xenograft tumors usually show extensive local 
growth but rarely metastasize, in contrast to pancreatic cancer behavior 
in humans (Fogh et al. 1980). 
 Orthotopic xenograft tumors. 
Pancreatic orthotopic tumors are generated by direct injection of cells 
into the pancreas, or by surgical implantation of 1 mm3 tumor fragments. 
Orthotopic implantation of pancreatic cancer cells is more time-
consuming, technically challenging and often requires image 
examinations or exploratory laparotomies to exclude or confirm the 
presence of tumor. However, the external milieu is more closely 
preserved in orthotopic tumors and theoretically better approximates 
the ‘natural’ setting of pancreatic cancer. Moreover, orthotopic 
implantation often results in higher metastasis efficiency and more 
relevant colonization patterns (similar to those of human cancer) than 
does ectopic implantation into mice; dissemination occurs in up to 60% 
of tumors to the peritoneum, liver, lungs, and lymph nodes (Wei et al. 
2003; Loukopoulos et al. 2004). 
Models initiated by direct orthotopic engraftment of primary human 
tumor samples into immunodeficient mice without a cell line 
intermediary are receiving increasing interest. Direct xenograft models 
better preserve tumor heterogeneity and limit the ex vivo manipulation 
inherent in the culturing of cancer cell lines. Most direct xenograft 
tumors grow with considerable stromal elements and recapitulate the 
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histological appearance of the original patient tumor over multiple 
passages in mice (Kim et al. 2009; Perez-Torras et al. 2011).  
3.1.3. Genetically engineered models. 
Genetically modified mice are generated by insertion of relevant genetic 
mutations into mouse genomic DNA in both a conditional and inducible 
format. Delivery of these genes is through transgenesis, embryo 
manipulation for knock-in/knockout technology, and retroviral delivery 
to somatic cells. 
Currently, there are over a dozen models available, which range from 
homogeneous preneoplastic lesions with remarkable similarity to human 
PanINs, to PDAC models or to models with a more heterogeneous 
population of lesions including cystic papillary and mucinous lesions. The 
molecular features of these models may also vary in a manner 
comparable with the differences observed in lesion morphology (Grippo 
and Tuveson 2010; Morris et al. 2010). First mouse models generated 
were based on the expression of an oncogene under the control of the 
tissue-specific promoter Elastase-1. Activated H-Ras and SV40 T-antigen 
transgenes resulted in pancreatic acinar tumor formation, whereas c-myc 
overexpression triggered mixed acinar/ductal neoplasms (see next 
section for further details) (Ornitz et al. 1987; Quaife et al. 1987; 
Sandgren et al. 1991). Murine models of pre-neoplasms (earlier-stage 
lesions) displaying complete penetrance (all mice with a gene mutation 
have phenotypic manifestation of that disease) have been generated by 
expressing the oncogenic Kras allele in pancreatic exocrine and/or 
progenitor cells (Tuveson et al. 2006). When combined with various 
tumor suppressor mutations, such as p16, p53 and/or Smad4 (Aguirre et 
al. 2003; Hingorani et al. 2005; Izeradjene et al. 2007), these models 
often times give rise to invasive and metastatic PDAC and related 
epithelial histologies. Models using inducible alleles of Cre recombinase, 
such as estrogen receptor–Cre fusion genes (CreER or CreERT) and 
tetracycline-responsive Cre expression alleles (TRE-Cre), are capable of 
being temporally controlled and thus initiated selectively in adult 
pancreata, better reflecting the somatic acquisition of genetic mutations 
thought to occur in humans (Guerra et al. 2007; Gidekel Friedlander et al. 





Transgenic Ela-myc mice was generated by Sandgren et al in 1991, by the 
insertion of the Ela1-myc cassete (Illustration 7A) in which the c-myc 
oncogene was under the control of the Elastase promoter, which targets 
c-myc expression to acinar cells (Sandgren et al. 1991). C-myc is a 
transcription factor implicated in growth and expansion of somatic cells, 
and is overexpressed in about 50% of human pancreatic ductal 
adenocarcinomas (Oster et al. 2002; Liao et al. 2006). 
Mice develop mixed acinar/ductal pancreatic adenocarcinomas, with 
100% penetrance and present a survival of 4-7 months. 10% of mice 
display tumor spread to peritoneal surfaces or liver (Sandgren et al. 
1991). This Ela-myc mouse is the only single-transgene model that gives 
rise to pancreatic tumors with ductal elements in the shortest latency 
period (Liao et al. 2006). Other mouse models such as Ela-TGF-, Ela-Kras 
or Mist-Kras develop acinar-to-ductal metaplasia but with a longer 
latency period (survival times: 12m, 18+ m and 11m, respectively) 
(Wagner et al. 2001; Grippo et al. 2003; Hruban et al. 2006; Tuveson et 
al. 2006).  
Ela-myc mice at 2 months of age already present small cancer nodules 
(1–6 mm in diameter) in 40% of animals. At the time of sacrifice, multiple 
nodules are observed. Two different tumor colorations are found: a fish-
meat-like white, a typical sign of solid cancer in humans, and a deep red 
color due to hemorrhage within the tumor (Illustration 7 B.A). 
Histologically, about one-half of the tumors are pure acinar cell 
carcinomas (Illustration 7 B.B and B.C), while the other one-half are 
mixed ductal and acinar carcinomas (Illustration 7 B.D). While acinar 
tumors can be either white or red in color, all ductal adenocarcinomas 
are white. Acinar cell tumors contained little stroma (Illustration 7 B.C), 
but invasive growth into the adjacent stroma, whilst ductal tumor cells 
were usually disseminated in the dense stromal tissue (Illustration 7 B.D 
and D.E), similar to the desmoplasia observed in human pancreatic ductal 
adenocarcinomas. The tumors are frequently associated with marked 




Illustration 7. Ela-myc mice. A) Construct of Ela-myc transgene. The 2.7 kb 
fragment of murine c-myc, which includes the entire protein coding region 
within exons 2 and 3, was cloned between the 3 kb rat Elastase-1 gene 
fragment, that includes the enhancer and promoter, and the 0.3 kb human 
growth hormone gene fragment that includes the 3' untranslated and poly(A) 
addition sequences. B) Gross morphology and histology. B.A) Black arrows 
indicate tumor nodules with white coloration. Red arrow indicates a tumor 
nodule with red coloration. B.B and B.C) Representative images of an acinar 
phenotype. Black arrows indicate apoptotic cells organized in clusters. B.D and 
B.E) Representative images of mixed and ductal phenotypes. Images adapted 













4. NOVEL THERAPEUTIC MODALITIES. 
4.1. Cancer Gene Therapy. 
4.1.1. Concept  
Gene therapy is an emerging advanced therapy that consists on the 
transfer of genetic material into cells in order to cure or at least 
ameliorate the course of a disease. The main objective of cancer gene 
therapy is to eliminate cancer cells or to restore their normal phenotype 
by restoration or inhibition of usually mutated genes in pancreatic cancer 
such as silencing of KRAS, or functional rescue of p53 or p16 (Calbo et al. 
2001; Miura et al. 2005; Bardeesy et al. 2006). 
The success of a gene therapy will largely depend on the activity induced 
by the introduced gene and the efficiency of gene delivery resulting from 
the combined effects of the delivery vector and the applied delivery 
route. 
4.1.2. Therapeutic systems. 
Different gene therapy approaches exist according to the different 
therapeutic genes transferred. A large number of genes have been tested 
for their therapeutic efficacy against pancreatic tumors.  
 Apoptotic genes. 
Some approaches consist on targeting hallmarks of cancer such as 
apoptosis resistance or angiogenesis. The re-engagement of the 
disrupted apoptosis program in pancreatic cancer cells is a general 
strategy for effective and tumor-cell-specific cancer therapy. Studies on 
single apoptosis-associated gene deregulated in pancreatic cancer have 
shown encouraging results; for example, downregulation of the anti-
apoptotic gene BCL-2 triggered anti-proliferative and pro-apoptotic 
effects in tumoral cells but not in non-malignant tissues (Ocker et al. 
2005). Overexpression of pro-apoptotic genes such as BAX and TRAIL also 
showed antitumoral effects and sensitization to gemcitabine 
chemotherapy (Wack et al. 2008). Interestingly, inhibition of particular 
inhibitors of apoptotic proteins (IAPs) such as cIAP-2 and XIAP proved to 
be very efficient to induce sensitivity to cisplatin, doxorubicin and 
plaxitaxel (Lopes et al. 2007; Vogler et al. 2007).  
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 Antiangiogenic gene therapy. 
Development of antiangiogenic gene therapies includes the suppression 
of angiogenic molecules and the upregulation of antiangiogenic 
molecules. A replication-deficient retrovirus encoding truncated VEGF-RII 
was used to block VEGF signaling through dominant-negative inhibition, 
and significantly reduced the growth rate of subcutaneous tumors in 
three pancreatic cancer cell lines (Buchler et al. 2003). On the contrary, a 
recombinant adenovirus expressing the angiogenesis inhibitor NK4 
suppressed the number and growth of pancreatic cancer metastasi foci in 
the liver after viral intrasplenic injection and reduced the development of 
pancreatic tumors in a mouse peritoneal model after viral intraperitoneal 
injection (Saimura et al. 2002; Murakami et al. 2005). 
 Restoration or inhibition of gene mutated functions. 
The inhibition of oncogene expression and restoration of tumor 
suppressor functions have also been studied in pancreatic cancer gene 
therapy. Strategies involving the silencing of mutated K-ras and/or the 
functional rescue of p53 or p16 tumor suppressor genes have shown 
significant antitumoral responses in mouse models. Adenoviruses 
carrying a dominant negative H-ras mutant that competed with K-ras for 
a guanine nucleotide exchange factor, or an antisense K-ras RNA reduced 
the dissemination of pancreatic cancer in rodent models (Takeuchi et al. 
2000; Miura et al. 2005). Similarly, an adenovirus containing the wt-p16 
cDNA or/and the wt-p53 cDNA decreased cell proliferation and increased 
the level of apoptosis (Cascallo et al. 1999; Calbo et al. 2001). Due to the 
fact that mutational activation of K-ras is such a common event in 
pancreatic cancer, targeting of key signaling pathways downstream of 
mutant K-ras has also been explored through gene therapy approaches 
(Fillat et al. 2011). Other oncogenes and tumor suppression genes used 
as therapeutic targets include Notch-1, survivin, SMAD4 and cyclin D1, 
among others (Xu et al. 2010). 
 Suicide gene therapy. 
Suicide or prodrug-converting cancer gene therapy conform another 
important group of anti-cancer therapies. This strategy is based on the 
transfer of an enzyme able to transform a prodrug into a toxic 
metabolite, resulting in cell death. This approach provides low systemic 
but high local intratumoral toxicity since the non-toxic prodrug is 
systemically administered, but the enzyme is specifically delivered to 
tumoral cells (Lanuti et al. 1999). Some examples of suicides systems are 
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the TK/GCV system, CD/5-FC and CYP2B1/CPA. In this thesis the TK/GCV 
system has been employed as antitumoral strategy. A detailed 
description of the TK/GCV system is presented in section 4.1.6.  
 Immunotherapy. 
The objective of immunotherapy is to stimulate the immune system to 
target and destroy cancer cells and confront the fact that pancreatic 
cancer cells have low immunogenicity. Tumor gene transduction of 
tumor specific antigens, costimulatory molecules or inflammatory 
cytokines constitute the major type of molecules assessed to facilitate 
the presentation of pancreatic tumor cells to the immune system. 
Vectors expressing IL-1, IL-2, IL-12, TNF-, GM-CSF have shown 
significant antitumoral responses (Mazzolini et al. 2005; Meng et al. 
2010). Combination of restricted replication-competent adenovirus with 
an adenovirus carrying IL-2 led to a remarkable inflammatory response 
and almost complete regression of established tumors (Motoi et al. 
2000). IFN-γ viral administration provoked an activation of antitumor 
immunity resulting in complete eradication of both primary and distant 
tumors (Sarkar et al. 2005). Tumor regression/stabilization was achieved 
in 50% of treated mice after in vivo lentiviral administration of hIFN-
(Ravet et al. 2010). A Phase I trial of intratumoral injection of an 
adenoviral vector encoding human IL-12 for pancreatic cancer showed to 
be well-tolerated but exerted only mild antitumor effects (Sangro et al. 
2004).  
Another promising strategy is the development of cancer cell vaccines, in 
which cells, usually antigen presenting cells (APC) such as dendritic cells, 
are manipulated to be more recognizable by the immune system via 
introduction of one or more transgenes, which include cytokines, 
costimulatory molecules and specific tumor associated antigens (Xu et al. 
2010). 
 Oncolytic virus therapy. 
Growing interest relies on the efficacy of virotherapy. Virotherapy is 
based on the viral replication itself as a mean to destroy cancer cells in a 
process referred to as viral oncolysis. The safety and efficacy of this 
approach depends on the selectivity of the virus to replicate only in 
cancer cells. To increase the antitumoral potency, replication-competent 
viruses can be further modified to express a transgene, originating 
“armed oncolytic viruses”. Several types of virus have been studied as 
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replication agents, some of them have been engineered to selectively 
replicate in tumoral cells, such as adenovirus (Ad), herpes virus (HSV) or 
measles virus (McAuliffe et al. 2000; Zhang et al. 2006; Huch et al. 2009), 
while others possess a natural oncolytic capacity as for example vaccinia 
viruses or reovirus (Kelly et al. 2009; Yu et al. 2009). The first virotherapy-
based clinical trial in pancreatic cancer was a Phase I/II carried out with 
repeated intratumoral administrations of ONYX-15 adenovirus by EUS-
guided. ONYX-15 was developed to selectively replicate and lysate in p53 
deficient cancer cells. The trial showed the feasibility and tolerability of 
the therapy; however, its very limited replication capacity compromised 
its antitumoral effect (Hecht et al. 2003). A Phase I study is ongoing to 
assess the safety and effectiveness of intratumoral injections of the 
oncolytic herpes simplex virus, OncoVEX GM-CSF into unoperable 
patients with pancreatic cancer (NCT00402025). A Phase I study 
combining suicide gene therapy delivered by the replication competent 
adenovirus expressing the TK and the CD enzymes (Ad5-
yCD/mutTKSR39rep-ADP) with chemoradiation therapy is currently 
recruiting patients with non-metastatic pancreatic adenocarcinoma 
(NCT00415454) (Fillat et al. 2011). 
 Combined therapies. 
The pathogenesis of pancreatic cancer is complex and single gene 
therapy approach is unlikely to achieve a cure. Therefore, nowadays 
many studies are based on the combination of gene therapy approaches, 
such as virotherapy with immunotherapy (Hu et al. 2006; Bortolanza et 
al. 2009), or combination of gene therapy with chemotherapy and 
radiotherapy (Freytag et al. 2007; Oberg et al. 2010). The replication 
deficient Ad-NK4 combined with gemcitabine significantly reduced tumor 
volume of orthotopically implanted SUIT-2 tumors and completely 
suppressed peritoneal dissemination and liver metastases, compared 
with Ad-NK4 or gemcitabine alone (Ogura et al. 2006). Similarly, the 
AdDeltaE1B19K replicative adenovirus synergized with gemcitabine to 
selectively kill cultured pancreatic cancer cells and xenografts in vivo with 
no effect in normal cells (Leitner et al. 2009). The combination of the 
replicative adenovirus 5/3COX2CRAdF with gemcitabine or 5-fluorouracil 
also showed improved antitumoral effect (Nelson et al. 2009). 
4.1.3. Delivery vectors. 
Delivery vectors can be classified into three main groups: viral vectors, 
non-viral vectors and cellular vectors.  
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Viral vectors are biological systems deficient in replication, derived from 
naturally evolved viruses capable of transferring their genetic material 
into the host cells. Basically, viruses are transformed to viral vectors 
capable of delivering genes by substituting key genetic components of 
the viral genome by the transgene of interest and providing viral genes in 
trans to generate recombinant viral particles (Morille et al. 2008). Many 
viruses, either with RNA or DNA genomes, enveloped or no-enveloped, 
integrative or non-integrative, with the ability to transduce both diving 
and non-diving cells, have been engineered as vectors. The most 
commonly used are adenovirus, retrovirus, lentivirus, herpes simplex 
virus (HSV) and adeno-associated virus (AAV). In particular, adenoviruses 
are leading gene therapy clinical trials (Illustration 8).  
 
Illustration 8. Vectors used in gene therapy clinical trials in 2011. Image from 
Wiley Gene Therapy Clinical Database. 
Viral vectors are very effective in achieving high efficiency for both gene 
delivery and expression. However, the limitations associated with viral 
vectors in terms of safety, immunogenicity, low transgene size and high 
cost, have encouraged researchers to focus on alternative systems. Non-
viral vectors are safe, low immunogenic and easy to produce at large-
scale; they can carry large inserts but they are quite inefficient at 
transfecting cells in vivo (Morille et al. 2008; Atkinson and Chalmers 
2010). Non-viral vectors include naked DNA, cationic liposomes 
(lipoplexes) and synthetic polymers (polyplexes). Naked DNA can be 
directly injected to the tumor site but it results in poor transfection 
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efficiency; alternatively it can be systemically delivered, although then it 
is rapidly degraded by serum nucleases. Physical methods that increase 
the permeability of cell membrane to facilitate the introduction of naked 
DNA into cells such as electroporation (EP) or ultrasounds have shown to 
improve its transfection efficiency (Niidome and Huang 2002). Lipoplexes 
and polyplexes are generated by interaction of cationic liposomes and 
synthetic polymers with negatively charged DNA through electrostatic 
interactions. Non-viral vectors have yet to consistently demonstrate 
transfection efficiency comparable to that of viruses, regardless of gene 
or target cell type (Morille et al. 2008). Recently, the use of nanoparticles 
to deliver DNA molecules has strongly emerged in the development of 
non-viral gene therapy approaches. 
Growing attention is paid on cellular vectors. Dendritic cells, fibroblasts, 
mesenchymal stem cells (MSC) and blood outgrowth endothelial cells 
(BOECs) have already been tested as delivery vectors. MSC are 
pluripotent progenitor cells that are actively recruited to the tumor 
environment (Kallifatidis et al. 2008). It has been shown that systemic 
delivery of TK transfected MSC to mice carrying orthotopic syngenic 
pancreatic tumors significantly reduced the primary tumor growth and 
the incidence of metastases (Zischek et al. 2009). Similarly, 
intraperitoneal administration of MSC-IFN suppressed tumor growth of 
orthotopic pancreatic tumors (Kidd et al. 2010). 
4.1.4.  Adenovirus biology. 
Adenoviruses are non-enveloped icosahedral viruses with a double 
stranded DNA genome of 30 to 40 kb enclosed in a capsid comprised 
predominantly of hexon, penton base and fiber proteins. Hexon is the 
most abundant structural component and constitutes the bulk of the 
mature virion. Five subunits of the penton base are found at each of the 
twelve vertexs of the capsid and form the platform for the twelve fiber 
homo-trimers that protrude from the virion. At the distal tip of each 
linear fiber is located the globular knob domain (Illustration 9B). Hexon 
appears to play structural role as a coating protein, while the penton 
base and the fiber are responsible for the key virion-cell interactions that 
constitute Ad tropism (Curiel and Douglas 2002). Recently, hexon protein 
has also been described as a major mediator of in vivo liver transduction 
by interaction with coagulation factor X (FX) (Kalyuzhniy et al. 2008; 
Vigant et al. 2008; Waddington et al. 2008). 
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There are about 50 serotypes of human Ad, most of which can recognize 
the cellular Coxsackie B virus-adenovirus receptor (CAR) as the primary 
receptor. For Ad2 and Ad5, the first step of Ad uptake occurs primarily 
through high affinity binding of the viral fiber protein to CAR. The second 
step of virus uptake is mediated by low affinity binding of the Arg-Gly-
Asp (RGD) residues of Ad penton base to integrin molecules v1, v3 
or v5 on the cell surface. Integrin binding induces internalization of Ad 
through receptor-mediated endocytosis in clathrin-coated vesicles. Ad is 
then released from the endosome and progresses through cytosol to the 
nuclear pore complex. Here the remainder of the capsid is disassembled 
as the genome enters the nucleus. Viral transcription, replication and 
packaging  occur in the nucleus (Meier and Greber 2004; Sadeghi and Hitt 
2005). 
 
Illustration 9. Adenovirus biology. A) Adenoviral genome. E1A induces the other 
viral regions included E1B (encodes proteins that block host mRNA transport, 
and inhibit E1A-induced apoptosis), E2 (encodes the DNA polymerase, terminal 
protein and DNA binding protein that mediate viral replication), E3 (encodes 
several proteins that modulate the host immune response to infection) and E4 
(encodes proteins involved in DNA replication, late gene expression, and host 
protein shut off). Most late genes are transcribed under the control of the Major 
Late Promoter (MLP), in a single primary transcript that is multiply spliced. The 
late mRNAs encode most of the structural proteins of the virion. B) Native entry 
mechanism of adenovirus. Ad5 binds to its receptor CAR through its fiber knob, 
and integrins interact with the RGD peptide motif in the penton base and 
facilitate cell entry by endocytosis. Panel B adapted from (Waehler et al. 2007).  
Adenovirus genome consist on a linear molecule flanked by inverted 























The viral packaging signal is located near the “left” end of the genome. 
The ITRs and packaging signal are the only sequences required in cis for 
Ad production. Viral coding sequences are divided into early (transcribed 
before viral DNA replication) and late (expressed after the onset of 
replication) regions. Early region 1A (E1A) is the first transcription unit 
expressed after Ad infection and induces the other viral early regions. 
E1A region is deleted in replication-defective adenoviral vectors, 
preventing lysis of the infected host cell and vector dissemination, and in 
addition, creates space for gene insertions (Sadeghi and Hitt 2005). 
Ad5 serotype has been the most extensively vector used in gene therapy. 
It presents low pathogenicity in humans causing mild acute respiratory 
infections. Ad vectors have a good safety profile and can be produced at 
high titers under GMP conditions, do not integrate, can transduce 
dividing and non-dividing cells and present high in vivo transduction 
efficiency. When administered systemically they are trapped by the liver, 
which limits tumor delivery and elicits hepatotoxicities. The fact that 
many individuals have pre-existing neutralizing antibodies against the 
most common vector strains (Ad2 or 5) can limit gene transfer. 
Moreover, residual expression of viral genes also causes direct toxicity 
and the activation of a cellular immune response that leads to the 
clearance of vector-transduced cells and to short duration of transgene 
expression (Fillat et al. 2011). Nevertheless, strategies to overcome such 
limitations are under development and include transductional and 
transcriptional targeting.  
4.1.5. Adenoviral targeting. 
To achieve therapeutic success, gene therapy vehicles must be capable of 
transducing target cells while avoiding harming non-target cells. Despite 
the high transduction efficiency of viral vectors, their tropism frequently 
does not match the therapeutic need. Many efforts are being conducted 
to modify current vectors to efficiently and specifically target pancreatic 
cancer cells. We will focus on adenoviral vector targeting towards 
pancreatic tumors although other tumor types are briefly mentioned. 
4.1.5.1. Transcriptional targeting. 
Transcriptional targeting of Ad transgene expression or replication 
exploits the unique transcriptional profile of the target cell by employing 
target cell-specific regulatory sequence elements to restrict the 
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therapeutic transgene expression or replication to target cells. In 
addition to promoter elements providing tissue- specific gene activation, 
tumor-associated regulatory sequences are also used for transcriptional 
targeting to cancer cells. A number of candidate tumor/tissue-specific 
promoters (TSPs) have been studied for pancreatic cancer gene therapy, 
but some promoters lack sufficient activity, specificity, or both. 
Therefore, recent research has focused on the evaluation of candidate 
promoters with regard to these attributes. 
Tumor-specific promoters (TSP) have been tested to drive the expression 
of either cytotoxic genes, such as TK or the pro-apoptotic genes Bax and 
TRAIL, or to control the expression of viral essential gens, such as are E1A 
and/or E4, in oncolytic adenovirus (Hoffmann and Wildner 2006b; Liu et 
al. 2007; Wack et al. 2008; Huch et al. 2009). Examples of TSP altered in a 
broad number of tumor types and in pancreatic cancer in particular, 
include the cyclooxygenase-2 (COX-2), midkine (MK), E2F1, cancer 
specific progression elevated gene-3 promoter (PEG-prom), human 
telomerase reverse transcriptase (hTERT), carcinoembryonic antigen 
promoter (CEA), urokinase-like Plasminogen activator receptor (uPAR), 
among others (Sadeghi and Hitt 2005; Fillat et al. 2011). 
Several features of tumor-associated vasculature are different from 
normal vasculature providing candidate targets for tumor-selective 
‘transcriptional targeting’. Tumor endothelia-selective expression of 
transgenes has been afforded using native promoters of genes such as 
VEGF, pre-endothelin-1 (PPE-1), ICAM-2, Flt-1, E-Selectin and KDR 
(Bazan-Peregrino et al. 2007).  
Another strategy for cancer gene therapy involves restricting gene 
expression with a conventional treatment methodology, such as 
chemotherapy or radiation. For example, the early growth response gene 
1 (EGR-1) promoter is inducible via external beam ionizing radiation or an 
iodine-125-labeled thymidine analog. The TNFerade (Ad.Egr-TNF) 
adenoviral vector has been evaluated in trials for patients with sarcomas, 
melanomas and cancers of the pancreas, esophagus, rectum and head 
and neck (Weichselbaum and Kufe 2009). 
Many enhancer-promoters derived from tissue-specific genes have been 
assessed for their ability to transcriptionally target first generation Ad 
vectors. Unfortunately, cis-acting viral sequences can sometimes distort 
the specificity of promoters and enhancers inserted into these vectors. 
Specificity can be restored in some cases by flanking the expression 
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cassette with additional polyadenylation signals or with insulator 
sequences, although these strategies are no successful with all enhancer-
promoters (Sadeghi and Hitt 2005). 
TSPs have the potential to decrease the toxicity of gene therapy for 
cancer and represent a powerful tool for the specific targeting of 
transgene expression to neoplastic cells. However, they do not modify the 
capacity of Ad infection since viruses are dependant on CAR for entry. 
4.1.5.2. Transductional targeting. 
Targeting therapeutic transgenes to the primary tumor and distant 
metastases requires delivery of the gene vector via the bloodstream. 
Unfortunately, following intravenous injection, adenoviral vectors are 
cleared very rapidly into the liver. Moreover, many viral vectors have an 
intrinsic tropism for non-target cells. Vectors capable of efficient delivery 
to tumoral cells must therefore usually be ‘detargeted’ in order to permit 
their persistence in the bloodstream sufficiently to enable access to 
target sites, and also ‘retargeted’ to enable infection of their target cells 
and tissues (Waehler et al. 2007). 
Several approaches have been developed to modify the vector tropism 
and redirect viral entry towards abundant receptors in tumoral cells. Two 
major strategies have been employed: i) targeting achieved via genetic-
structural manipulation of the Ad capsid, and ii) adapter molecule-based 
targeting. 
 Genetic modification of the proteins participating in viral entry. 
Several genetic attempts have been made to detarget Ad5 from murine 
liver by ablating CAR-binding, integrin-binding, heparan sulfate 
proteoglycan-binding sites and blood factors-binding via fiber 
modifications (Smith et al. 2002; Akiyama et al. 2004; Shayakhmetov et 
al. 2005; Bayo-Puxan et al. 2009). Results have shown that some 
detargeting can be achieved using genetic modifications, although the 
variety of infection pathways operative in vivo makes this less successful 
than expected. As previously mentioned, hexon protein mediates in vivo 
liver transduction; substitution of hexon protein of Ad5 for hexon protein 
of Ad3 has demonstrated reduced FX binding, decreased liver tropism, 
and improved antitumor efficacy (Short et al. 2010). 
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Genetic manipulation of capsid proteins is a conceptually elegant 
targeting approach, but genetic targeting efforts must work within 
narrow structural constraints since Ad tropism has to be modified 
without disrupting native molecular interactions indispensable for proper 
biological function. Rigorous structural analysis of adenoviral particles 
has exploited two separate locations within the knob domain that 
tolerate genetic manipulation without loss of fiber function, the C-
terminus and the HI-Loop. The introduction of the Arg-Gly-Asp (RGD) 
peptide into the HI loop of the knob domain of the fiber protein has been 
shown to target adenovirus to alpha-beta integrins and improves 
adenoviral transduction in pancreatic carcinoma (Jacob et al. 2005). Poly-
lysine ligand introduction into the C-terminal have successfully targeted 
adenovirus to heparan sulfates (Koizumi et al. 2003). Insertion of the 
protein transduction domain TAT into the HI-loop or C-terminus of fiber 
protein has also demonstrated enhanced infectivity of CAR-negative cell 
lines in vitro and in vivo (Han et al. 2007; Kurachi et al. 2007).  
Pseudotyping is the process of changing the natural tropism of a virus to 
that of another virus by switching their surface proteins. Genetic 
replacement of either the entire fiber or knob domain with other from 
another human Ad serotype that recognizes a cellular receptor other 
than CAR has been achieved. Adenovirus serotypes 11 and 35 present 
enhanced infectivity compared to Ad5 in pancreatic cancer (Glasgow et 
al. 2004). The combination of different fibers in the adenovirus, such are 
fibers 5 and 35, or fibers 16 and 50 mediate more efficient and specific 
gene transfer to pancreatic cancer cells (Toyoda et al. 2008; Kuhlmann et 
al. 2009).  
 Adapter molecule-based targeting. 
The adapter molecule-based concept is based on the formulation of 
molecular conjugates that link the vector with specific cellular receptors. 
Bispecific conjugates bear one component recognizing a region of the 
adenoviral vector and the other component specific for a cellular 
receptor, bypassing the native CAR-based tropism. They mainly consist 
on the fusion or conjugation of antibody fragments (Fab) with cell-
selective ligands or antibodies against target cell receptors such as EGFR 
(Glasgow et al. 2004). The fusion of a Fab fragment against the 
adenovirus knob region with the fibroblast growth factor (FGF-2) ligand, 
resulted in retargeting to FGFR positive cells, leading to improved 
transduction of pancreatic tumor cells in vitro and in vivo (Kleeff et al. 
2002; Huch et al. 2006). Adenoviruses retargeted with a bispecific fusion 
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protein composed of a soluble form of truncated sCAR fused to the EGF 
ligand led to enhanced gene transfer efficiency in pancreatic carcinoma 
cells (Wesseling et al. 2001).  
Although adapter-based targeting studies have shown promising results 
for retargeting adenovirus to new receptors, these Ad based delivery 
systems have more complex pharmacodynamics and kinetics. Therefore, 
one-component systems may be more easily applicable to human gene 
therapy trials. 
4.1.6. The therapeutic system TK/GCV. 
4.1.6.1. Mechanism of action. 
The herpes simplex virus thymidine kinase gene/ganciclovir prodrug 
system (TK/GCV) is a well-studied gene-directed prodrug activation 
approach for the treatment of cancer, presenting promising results 
against some malignant conditions (Immonen et al. 2004). It consists on a 
first step where the TK gene is delivered into to the tumoral cells, and a 
second step where the prodrug GCV is administered and is selectively 
activated by the TK enzyme (Moolten 1986).   
GCV, an acyclic analog of the natural nucleoside 2’-deoxyguanosine, is an 
antiviral agent used against human cytomegalovirus, herpes simplex type 
1 and 2, varicella zoster virus and Epstein-Barr virus (Faulds and Heel 
1990). In the TK/GCV system, the HSV-TK enzyme converts the 
nucleoside analog GCV to its monophosphate form, which is later 
converted by the cellular enzymes guanylate kinase and 
phosphoglycerate kinase, into GCV triphosphate (GCV-TP), which 
competes with endogenous dGTP for subsequent incorporation into 
DNA. GCV-treated cells undergo a round of DNA replication, doubling in 
number and incorporating GCV-TP into the nascent DNA strand. 
However, the lack of a complete sugar ring makes GCV a poor substrate 
for continuing chain elongation, triggers the formation of double-strand 
breaks and, finally, cause cell death by apoptosis (Fillat et al. 2003; 
Abate-Daga et al. 2010). Incorporation of GCV-TP also leads to cell death 
as a result of chromosomal aberrations and sister chromatid exchange. 
Adverse effects are minimal because of the selective cytotoxicity of the 
prodrug for HSV-TK expressing cells, since GCV is not phosphorylated by 
mammalian cellular kinases. Moreover, since the toxicity of the prodrug 
is associated with DNA replication, cell killing will mainly occur in rapidly 
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dividing cells (e.g. tumor cells) and not in normal tissue (van Dillen et al. 
2002). 
One of the most important findings in the validation of the HSV-TK/GCV 
system as a potentially powerful tool in cancer gene therapy was the 
discovery of the bystander effect (BE). BE is mediated by the transfer of 
GCV metabolites from the TK-expressing cells to the adjacent cells 
(Illustration 10). Early studies have shown that a transfection percentatge 
of only 1% was sufficient to kill virtually the complete cell population in 
vitro (Moolten 1986), and that complete tumoral regression was 
achieved when 10-50% of cells expressed TK (Culver et al. 1992; Caruso 
et al. 1993). The more accepted mechanism by which the bystander 
effect occurs is through gap junctions (GJIC) and is mediated by 
connexins (Vrionis et al. 1997). The reintroduction of connexins into poor 
communicating cells can help reestablish gap junction intercellular 
communication and enhance TK/GCV toxicity (Carrió et al. 2001; Jimenez 
et al. 2006). It has also been demonstrated that cell adhesion molecules 
as for example E-cadherin, have a marked influence on gap junction 
assembly and communication and consequently on the magnitude of the 
bystander effect (Garcia-Rodriguez et al. 2011).  
 
Illustration 10. TK/GCV mechanism of action and bystander effect. TK enzyme 
phosphorylates GCV to its monophosphate form (GCV-P), while cellular kinases 
phosphorylate GCV-P to di and triphosphate forms (GCV-PP, GCV-PPP). Then, 
GCV-PPP enters to the nucleus competing with dGTP for incorporation into DNA, 
blocks DNA synthesis, generates DSB and triggers apoptotic cell death. 
Bystander effect is produced by the transfer of GCV metabolites from 










GCV-P,    
-PP, -PPP
Transduced cell Neighboring cell
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Another proposed mechanism to mediate BE was through phagocytosis 
of apoptotic bodies. Apoptotic vesicles generated from dying TK-
expressing cells would be phagocytized by nearby intact unmodified 
tumor cells provoking their death (Freeman et al. 1993).  
In vivo experiments have demonstrated that the immune system also 
plays a role in the bystander effect. The immune response, generated 
due to the expression of non-human proteins or due to the death of 
transduced cells, can stimulate recognition of tumor antigens triggering 
the immune system and finally ending up with the death of non-
transduced cells (Barba et al. 1994). 
4.1.6.2. Strategies to enhance the therapeutic response of the 
TK/GCV system. 
Different approaches have been studied to augment the efficacy of the 
TK/GCV system. Some examples are the use of TK mutants, the 
improvement of GJIC facilitating TK intercellular spreading and the use of 
combined therapies. TK mutants have been engineered to overcome the 
low sensitivity of cells to GCV or other nucleoside analogues (Kokoris et 
al. 2000; Qiao et al. 2000; Black et al. 2001). Improvement of GJIC has 
been achieved pharmacologically by the use of drugs such as lovastatin 
or retinoic acid (Hossain and Bertram 1994; Touraine et al. 1998), or by 
the overexpression of connexins, such as Cx43 or Cx26 (Estin et al. 1999; 
Carrió et al. 2001), or E-cadherin (Garcia-Rodriguez et al. 2011). The use 
of combined therapies and the improvement of TK intercellular 
spreading are explained in detail below.  
 Combined therapies; TK/GCV and chemotherapy. 
Different combined therapies have been used to enhance the cytotoxic 
effect of the TK/GCV system. One strategy has been the combination of 
two suicide genes such as TK and Cytosine deaminase (CD) or TK and 
Cytochrome P450, that proved to be synergistic (Carrio et al. 2002; 
Freytag et al. 2007). Another strategy explored by several authors has 
been the combination with radiotherapy. Studies have reported that the 
TK/GCV treatment sensitizes the cell to radiation in vitro and in vivo 
(Nishihara et al. 1997; Hodish et al. 2009; Chen and Tang 2010). A triple 
combined strategy include the application of the replicative adenovirus 
Ad5-yCD/mutTK(SR39)rep-ADP expressing a mutant TK and the suicide 
gene (CD) together with radiotherapy (Freytag et al. 2007). The authors 
demonstrated that this suicide gene therapy strategy had the potential 
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to augment the effectiveness of pancreatic radiotherapy without 
resulting in excessive toxicity.  
Several chemotherapeutic agents have also been combined with the 
TK/GCV system. Some of them have afforded synergistic toxicity, such as 
topotecan, UCN-01, gemcitabine or temozolomide, while others were 
antagonistics such as Taxol or camptothecin (Fillat et al. 2003). The final 
effect of the combined therapy will very much depend on the 
interference or synergy between the operating mechanisms of action of 
each treatment and the genetic background of the tumor cell. In this line, 
Abate-Daga and collaborators demonstrated that TK/GCV –UCN-01 
combined therapy synergized or antagonized in vitro in different 
pancreatic cancerous cells depending on its sensitivity to the TK/GCV 
system (Abate-Daga et al. 2010).  
Two recent studies have demonstrated that the combination of TK/GCV 
with gemcitabine synergize in vitro and in vivo in cultured SW620 human 
colon carcinoma cells as well as in murine xenograft models (Boucher 
and Shewach 2005; Fridlender et al. 2010).  
  Intercellular spreading: the optimized Tat8TK/GCV system. 
It has been described that certain proteins or peptides, termed 
translocatory proteins, can efficiently translocate across the membrane 
of mammalian cells and are able to mediate the intracellular delivery of 
heterologous proteins fused to them, suggesting that a new type of 
bystander effect might take place in a given tissue. Examples of such 
proteins are the TAT protein of the human immunodeficiency virus, 
Drosophila antennapedia and herpes simplex virus VP22 (Harada et al. 
2006). The intercellular transfer function has been related to short 
peptides of highly basic residues that have been termed protein 
transduction domains (PTDs) (Beerens et al. 2003; Leifert and Whitton 
2003). The most widely used domain responsible for TAT translocation 
corresponds to the short basic region of 11 aa comprised by the residues 
47-57:YGRKKRRQRRR (Vives et al. 1997). However, Cascante et al showed 
that an 8 aa peptide also had PTD properties (Cascante et al. 2005). The 
common feature among these peptides is their highly cationic nature due 
to their high proportion of basic aminoacids. Several therapeutically 
active macromolecules have been fused to these PTDs and have shown 
to successfully transduce living cells, such as peptides, proteins, oligo 
DNAs, super magnet beads, liposomes,  phages and adenovirus (Harada 
et al. 2006). To date, fusion proteins with TATPTD have shown markedly 
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better cellular uptake than similar fusions with antennapedia or VP22 
(Wadia and Dowdy 2005). 
An approach to increase the cytotoxic effect of the TK/GCV therapy has 
been to provide the system with a new type of bystander effect resulting 
from the transduction capacity of an engineered TK protein. It consisted 
on the modification of the TK enzyme, by the fusion with the 8 aa TATPTD 
to generate the TAT8-TK protein. The increased cytotoxicity of the 
system was associated to a remarkable antitumor effect in pancreatic 
xenograft tumors (Cascante et al. 2005).  
4.2. Tumor ablation techniques. 
Several image-guided ablation techniques have been developed to treat 
patients with cancer not elected for surgery. These minimally invasive 
procedures can achieve effective and reproducible tumour destruction 
with low morbidity. Over the past two decades, several methods for 
chemical ablation or thermal tumor destruction have been developed 
and clinically tested. These include the injection of ethanol or acetic acid 
and the administration of localized heating (radiofrequency, microwave, 
laser ablation) or freezing (cryoablation) (Crocetti and Lencioni 2008). 
Ethanol injection induces coagulation necrosis of the lesion as a result of 
cellular dehydration, protein denaturation, and chemical occlusion of 
small tumour vessels. Its major limitation is the high local recurrence rate 
(about 30-40%). It is a well-established technique for the treatment of 
nodular-type hepatocellular carcinoma (HCC), leading to complete 
necrosis of about 70% of small lesions (Lencioni et al. 1995).  
Radiofrequency ablation (RFA) induces thermal injury to the tissue 
through electromagnetic energy deposition. RFA ablation has been the 
most widely assessed alternative to ethanol injection for local ablation of 
HCC (Lencioni and Crocetti 2005). Studies with patients with 
unresectable pancreatic adenocarcinoma have shown that RFA is a 
feasible palliative treatment that leads to tumor reduction and improved 
quality of life. However, its safety remains still under debate, with a high 
complication rate without a clear benefit of survival (D'Onofrio et al. ; 
Pezzilli et al. 2011). 
Microwave ablation is the term used for all electromagnetic methods 
using devices with frequencies greater than or equal to 900 kHz. 
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Although no statistically significant differences were observed in the 
efficacy when compared with RFA, a tendency favoring RFA was 
observed in local recurrences and complications rates (Lu et al. 2001). 
Cryosurgery uses freezing temperature to produce ice crystals which 
removes water from the cells and leads to deleterious events. Freeze-
thaw cycles produce cell death by necrosis in the central part of the 
cryogenic lesion and by induces apoptosis at the periphery (Gage et al. 
2009). 
Although some ablative techniques, such as RFA and microwave ablation, 
have been widely used in treating patients with liver, lung, and kidney 
tumors, they are limited in that they rely upon the indiscriminate use of 
thermal energy to induce necrosis of tumor cells, a process that can 
result in damage to nearby structures including blood vessels, bile ducts, 
and nerves. In addition, the blood flow of large vessels creates a heat 
sink effect that severely inhibits the ability to ablate cancer cells in the 
vicinity of large vessels (Patterson et al. 1998). These limitations are 
especially relevant to the pancreas which lies immediately adjacent to 
the superior mesenteric artery, portal vein, and common bile duct. 
Furthermore, the use of ablative therapies in the pancreas has largely 
been avoided altogether due to the possibility of thermal injury induced 
pancreatitis (Bower et al. 2011). 
Electrolytic ablation (EA) is a non-thermal technique that produces 
localized necrosis through local pH and electrochemical changes in the 
local microenvironment induced by a low voltage direct current. The 
technique is particularly safe especially close to major vessels. Although 
some clinical studies were carried out in patients with HCC, no clinical 
study has been performed in patients with pancreatic cancer (Gravante 
et al. 2011). 
Irreversible electroporation (IRE) is an emerging technology for non-
thermal tumor ablation. Electroporation utilizes targeted delivery of 
millisecond electrical pulses to induce permeabilization of cell 
membranes through nanoscale defects (Rubinsky et al. 2007). 
4.2.1. Irreversible electroporation. 
Electroporation is a non-thermal phenomenon in which cell membrane 
permeability to ions and macromolecules is increased by exposing the 
cell to high electric field pulses. If short pulses of low electric field 
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magnitude are applied, such permeabilization will be reversible and the 
treated cells will be viable after the procedure. However, when such 
artificially induced permeabilization is too high (range, 1500 to 3000 
volts), it causes a disruption of cellular homeostasis through dismantling 
the cell membrane wall with innumerable nanopores, and cells end up 
dying by necrotic or apoptotic processes (Rubinsky 2007). Optimum 
results are achieved when more than 80 electrical pulses are delivered, 
contrasting with the 8 pulses used in most reversible electroporation 
settings (Lee et al. 2010c).  
Studies in animal models have shown that IRE can ablate substantial 
volume of tissues and the efficacy of IRE to target breast, brain and 
hepatocarcinomas has already been evaluated and reported anti-tumor 
efficacy (Neal and Davalos 2009; Guo et al. 2010; Ellis et al. 2011). 
Recently, IRE has been proposed as a method for solid tumor ablation 
and it is now being assayed clinically for liver tumors (Lee et al. 2010b), 
lung tumors and kidney tumors (Ball et al. 2010). A Phase I clinical study 
to treat renal carcinomas with IRE has shown to be a safe technique that 
can offer some potential advantages over current ablative techniques 
(Pech et al. 2011). 
 Characteristics of IRE procedure. 
Several unique characteristics of IRE distinguish it from other currently 
available tumor ablative techniques, such as radiofrequency ablation, 
cryoablation or microwave ablation. 
Short ablation time: a typical IRE procedure for a solid tumor, with a size 
of approximately 3 cm in diameter takes less than one minute. If three or 
four overlapping ablations are required, total IRE treatment time is below 
5 minutes. The time required for RFA or Cryo range 15 to 60 min. This 
correlates with reduced anesthesia time, reduced post-ablation pain and 
decreased ablation-related complications (Solbiati et al. 2001; Lee et al. 
2010c). 
Preservation of vital structures within IRE-ablated zone: extracellular 
matrix is not damaged by IRE ablation. This has been proposed to lead to 
the preservation of structural scaffoldings of vessels and ducts (Maor and 
Rubinsky 2010).  
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Avoidance of heat/cold-sink effect: IRE treatment uses multiple ultra-
short pulses with brief intervals which increases therapeutic effect and 
decreases thermal effects (Davalos et al. 2005).  
IRE-induced complete ablation with well-demarcated margin: other 
thermal methods, such as RFA or MWA, create a “grey-zone” of ablation, 
where the most outer margin of ablation contains some living cells that 























“El motivo no existe siempre para ser alcanzado, sino para servir 
de punto de mira.” 
Joseph Joubert(1775-1824)  








The general objective of this thesis has been the development of novel 
antitumoral strategies for the treatment of pancreatic tumors.  
The work has focused on three major principles: i) improve adenoviral 
based therapies by exploring novel delivery routes and retargeting 
strategies, ii) search for synergistic treatments, and iii) evaluate novel 
approaches based on non-thermal ablative techniques . 
The specific objectives have been: 
I. To explore the effectiveness of adenovirus to transduce pancreatic 
tumors by a pancreatic intraductal injection method. 
II. To determine the efficacy of the antitumoral cytotoxic 
AduPARTat8TK/GCV gene therapy to treat Ela-myc pancreatic tumors 
by intraductal or intravenous delivery. 
III. To analyze the impact of the combined therapy AduPARTat8TK/GCV 
and gemcitabine in pancreatic tumors from Ela-myc mice. 
IV. To study the tumor selectivity of the matrix metalloproteinase 
activatable adenovirus AdTATMMP. 
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1. METHODS RELATED TO ADENOVIRUS 
MANIPULATION. 
All the adenoviruses used in this thesis are deficient in replication and 
derived from human adenovirus serotype 5 (Ad5). Their origin and 
characteristics are shown in Table 12. Some of them were generated as 
part of this thesis, while others were previously generated in our 
laboratory or kindly ceded by Dr. Ramon Alemany (IDIBELL-Institut Català 
d’Oncologia). 
1.1. Adenoviral vectors generation. 
We followed the protocol described by the group of Dr. Vogelstein (He et 
al. 1998) (Luo et al. 2007a) to generate adenoviral vectors. Two slightly 
different protocols were used to generate the adenoviral vectors 
depending on the type of viral modification assessed. In general terms, 
the gene of interest was cloned into a plasmid called pShuttle that 
contains homologous regions to the adenoviral genome. After 
homologous recombination between the recombinant pShuttle plasmid 
and a plasmid that contains the adenoviral genome (called pBackbone), 
the recombinant vector was generated. Then, the recombinant vector 
was linearized and transfected to HEK 293 cells, that produce the 
recombinant adenoviral particles. 
1.1.1. Generation of plasmid DNA constructs. 
In this thesis we have generated the viruses AduPARTat8TK, AdTAT and 
AdTATMMP. To generate the AduPARTat8TK virus, the cassete uPARp-
Tat8TK-SV40 polyA was cloned into the pShuttle vector (AdEasy™ XL 
Adenoviral Vector System, Stratagene) in three consecutive steps. Briefly, 
Tat8TK was inserted into the NotI/XhoI sites of the pShuttle vector; next, 
SV40 polyA tail was cloned into the XhoI/XbaI sites of the previously 
generated plasmid, and lately uPAR promoter fragment was inserted into 
the NotI sites, generating the plasmid pS-uPAR-TTK-pA. 
To generate AdTAT and AdTATMMP vectors we followed the protocol 
shown in Ilustration 11.  
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Ilustration 11. AdTAT and AdTATMMP generation scheme. pBSatYTRGE, pXK3.1 
and pVK50TL swa mut plasmids were kindly ceded by Dr. Ramon Alemany 
(IDIBELL-Institut Català d’Oncologia). 
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TAT and TATMMP sequences were cloned at the end of fiber sequence 
by two consecutive Touch-Down PCRs (TD-PCR), a modified PCR 
technique that reduces nonspecific amplifications. TAT sequence was 
amplified from the plasmid pBSatYTRGE by TD-PCR using the primers 
Fibra 1Fw and Rv 1.Tat and the PCR conditions listed in Table 1 and Table 
2, respectively. The PCR product, that contained the YTRGE mutations 
and TAT sequence, was cloned into a T-vector following the 
manufacturer instructions (pGEM®-T Easy Vector System I, Promega), 
generating the plasmid pGEM-T fiber TAT. Next, a second TD-PCR was 
employed to introduce the 3’-UTR region or the MMP-cleavable linker-
Blockage-3’ UTR region. We used the primers Fibra 1Fw and Rv2b.cua or 
Fibra 1Fw and Rv 2a.MMP-cua and the PCR conditions listed in Table 1 
and Table 2 to generate the plasmids pGEM-T Fiber TAT end and pGEM-T 
Fiber TATMMP end, respectively, after ligation of the PCR product into a 
T-vector. Confirmation of the correct sequence was assessed by direct 
sequencing. The cloned sequences were then digested with NcoI/MfeI 
and ligated to the pXK3.1 plasmid, a plasmid containing the wt fiber, 
generating the pShuttles pXK3.1 YTRGE TAT and pXK3.1 YTRGE 
TATMMP. 
 
 Primer sequences 
Primer 
Length 



















Table 1. Primer sequences employed to generate TAT and TATMMP fibers. 
Nucleotides complementary to template sequence are underlined; the 
remaining nucleotides correspond to primer tail. 
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 TAT MMP/End Cycles 
Step 1 95 C, 5 min 95 C, 5 min  
Step 2 95 C, 1 min 95 C, 1 min 
14 Step 3 
55,6 C, decrease 
0,5 C/cycle, 30 s 
60,2 C, decrease 
0,5 C/cycle, 30 s 
Step 4 72 C, 70 s 72 C, 80 s 
Step 5 95 C, 1 min 95 C, 1 min 
19 Step 6 48.6 C, 30 s 53.2 C, 30 s 
Step 7 72 C, 70 s 72 C, 80 s 
Step 8 72 C, 5 min 72 C, 5 min  
Table 2. TD-PCR conditions to generate TAT and TATMMP fibers. 
1.1.2. Homologous recombination in E.coli BJ5183 strain and 
transfection to HEK293 cells. 
To generate pAduPARTat8TK plasmid, 300 ng of pS-uPAR-TTK-pA were 
digested with 50 U of PmeI at 37C for 30h and purified using the 
QIAquick® PCR purification kit (QIAGEN). The digested plasmid was co-
transformed into Escherichia coli BJ5183, together with the pBackbone 
plasmid p3602 that contains the full length Ad5 genome. Positive clones 
corresponding to pAduPARTat8TK plasmid were identified by PacI 
digestion, and transformed into E.coli DH5. Correct sequence was 
verified by direct sequencing. 
To generate pAdTAT and pAdTATMMP plasmid, 1 µg of pXK3.1 YTRGE 
TAT or pXK3.1 YTRGE TATMMP were digested with 4U of XbaI and 4U of 
KpnI in two consecutive steps. The digested fragment was obtained from 
an agarose gel and purified using the QIAquick® Gel extraction kit 
(QIAGEN). In parallel, 4 µg of the pBackbone plasmid pVK50TL swa mut, 
that contains the full length Ad5 genome with the expression cassete 
CMVpGFPCMVpLuc cloned into the E1A region, were digested with 4U of 
SwaI enzyme at 37C for 16h, and purified by chloroform extraction and 
DNA precipitation with sodium acetate 3M. The digested fragments TAT 
or TATMMP and the linearized plasmid pVK50TL swa mut were co-
transformed into Escherichia coli BJ5183, and positive clones were 
identified by Fiber PCR (Primer sequences and PCR conditions listed in 
Table 6 and Table 5 ) and HpaI digestion, and transformed into E.coli 
DH5. Correct sequence was verified by direct sequencing. 
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 AduPARTAT8TK AdTAT/AdTATMMP 
pShuttle  
Plasmid pShuttle pXK3.1 
Digested with PmeI XbaI/KpnI 
pBackbone 
Plasmid p3602 pVK50TL cau Swa mut 
Digested with --- SwaI 
DNA quantities insert:vector 
- 45 ng : 100 ng 
- 80 ng: 100 ng 
-  2,5 ng: 10 ng 
-  40 ng: 160 ng 
Electroporation conditions 200 Ohms, 25 F, 2500 V 
Antibiotic of selection Kanamycin Ampicillin 
Screening by Digestion with PacI 
-  PCR of fiber 
-  Digestion with HpaI 
Table 3. Conditions of homologous recombination 
20 µg of pAduPARTat8TK, pAdTAT and pAdTATMMP were linearized by 
PacI digestion and 5µg of purified digestions were transfected into 
450.000 (AduPARTat8TK) or 250.000 (AdTAT and AdTATMMP) HEK293 
cells with SuperFect transfection reagent (QIAGEN). Cells and 
supernatant were harvested when cytophatic effect (CPE) was observed, 
then they were exposed to three cycles of freeze-thaw-vortex and 
centrifuged at 600 x g. The obtained supernatant corresponded to the 
first viral lysate (p1).  
1.1.3. Adenovirus large scale amplification. 
Large scale viral amplification was performed from viral lysate p1 as well 
as from purified virus. AduPARTat8TK vector was propagated on 911 cells 
and HEK293 cells, and the rest of the viruses in HEK293 cells. 
Several steps of viral amplification were carried out until obtaining a viral 
lysate able to lysate a HEK293 cell plate of 150 mm diameter (p150) in 
36-72h. To generate AduPARTat8TK virus, 30 p150 plates of HEK293 cells 
were infected with 0.5 mL of viral lysate p3 and CPE was complete at 
40h. To generate AdTAT and AdTATMMP viral vectors, we required much 
more steps of viral amplification as these viruses expressed modified 
fibers that hampered virus generation. Moreover, cells were infected at 
lower densities with the help of polybrene (4µg/mL), and they initially 
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required 5 days to show CPE. After several steps of viral amplification, 30 
p150 plates of HEK293 cells were infected with 0.5-2 mL of viral lysate 
p11 and CPE was complete at 48h. Cells were harvested, pelleted at 600 
x g, resuspended in PBS++exposed to three freeze-thaw-vortex cycles and 
centrifuged at 600 x g. The obtained supernatant corresponded to the 
crude extract. Fiber sequence integrity was verified by PCR and 
sequencing at different steps. 
To amplify a viral vector from the purified virus, a p150 plate of HEK293 
cells was infected with 1-4µl of purified virus. The obtained viral lysate 
was named as p1. 30 p150 plates of HEK293 cells were infected with 0.5-
1 mL of p1 or p2, and CPE was observed in 36-72h. Crude extract was 
obtained as previously described.  
REAGENTS: 
- PBS++: PBS 1x supplemented with 0.68 mM CaCl2·2H2O and 5 mM 
MgCl2·6H2O. 
1.2. Adenovirus purification. 
Adenoviral purification was performed in accordance with the standard 
method described by Becker et al in 1994 (Becker et al. 1994), based on 
ultracentrifugation of a cesium chloride (CsCl, Calbiochem) density 
gradient, which allows viral particles separation from non-desired 
elements present on the crude extract (empty viral capsids, cellular 
debris…). 
A CsCl gradient was carefully prepared in ultracentrifuge tubs (Beckman) 
as it is shown in Illustration 12. Tubs were centrifuged for 1.5 h at 35.000 
rpm, 15C in a SW41Ti (Beckman) rotor. Viruses were separated from the 
cellular debris in a blue-whitish band located between 1.25 and 1.35 g/ml 
CsCl solutions. Virus was collected with the help of a micropipette, mixed 
with CsCl 1.35 g/ml and centrifuged for at least 18h in the same 
conditions as before, which allows virus separation from empty viral 
capsids. Viral vector band was collected with the help of a micropipette, 
and desalted by filtration in a prepacked Sephadex™ G-25 column (PD-10 
Desalting columns, GE Healthcare). The eluted virus was mixed with 10% 
glycerol for its correct conservation. 








1.3. Titration of adenovirus. 
1.3.1. Titration by O.D at 260nm (vp/ml). 
Viral titration by optical density determines the number of viral particles 
without distinguish between infective and defective particles as the 
method is based on the absorbance by viral DNA at =260 nm.  
Purified virus diluted in lysis buffer (10 mM Tris, 1 mM EDTA, 0.1% SDS) 
was incubated for 10 min at 56C and centrifuged 30 s at 10.000 rpm. 
Supernatant O.D.260 was determined in a spectrophotometer 
(Nanodrop®) and viral titer was calculated as follows: 
  
  ⁄                                                          
    
1.3.2. Titration by hexon staining (pfu/ml). 
Viral titration by hexon staining determines the number of infective 
particles, and it is based on the number of hexon-positive cells of an 
infected monolayer after immunostaining against the viral protein hexon. 
50.000 HEK-293 cells previously seeded in a 96-well plate, were infected 
with 100 µl of a viral serial dilution bank (104-1012) in triplicate, and 
incubated for 20h at 37C. Hexon immunodectection was performed at 
this time. Briefly, cells were fixed with cold MeOH 20 min at -20C, 
washed three times 5 min with PBS++ 1% BSA, and incubated for 1h at 
37C with mouse anti-hexon hybridoma (dilution 1/3). Then, cells were 
Illustration 12. Scheme of CsCl gradient density tub. 
CsCl 1.25 g/ml (3 ml) 
CsCl 1.35 g/ml (3 ml) 
PBS
++
  (0.5 ml) 
Crude extract (5 ml) 
CsCl 1.5 g/ml (0.5 ml) 
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washed and incubated with the secondary antibody anti-mouse Alexa 
Fluor® 488 (Invitrogen) (dilution 1/400), 1h at R.T. After 3 washes with 
PBS++ 1% BSA, positive cells were counted under a fluorescence 
microscope (Observer/Z1; Zeiss). The titer of virus was calculated 
according the following formula: 
   
  
⁄   
                  
     
  
1.4. Adenovirus characterization. 
Purified viruses were tested for Replicative Competent Adenovirus 
(RCAs) absence by E1A PCR. AdTAT and AdTATMMP fiber integrity was 
also tested by PCR and sequencing. Moreover, fiber integrity was also 
analyzed at protein level by electrophoresis of the capsid proteins of 
adenovirus. 
1.4.1. Viral DNA extraction, PCR and sequencing. 
Viral DNA was obtained from cells previously infected with 1 l of 
purified virus or 1 ml of viral lysate. To analyze E1A expression, cells were 
different from HEK293 or 911. Infected cells were harvested and 
centrifuged 5 min at 1200 rpm. Pelleted cells were resuspended in 700µl 
of HIRT’s 1X solution and incubated for 1h at 56C. Then, 200 l of NaCl 
5M were added in agitation, and incubated 16h at 4C. Cellular debris 
were separated by centrifugation 30 min, 13.000 rpm at 4C. 
Supernatant was collected and DNA was extracted with phenol-
chloroform and precipitated with ammonium acetate 3M. DNA was 
resuspended in 25 l H2O. 
PCR was done to amplify the E1A and the fiber genes from the adenoviral 
genome. PCR reagents, reactive conditions and primer sequences are 
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Reagents Final concentration 
DNA 250 ng 
dNTP’s 1.25 mM 200 M 
Primer Fw 10 M 1 M 
Primer Rv 10 M 1 M 
Buffer 10x 1x 
Taq DNA pol 5U/l 0.025 U 
H2O Up to 20 l 
Table 4. PCR reagents. 
 Fiber E1A 
1. Initial Denaturalization 94 C, 5 min 94 C, 3 min 
2. Denaturalization 94 C, 30 s 94 C, 15 s 
3. Annealing 55 C, 30 s 58 C, 15 s 
4. Elongation 72 C, 30 s 72 C, 30 s 
5. Final elongation 72 C, 5 min 72 C, 5 min 
Cycles (Step 2-4) 35 35 
Table 5. Reaction conditions for Fiber and E1A viral gene PCR amplification. 
 Primer sequences Product size 
Fiber 







913 nt Fibra 4Rv GTATAAGCTATGTGGTGGTGG 
E1A 
E1A Fw ATCGAAGAGGTACTGGCTGA 
416 nt 
E1A Rv CCTCCGGTGATAATGACAAG 
Table 6. Primer sequences of Fiber and E1A PCR. 
Fiber sequencing was carried out using as a template the fiber PCR 
product purified with the commercial QIAquick® PCR purification Kit 
(QUIAGEN). Sequencing mixture was prepared mixing 5 l of purified PCR 
with 1.5 µl of primer 3.2 µM (Fibra 1Fw or Fibra 4Rv) and 3 µl of Big Dye 
3.1 (Applied Biosystems; contains dNTPs, polymerase and marked 
ddNTPs). Reaction conditions were: 
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- Initial Denaturalization: 94C, 5min. 
- 35 cycles:  94C 30s ;   50C 15s ;   60C 4min. 
- Final elongation:  60C, 7min. 
Sequence reactions were purified in a Sephadex G-50 column and dried 
out in a SpeedVac® concentrator (Thermo Electron Corporation). 
Sequences were analyzed in an automatic DNA sequencer by Unitat de 
Seqüenciació i Anàlisi from the Servei de Genòmica of the Universitat 
Pompeu Fabra.  
REAGENTS: 
- HIRT’s 2X solution: 10 mM Tris pH 8.0, 20 mM EDTA, 1.2% SDS. 200 
g/ml proteinase-K was added to HIRT’s 1x. 
1.4.2. Electrophoresis of the capsid proteins of Ad. 
1010 purified viral particles were diluted in 6x Laemmli buffer, incubated 
for 5 min at 95°C and separated by 10% SDS-polyacrylamide gel. Proteins 
were detected by silver staining, which allows protein detection in the ng 
range. Silver staining was carried out as described in (Chevallet et al. 
2006). Briefly, proteins were fixed with Fixation solution for 3h in 
agitation. After three washes with EtOH 50% of 20 min each, the 
polyacrylamide gel was soaked in Pretreatment solution for 1 min at R.T 
to increase sensitivity and contrast of the staining. Gel was washed three 
times with deionized water for 20s. Staining was performed by gel 
incubation in pre-cooled Staining solution for 16h at 4C. Gel was washed 
three times with deionized water for 20s and incubated in Development 
solution at R.T until bands appeared (5-10 min). Development reaction 
was stopped by incubation with deionized water for 2 min and Fixation 
solution for 10 min. Gel was scanned using a flat-bed scanner set in the 
transillumination mode (Epson Expression 1680 Pro). 
REAGENTS: 
- Laemmli 6X buffer: 350 mM Tris-HCl pH 6.8, 30% glycerol, 10% (w/v) 
SDS, 0.6 M DTT, 0.012% Bromophenol Blue 
- Fixation solution: 40% EtOH, 10% acetic acid. 
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- Pretreatment solution: 0.02% Na2S2O3, 30% EtOH, 6.8% sodium 
acetate. 
- Staining solution: 0.02% AgNO3, 0.015% formaldehyde.  
- Development solution: 6% Na2CO3, 0.0004% Na2S2O3, 0.02% 
formaldehyde. 
 
2. METHODS RELATED TO RNA 
MANIPULATION.  
2.1. RT-PCR. 
RT-PCR technique was used to analyze gene expression of Keratin7, 
Keratin 19, Elastase-2, Trypsin, c-Myc, and uPAR genes on Emyc primary 
cultures and mouse pancreatic tissue. Gdx and 15S genes were used as 
controls. 
Total RNA was prepared from adherent cell cultures and mouse 
pancreatic tissue using RNeasy® Mini kit (QIAGEN). To avoid genomic 
contamination of pancreatic tissue samples, they were treated with 
DNAse (TURBO DNA-free™, Ambion®), as described by manufacturer's 
protocol. 
1 µg of total RNA from each sample was reverse transcribed with a 
RETROscript® kit (Ambion®). 2 µl of cDNA was PCR amplified using 200 
µM dNTPs, 1X PCR buffer (Roche Diagnostics), 0.025 U Taq DNA pol 
(Roche Diagnostics) and 2 µM of the corresponding primers listed in 
Table 7. PCR conditions used to characterize Emyc primary cultures were 
the same for the analyzed genes and consisted on an initial denaturation 
step of 5min at 94C followed by 30 cycles of 94C 30 s, 57C 30 s, 72C 
30 s, and a final elongation step of 5min at 72C. PCR conditions used to 
analyze uPAR gene expression in pancreas of Ela-myc and C57Bl6/J mice 
were slightly different and consisted on 40 cycles of 94C 30 s, 60C 30 s, 
72C 30 s; initial denaturation step and final elongation step conditions 
were mantained. PCR products were run in a 2% agarose gel stained with 
ethidiumbromide. 
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 Gene Primer sequences 
Product 
size 
































Table 7. Primers used for RT-PCR analyses and PCR product sizes. Underlined 
mismatch with mouse cDNA template. 15S gene primers were supplied by the 
RETROscript® kit (Ambion®). 
 
3. METHODS RELATED TO PROTEIN 
MANIPULATION. 
3.1. Western Blot. 
Western Blot technique was used to analyze the expression of Connexin 
43 (Cx43) and matrix metalloproteinase 2 and 9 (MMP2/9) in cell extracts 
and cell supernatants, respectively. 
Cell extracts were obtained as follows: confluent cultures were collected 
at 4C and resuspended in Cx43 lysis buffer containing 1% Complete Mini 
Protease Inhibitor (Roche Diagnostics) and phosphatase inhibitors (20 
mM Na4P2O7 and 100 mM NaF) and sonicated for 5 s at 50 W three times. 
Cell lysates were centrifuged for 15 min at 14000 rpm and protein 
concentration determined from the cleared lysate (BCA assay; Pierce-
Thermo Fisher Scientific).  
MATERIALS AND METHODS   
 66 
Cell supernatants were obtained from confluent cultures grown in plates 
of 60 mm of diameter with 1 ml of medium without FBS. Conditioned 
media samples were concentrated using Microcon® centrifugal filters 
(ultracel YM-30 membrane, Millipore) up to a final volume of 30 µl.  
60 µg of total protein from cell extracts, 15 µl of concentrated 
supernatant or 100 ng of purified MMP2 plus 100 ng of purified MMP9 
(Calbiochem) were mixed with loading Laemmli 6x buffer and incubated 
at 98C for 10 min. 
Proteins were separated in a 12% or 8% SDS-PAGE gel (Cx43 or MMP2/9, 
respectively) and transferred onto nitrocellulose membranes (Hybond™ 
C Extra, Amersham Biosciences) by standard methods. The membranes 
were blocked in 10% non-fat dried milk dissolved in TBS-T for 1 h at room 
temperature and then incubated overnight at 4°C with the primary 
antibody anti-Connexin43 or anti-MMP2 diluted in 5% powdered milk in 
TBS-T (specific antibodies, dilutions and incubation conditions are shown 
in Table 8). Protein loading from cell extracts was monitored using a 
mouse antibody against α-tubulin. Incubation with anti-mouse IgG/HRP 
(horseradish peroxidase) antibodies (Dakocytomation) was performed at 
room temperature for 1 h. Membranes were rinsed in TBS-T and 
antibody labeling was detected by chemiluminescence with an ECL 
detection system (Promega)  following the manufacturer's instructions. 
Chemiluminiscence was determined with a LAS-3000 image analyzer (Fuji 
PhotoFilm Co.). MMP9 expression was analyzed after MMP2 detection 
with the ECL system. The membrane was washed 3 times in TBS-T for 30 
min and incubated with the primary antibody anti-MMP9 for 2h at R.T. 

















 sc-21733 Mouse 1:100 2h, R.T 
-tubulin Sigma T9026 Mouse 1:2000 1h, R.T 
Mouse IgG Dakocytomation P0260 Rabbit 1:2000 1h, R.T 
Table 8. Antibodies and incubation conditions used in WB. 
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REAGENTS: 
- Cx43 lysis buffer: 10 mM Na2HPO4 (pH 7.2), 150 mM NaCl, 2 mM EDTA, 
1% Triton X-100, 1% sodium deoxicholate, 1% SDS.  
- Laemmli 6X buffer: 350 mM Tris-HCl pH 6.8, 30% glycerol, 10% (w/v) 
SDS, 0.6 M DTT, 0.012% Bromophenol Blue. 
- Electrophoresis running buffer: 25 mM Tris Base, 200 mM glycine, 
0.1% (w/v) SDS. 
- Transference buffer: 25 mM Tris-HCl pH 8.3, 200 mM glycine, 20% 
(v/v) methanol. 
- TBS-T: 10 mM Tris HCl pH 7.5, 100 mM NaCl, 0.1% Tween-20. 
3.2. Zymography. 
106 cells were seeded in plates of 60 mm of diameter and allowed to 
adhere. Next day media was replaced by 1 ml of serum-free medium. 
Conditioned medium was harvested 24h later and concentrated using 
Microcon® centrifugal filters (ultracel YM-30 membrane, Millipore) up to 
30 µl. 15 µl of concentrated supernatant or 2 ng of purified MMP-2 plus 2 
ng of purified MMP9 were mixed with 15 µl of zymography loading 
buffer 2x and incubated for 10 min at R.T. Gelatin zymography was 
performed as described in (Kleiner and Stetler-Stevenson 1994; Leber 
and Balkwill 1997). Briefly, total proteins were separated on 10% SDS-
PAGE gels containing 0.1% gelatin. Next, gels were treated with 2.5% 
Triton X-100 at R.T for 1h to remove SDS and then incubated overnight at 
37C in Developing buffer. Gels were stained with 5% Coomassie Blue R-
350 (Phastgel™ Blue R-350, GE Healthcare Life Science) in 30% methanol, 
10% glacial acetic acid at room temperature for 30-90 min. The activities 
of enzymes were identified as clear gelatin-degrading bands against the 
blue background. Gels were scanned using a flat-bed scanner set in the 
transillumination mode (Epson Expression 1680 Pro).  
REAGENTS: 
- Zymography loading buffer (2x): 125mM Tris–HCl pH 6.8, 20% (v/v) 
glycerol, 4% (w/v) SDS, 0.005% (w/v) bromophenol blue. 
- Developing buffer: 10x Zymogram Development Buffer (Bio-Rad) (50 
mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl2) diluted in water. 
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3.3. Luciferase Assay. 
Firefly luciferase transgene expression was measured in cell lysates or in 
liver and pancreatic tissues. Cell lysates were prepared with 50 µl of 
Reporter Lyses buffer (RLB, Promega) in accordance with the 
manufacturer's instructions (Luciferase Assay System; Promega). Liver or 
pancreatic tissues were mechanically homogenized in a cold potter with 
liquid nitrogen to obtain a fine powder. Powder was mixed with lyses 
buffer (Cell culture Lysis Reagent, Promega) (400 µl of lyses buffer per 
100 mg of tissue) and incubated for 15 min at 25 C. Samples were 
centrifuged for 10 min, 16000 x g at 4 C and supernatants were collected. 
Luciferase activity from 10 µl of in vitro or in vivo samples was measured 
in a Centrol LB 960 microplate luminometer (Berthold Technologies) or a 
tube luminometer Autolumat Plus LB953 (Berthold Technologies) 
respectively, and normalized to total protein levels. Protein 
concentration was determined with a BCA protein assay (Pierce 
Biotechnology). 
3.4. MMP-Cleavable-Peptide (MCP). 
3.4.1. MCP and MCP* preparation. 
The MMP-Cleavable-Peptide (MCP) and the MCP peptide linked to 
fluorescein (MCP*) were produced by the group of Dr. David Andreu 
(Proteomics and Protein Chemistry Unit, Department of Experimental 
Health Sciences). Lyophilized peptides were dissolved in Tris-HCl 100 mM 
pH 7.4 and prepared at 0.5 mM and 1 mM respectively. 





MCP 0.5 mM 1.075 mg 3528,78 Da 600 µl 
MCP* 1 mM 1.5 mg 4010 Da 374.1 µl 
Table 9. MCP and MCP* properties. 
3.4.2. MCP and MCP* cleavage by MMP2. 
30 µl of MCP or MCP* were incubated with 2.5 µg of recombinant MMP2 
(Calbiochem) in 45 µl of 50 mM Tris-HCl pH 7.4 at R.T for 4h or 9h 
respectively. MCP samples were obtained at 30 min, 60 min and 240 min 
and reaction was stop by the addition of an acidic solution. MCP cleavage 
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was analyzed by HPLC (High-Performance Liquid Chromatography) by the 
group of Dr. David Andreu (Proteomics and Protein Chemistry Unit, 
Department of Experimental Health Sciences). 
 
 
4. CELL CULTURE. 
4.1. Cell lines. Maintenance and culture conditions. 
1) Cell lines used to generate and amplify adenoviral vectors: 
HEK293: cell line derived from human embryonic kidney tissue, 
established by Graham et al (Graham et al. 1977). 
911: cell line derived from human embryonic retinoblasts. It was 
generated by the group of Dr. Van Der Erb (Fallaux et al. 1996). 
The two cell lines express the E1A gene of the Adenovirus type 5. 
They are commonly used for the generation, amplification and 
titration of recombinant adenoviruses. 911 cell line is used because 
reduces the probability of E1A recombination with the transgene 
cloned into the E1A region of the produced adenovirus. Both cell 
lines were kindly provided by Dr. Ramon Alemany’s laboratory 
(IDIBELL-Institut Català d’Oncologia, Barcelona). 
2) Cell lines derived from human tumors: 
PANC-1: cell line derived from a human pancreatic ductal carcinoma. 
ATCC nº: CRL-1469. 
RWP-1: cell line derived from a hepatic metastasis originated from a 
human pancreatic ductal adenocarcinoma. It was generated by 
subcutaneous implantation of an hepatic metastasis fragment in 
nude mice (Dexter et al. 1982). This cell line was kindly provided by 
Dr. FX. Real (IMIM, Barcelona). 
BxPC-3: cell line derived from a human pancreatic adenocarcinoma. 
ATCC nº: CRL-1687. 
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NP18: cell line derived from a hepatic metastasis originated from a 
human pancreatic ductal adenocarcinoma. It was generated by 
orthotopic implantation of an hepatic metastasis fragment in the 
pancreas of nude mice. This cell line was generated and kindly ceded 
by Servei Digestiu of the Hospital de la Santa Creu i Sant Pau de 
Barcelona (Reyes et al. 1996).   
HT-1080: cell line derived from a fibrosarcoma. ATCC nº: CCL-121™.  
This cell line was kindly provided by Dr. Ramon Alemany (IDIBELL-
Institut Català d’Oncologia, Barcelona). 
PANC-1-Luc and BxPC-3-Luc: luciferase-expressing cells previously 
generated in our laboratory. Parental cells (PANC-1 and BxPC-3) 
were transduced with luciferase recombinant retrovirus, selected in 
0.2 mg/ml hygromycin, cloned and tested for luciferase expression. 
3) Cell lines derived from mouse tumors: 
266-6: pancreatic acinar cell line derived from a pancreatic tumor 
grown in a transgenic mice that express the SV40 T antigen under 
the control of Elastase I promoter (Ornitz et al. 1985). This cell line 
was obtained from the cell bank at the IMIM-Hospital del Mar. 
Emyc-1, Emyc-3 and Emyc-10: these cell lines were established in 
our laboratory from pancreatic tumors of Ela-myc transgenic mice. 
Three Emyc cell lines were generated from eleven primary cultures 
of pancreatic tumors from six independent Ela-myc mice of 2.5-4 
months of age. In this work tumor characteristics, medium 
conditions, type of plates and passage dilutions were assessed. 
Fragments from different parts of the pancreatic tumor (white or 
red) were mechanically minced and incubated in primary culture 
medium in p60 plates at 37C, in a humid atmosphere of 5% CO2. 
Media was first changed at 4-8 days after establishing the primary 
culture and first passaged at 11-20 days. Cells were trypsinized for 
30-60 min, resuspended in primary culture medium and filtered in a 
cell strainer (ref 352350, BD Falcon™); cells were plated in special 
dishes (ref 353803, BD Falcon™). Medium was changed once per 
week, and cells were passed when reached confluence. Cultures 
generated from a white tumor produced a viable primary culture; 
however, it was not possible to establish any primary culture from 
red fragments. Cultures required about 10 passages to get rid of 
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fibroblasts. Around passage 20, a primary culture was considered an 
established cell line (4-5 months after initial plating). 
4) Non tumoral cell lines: 
NIH-3T3: cell line derived from mouse embryo fibroblasts. ATCC nº: 
CRL-1658. 
 
All cell lines were maintained at 37C in a humid atmosphere of 5% CO2.  
- DMEM: all previously mentioned cells, except NP18, were growth in 
Dulbecco’s Modified Eagle Medium (DMEM), that contains L-glucose 
(4500 mg/l), L-glutamine and sodium piruvate; supplemented with 
10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin and 2 mM L-
glutamine (Gibco-Invitrogen).  
- RPMI: NP18 cells were grown in RPMI 1640 medium (Roswell Park 
Memorial Institute), that contains L-glucose (4500 mg/l), glutamax 
and sodium piruvate; supplemented with 10% FBS, 100U/ml 
penicillin, and 100g/ml streptomycin (Gibco-Invitrogen).  
- Primary culture medium: DMEM supplemented with 20% FBS, 1x 
Non Essential Aminoacids (NEA), 20 ng/mL EGF, 200 U/ml penicillin, 
200 g/ml streptomycin and 0.25 µg/mL fungizone. 
4.2. Drug treatments. 
4.2.1. Ganciclovir (Cymevene®, Roche) 
- In vitro experiments (10 mg/ml): stock solution (1000x) was 
prepared diluting 10 mg of the commercial Cymevene® (Roche) in 1 
ml of injectable water (B.BRAUN), and filtered with 0.22 m filters. 
- In vivo experiments (10 mg/ml): GCV was administered to mice at 
100 mg/kg. Stock solution was prepared at 10 mg/ml in saline 
(B.BRAUN) and filtered with 0.22 m filters.  
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4.2.2. Gemcitabine (GEMZAR®, Lilly Co.) 
- In vitro experiments (10 mM): 10 mM stock solution was prepared 
diluting 6.18 mg of GEMZAR® in 1 mL of injectable water (B.BRAUN), 
and filtered with 0.22 m filters. The commercial drug GEMZAR® 
contains 43.8 g of active principle in 100 g of GEMZAR®. The stock 
solution was stored at RT for 35 days. 
- In vivo experiments (16 mg/ml): GE was administered to mice at 160 
mg/kg. Stock solution was prepared at 16 mg/ml in saline (B.BRAUN) 
and filtered with 0.22 m filters. The solution was stored at RT for 
35 days. 
4.2.3. Dose-response analyses.  
Cells were treated with gemcitabine alone, AduPARTat8TK plus GCV 
alone or gemcitabine plus AduPARTat8TK and GCV. Three days later, cell 
viability was measured and quantified by a colorimetric assay system 
based on the tretrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT; Roche Molecular Biochemicals), in 
accordance with the manufacturer’s instructions. Results were expressed 
as the percent absorbance determined in treated wells relative to that in 
untreated wells. ID50 values were estimated from dose–response curves 
by standard non-linear regression, using an adapted Hill Equation (GraFit 
v3.0, Erithacus Software). 
4.2.4. Drug interaction analysis. 
The induction of synergism, addition or antagonism between 
gemcitabine (GE) and TK/GCV treatments was analyzed by Combination 
Index (CI) analysis as previously described (Chou and Talalay 1984). 
Combination Index analysis is one of the most popular methods for 
studying in vitro drug interactions in combination cancer chemotherapy. 
Dose–response curves were constructed for the treatments with either 
GE, TK/GCV or a combination of both, from which Hill coefficient and ID50 
values were calculated by non-linear regression based on a modified Hill 
Equation using the GraFit v3.0 software. Estimated equation was used to 
calculate the doses of each treatment, administered independently or in 
combination, necessary to induce an inhibition (IF: Inhibitory Fraction) of 
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and 90%. 
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Combination Index value was calculated as indicated below. CI values <1 
indicates synergism, CI values =1 indicates addition, and CI values >1 
indicates antagonism between treatments. 
       
       
     
   
       
   
  
     = Combination index, for a given IF. 
       = Dose of AduPARTat8TK/GCV needed to produce 
given IF when applied in combination with GE.  
DAdTK = Dose of AduPARTat8TK/GCV needed to produce given 
IF when applied alone. 
DGE,AdTK  = Dose of GE needed to produce given IF when applied 
in combination with AduPARTat8TK/GCV. 
DGE  = Dose of GE needed to produce given IF when applied 
alone. 
 
5. METHODS RELATED TO ANIMAL 
MANIPULATION. 
Animal procedures met the guidelines of European Community Directive 
86/609/EEC and were approved by the Comité de Experimentación 
Animal (CEEA) of the PRBB (Parc de Recerca Biomèdica de Barcelona). 
5.1. Animals  
Animals were housed in plastic cages in controlled environmental 
conditions of humidity (60%), temperature (22°C ± 2°C) and light with 
food and water ad libitum. Transgenic Ela-myc mice and 
immunodeficient nude mice (Athymic Nude-Foxn1nu, Harlan) were used 
in this thesis. Immunodeficient mice were males of 6 weeks of age and 
20-30 g of weight. TgEla-myc mice were males and females of 11-17 
weeks of age and 16-30 g of weight. To maintain the Ela-myc colony, Ela-
myc males were mated to C57Bl/6J females and progeny was genotyped 
by PCR analysis. 
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5.1.1. Ela-myc mice genotyping. 
Mouse DNA was extracted from a tail fragment by heating in 300 µl of 
basic solution (50 mM NaOH) for 30-60 min at 98C. 30µl of 
neutralization solution (1M Tris-HCl pH 8.0) was added and tail debris 
were centrifuged at 13000 rpm for 5 min. Genotyping of the progeny was 
performed by multiplex PCR analysis using 1 µM c-Myc primers and 0.5 
µM Gdx primers (primer sequences shown in Table 10). PCR conditions 
are indicated below. Products of PCR were run in a 2% agarose gel for 30-
60 min at 95V. 
- Initial Denaturalization: 94C, 5min. 
- 35 cycles:  94C, 20 s  ;   63C 20 s  ;   72C 20 s. 
- Final elongation:  72C, 7 min. 









Table 10. Primers for Ela-myc mice genotyping. 
5.2. Orthotopic tumor model. 
Orthotopic human pancreatic cancer xenografts were generated as 
previously described (Kim et al. 2009). Nude mice were anesthetized with 
a mixture of isofluorane and oxygen, and placed on their right side. 
Buprenorphine (0.05-0.1 mg/Kg) was administered intraperitoneally 20 
min before surgery. The left side was sterilized with iodine solution and a 
minilaparatomy of 1 cm was performed. The spleen/pancreas was 
externalized and 5x105 BxPC-3-Luc cells (50 µl) were injected using a 29G 
needle into the tail of the pancreas and passed into the body/head 
region. Cell injection formed a fluid-filled region within the pancreatic 
parenchyma. The needle was removed and Histoacryl® (B.Braun) was 
added to avoid leakage. Pancreas/spleen was internalized, the muscle 
layer was closed with interrupted 4-0 silk suture and the overlying skin 
with Autoclips® (Stoelting Europe). Iodine solution was applied to the 
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region of surgery, and animals were maintained under a heating source. 
Autoclips® were removed 4-7 days after surgery. 
5.3. Delivery routes. 
Buprenorphine, meloxicam, D-luciferin, ganciclovir and gemcitabine were 
administered intraperitoneally (i.p) with a 26G needle. 
Saline solution or glucosaline was administered subcutaneously (s.c) or 
intraperitoneally with a 26G needle. 
Viruses were systemically or locally administered. For systemic 
administration, 5·1010 vp of virus diluted in saline (200µl) were injected 
intravenously into the lateral vein of the tail with a 29G needle. For 
locally administration, 1010 vp, 5·1010 vp or 1011 vp of virus diluted in 
saline (50 µl) were intraductally administered with a 30G needle. 
5.3.1. Intraductal injection into the common bile duct. 
Ela-myc mice received i.p 20 min before 
surgery an analgesia mixture composed of 
buprenorphine (0.05-0.1 mg/Kg) and 
meloxicam (1-2 mg/Kg). Mice were 
anesthetized with a mixture of isofluorane 
and oxygen. The abdominal region was 
shaved and sterilized with iodine solution. A 
laparatomy of 2 cm was done in the 
abdominal region below the xiphoid. Skin and 
muscular layers were maintained separated 
by the use of a colibri retractor of 9 mm of 
teeth width (Fine Science Tools, FST). With a 
pair of ring forceps duodenum was exposed and the ampulla of Vater 
(also named as hepatopancreatic ampulla) was localized. Common bile 
duct was clamped with a micro serrefine (FST) near to the liver to avoid 
infection of the liver. Then a 30G needle was inserted into the ampulla of 
Vater, passed through the common bile duct a pair of mm and clamped. 
50 µl of virus were slowly injected (approximately 10 µl every 10 s), and 1 
min was left before removing the duodenal clamp to avoid virus 
regression into the duodenum. Histoacryl® (B.Braun) was added with the 
help of a 26G needle to close the wound on the papilla. One minute later, 
the clamp of the bile duct was removed, the organs were internalized 
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and the muscle layer was closed with interrupted 4-0 silk suture and the 
overlying skin with Autoclips® (Stoelting Europe). Iodine solution was 
applied to the region of surgery, and animals were maintained under a 
heating source. 
Meloxicam was readministered the day after surgery to avoid pain. 
Autoclips® were removed 4-7 days after surgery. 
5.4. Irreversible Electroporation (IRE) 
Animals received buprenorphine (0.05-0.1 mg/Kg) 20 min before surgery. 
Nude mice were anesthetized with a mixture of isofluorane and oxygen. 
A minilaparotomy incision in the left dorsal 
side of the mouse was performed to expose 
the BxPC-3-Luc tumor within the body/tail of 
the pancreas. Tumor nodules were identified 
visually or by palpation and were measured 
with an electronic caliper. A partially 
conductive gel (Aquasonic 100 Sterile, Parker 
Laboratories) was applied and the nodule was 
gently squeezed between the tweezertrodes. 
Two electrode setups were employed depending on the size of the tumor 
nodule. Then, an IRE pulse train was applied (see below). 
Pancreas/spleen were internalized and the muscle layer was closed with 
interrupted 4-0 silk suture, and the overlying skin with Autoclips® 
(Stoelting Europe). Iodine solution was applied to the region of surgery, 
and animals were maintained under a heating source. 
The IRE pulse was delivered by a commercial electroporator (ECM830, 
BTX Instrument Division). The pulse consists on deliver sequences of ten 
pulses of 2500 V/cm (i.e. distance between plates × 250 V) with duration 
of 100 µs and repetition frequency of 1 Hz. The whole electroporation 
treatment consisted of ten of those ten pulses sequences (i.e. 100 pulses 
in total). Between those sequences, a manual pause of 10 seconds was 




IRE pulse train = 10 x Sequences.       10s between sequences. 
Sequence = 10 pulses x 2500V/cm.   100µs each pulse and 1s 
between pulses (1Hz). 
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5.5. Bioluminescence. 
In vivo luciferase expression was visualized and quantified in living 
animals using an in vivo bioluminescent system (IVIS50; Xenogen). 
Briefly, the substrate firefly D-Luciferin (Xenogen) was administered i.p 
(32 mg/kg) and 10 min later animals were anesthetized with a mixture of 
isofluorane and oxygen preparation. Mice were introduced into the 
IVIS50 coupled to an inhaled anesthesia system, and images were 
captured. All images from the same experiment were obtained under the 
same measurement conditions. To study ex vivo luciferase expression, 
organs were rapidly removed from animals recently measured in the IVIS 
system, placed in a dish and introduced inside the black cage to capture 
the images. 
Luciferase activity was quantified from non-saturated captured images 
using the software Living Image 2.20.1 Igor Pro4.06A. Images were 
represented as photons per second per square centimeter and per 
steradian. ROI quantification was expressed as total flux (photons/s). 
5.6. Mouse sample analysis.  
5.6.1. Organs and tumors dissection. 
Animals were euthanized by cervical dislocation or by CO2 inhalation, 
organs and tumors were collected and in some cases photographs were 
taken. Depending on their posterior analysis, tissue was frozen at -80ºC, 
fixed on 4% Phosphate-buffered formaldehyde (PFA) or included/frozen 
in OCT (Tissue Tek, Akura Finetek). 
5.6.2. Measurement of Ela-myc pancreas/tumor volume. 
Pancreas of Ela-myc mice was measured with an electronic caliper and 
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5.6.3. Biochemical analysis in serum samples. 
Blood samples were collected by cardiac puncture or from the orbital 
sinus. In both cases the animal was anesthetized with a mixture of 
isofluorane and oxygen. Cardiac puncture was a terminal procedure, 
while retro-orbital puncture was performed in time-course experiments. 
Cardiac puncture was done using a 26 gauge needle. Retro-orbital 
puncture was done using a micro haematocrit blood tube (BRAND); 200 
µl of glucosaline (B.BRAUN) were injected s.c to hydrate the animal.  
To obtain the serum, blood samples were allowed to clot for 30 min at 
R.T and then were centrifuged at 3600 rpm 15 min. Serum was collected 
and stored at -20C until its analysis. Serum levels of ALT, AST, lipase, 
amylase and glucose were analyzed by Servei de Bioquímica Clínica 
Veterinària of the Facultat de Veterinària of the  Universitat Autònoma 
de Barcelona. 
 
6. HISTOLOGICAL TECHNIQUES. 
6.1. Sample processing.  
Preparation of paraffin embedded samples, as well as their sectioning 
and sectioning of frozen samples were done by the Histology Unit of the 
CRG (Centre de Regulació Genòmica). Paraffin-embedded sections were 5 
µm thick and frozen sections were 10 µm thick. 
Hematoxylin/eosin staining of paraffin-embedded sections was used to 
evaluate tissue structure and was performed by the Histology Unit of the 
CRG (Centre de Regulació Genòmica). 
6.2. Immunohistochemistry (IHC). 
Five-micrometer paraffin-embedded sections were deparaffinized, 
rehydrate, permeabilized in PBS-T (PBS supplemented with 0.3% Triton 
X-100) and treated 25 min with boiling 10 mM citrate buffer (pH 6.0) for 
antigen retrieval. After washing twice with PBS-T, tissue sections were 
incubated with blocking solution for 1 h at R.T. Sections were then 
incubated overnight at 4°C with the primary antibody in diluting solution. 
Subsequently, sections were washed twice in PBS-T and incubated in 
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Peroxidase blocking solution for 5 min. Sections were processed by the 
avidin–biotin-peroxidase method (LSAB+2 system-HRP, Dako). Briefly, 
after washing, sections were incubated for 30 min with biotinylated 
secondary antibody against mouse and rabbit IgGs, followed by 
incubation for 30 min with a Streptavidin–HRP solution. Following 
washing, peroxidase activity was visualized by incubation of tissue 
sections with DAB+ (Dako, diaminobenzidine in hydrogen peroxide). 
Tissue sections were counterstained with Harris's hematoxylin, 
dehydrated and mounted with EUKITT® (Sigma-Aldrich). Images were 
captured with a microscope (Leica DM6000 B) and digital camera (Leica 
DFC300 FX; Leica Microsystems) and processed with Leica Application 
Suite software.  
To analyze uPAR expression incubation with blocking solution was for 










Luciferase Sigma L0159 Rabbit Yes 1/500 
GFP Invitrogen A6455 Rabbit Optional  1/500 
uPAR R&D AF534 Goat  Yes 15 µg/ml 
 Anti-human 
Ki67 
Dako M7240 Mouse Yes 1/200 
Active 
caspase-3 
BD Pharmingen 559565 Rabbit  Yes 1/500 
Table 11. Primary antibodies used for immunohistochemistry. 
REAGENTS: 
- Citrate Buffer (for 1L): 2.1 g citric acid, 1 g NaOH in dH2O, pH 6.0. 
- Diluting solution: 1% BSA (w/v), 0.2% Tween-20 in PBS. 
- Blocking solution: 10% FBS in Diluting solution. 
- Peroxidase Blocking solution: 3% hydrogen peroxide in methanol. 
6.3. Immunofluorescence (IF). 
Immunofluorescence was performed to detect CD31 expression. Briefly, 
10 µm frozen tissue sections were air-dried during 30 min and fixed in 
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cold acetone for 5 min, acetone/chloroform 1:1 treatment was applied 
for 5 min and then acetone during 5 min. After washing in PBS, sections 
were blocked for 1h in PBS-10% FBS and incubated with anti-mouse CD31 
antibody clone MEC 13.3 (dilution 1/50, BD Pharmingen) for 16h at 4°C. 
The following day, samples were rinsed 3 times with PBS and incubated 
with the secondary antibody Alexa Fluor 488 goat anti-rat antibody 
(dilution 1/500, Molecular Probes). Nucleus were counterstained with 5 
µg/ml bis-benzimide (Hoechst 33342, dilution 1/1000; Sigma) and slides 
were mounted with VECTASHIELD® Mounting Media (Vector 
Laboratories). Sections were visualized under a fluorescent microscope 
(Observer/Z1; Zeiss) and images were captured with a digital camera 
(AxioCamMRm; Zeiss). 
 
7. STATISTICAL ANALYSIS. 
The statistical analysis was performed using the SPSS 12.0 software. 
Results are expressed as the mean ±SEM (Standard Error of the Mean). 
A Mann-Whitney nonparametric test was used for the statistical analysis 
(2-tailed) of in vitro and in vivo studies. Differences were considered 
statistically significant (*) when p value≤0.05, and highly statistically 
significant (**) when p value≤0.01. 
Differences between more than two independent samples/means were 
analyzed using the nonparametric Kruskal-Wallis test with Mann-
Whitney U test for post hoc analyses. P value≤0.05 for the Kruskal-Wallis 
test indicates that the analyzed samples belong to different populations. 
Survival analyses were performed to analyze time-to-event probability by 
the Kaplan-Meier test. The survival curves obtained were compared for 
the different treatments. Animals that were alive at the end of the 
experiment or leave the study to be used in other experiment were 
included as right censored information. A log-rank test was used to 
determine the statistical significance of the different treatments. 
Differences were considered statistically significant (*) when p 
value≤0.05, and highly statistically significant (**) when p value≤0.01. 
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8. LIST OF EMPLOYED ADENOVIRUS. 
AdCMVGFPLuc 
Reporter adenovirus that expresses the eGFP gene under the control of 
the constitutive promoter CMV, and the Luciferase gene under the 
control of a second CMV promoter. This cassette is named as TL. The 
eGFP gene encodes for the Enhanced Green Fluorescent Protein, a 
mutated form of the GFP from Aequorea Victoria. The gene Luciferase 
encodes the Firefly Luciferase protein. This virus was kindly ceded by Dr. 
Ramon Alemany (IDIBELL-Institut Català d’Oncologia). 
AduPARLuc 
Reporter adenovirus that expresses the eGFP gene under the control of 
the constitutive promoter CMV, and the Luciferase gene under the 
control of the uPAR promoter. The genes eGFP and Luciferase are 
described above. The uPAR promoter corresponds to a 450 bp fragment 
of the promoter region of the human gene PLAUR, that encodes for the 
urokinase Plasminogen Activator Receptor (uPAR). This virus was 
previously generated in the laboratory by Dr. Meritxell Huch.  
AdTK 
Therapeutic adenovirus that expresses the TK transgene under the 
control of the constitutive promoter CMV. The TK gene encodes for the 
Thymidine Kinase enzyme from the Herpes Simplex Virus 1 (HSV-TK). This 
virus was previously generated in our laboratory in collaboration with 
Dra. Ana Mª Gomez. 
AduPARTat8TK 
Therapeutic adenovirus that expresses the Tat8TK transgene under the 
control of the uPAR promoter. The uPAR promoter is described above. 
The Tat8TK gene encodes a modified form of the HSV-TK with enhanced 
cytotoxicity, previously described in our laboratory by Dr. Anna Cascante 
(Cascante et al. 2005). In particular, TK gene is fused to the 8nt reduced 
variant of the protein transduction domain TAT.  
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AdYTRGE 
Reporter adenovirus that expresses the TL cassette and presents specific 
fiber mutations that significantly reduce binding to CAR and to the blood 
factors C4BP and FIX, resulting in a low efficient liver transduction and in 
a reduced hepatotoxicity in vivo (Shayakhmetov et al. 2005). The fiber 
mutations were: 
- Y477A single point mutation: ablates Ad binding to CAR.  
- TAYT: deletion of amino acids 489 to 492 (TAYT) in the FG loop; 
changes the overall conformation of the knob domain without 
disturbing its ability to trimerize. 
- RGE: peptide insertion (SKCDCRGECFCD) into position 547 of the 
HI loop; creates additional sterical hindrances, preventing 
interaction with natural ligands. 
This virus was kindly ceded by Dr. Ramon Alemany (IDIBELL-Institut 
Català d’Oncologia). 
AdTAT  
Reporter adenovirus that expresses the TL cassette, carries the YTRGE 
fiber mutations and expresses the 11 nt TATPTD into the C-ter of the fiber 
protein. 
AdTATMMP 
Reporter adenovirus that expresses the TL cassette, carries the YTRGE 
fiber mutations and expresses the 11 nt TATPTD blocked with a glutamic 
tail into the C-ter of the fiber protein. The glutamic tail was linked to 
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1. EVALUATION OF THE EFFICACY OF 
INTRADUCTAL DELIVERY OF ADENOVIRUS 
TO TREAT PANCREATIC TUMORS. 
The success of gene therapy is largely dependent on the viral 
transduction efficiency of the tumor. This relies in one hand on the 
delivery vector and in the other hand on the delivery route of vector 
administration. Three major delivery routes are commonly used to 
administer adenovirus for tumor treatment: intravenous (i.v) 
administration, intratumoral (i.t) injections and intraperitoneal 
administration. Systemic delivery (i.v) is specially indicated for pancreatic 
tumors that present with distant metastasis, while locoregional delivery 
is restricted to non-advanced carcinomas (Fillat et al. 2011). 
All routes face with difficulties to achieve optimal delivery. In theory, 
vascular delivery of vectors will lead to a larger distribution of virus 
within the tumor. However, often blood vessels are confined to the 
tumor stroma, and therefore several layers of stromal cells must be 
passed before viruses reach malignant cells (Kuppen et al. 2001). 
Moreover, 90% of the adenovirus are sequestered into the liver by 
Kupffer cells and by hepatocyte transduction through interaction with 
clotting factors (Di Paolo et al. 2009). Another hurdle of systemic delivery 
is the preexistence of a humoral response that could compromise gene 
transfer (Harvey et al. 1999). 
Intratumoral injections also show limitations to reach the bulk of tumoral 
cells. The stromal compartment and extracellular matrix components in 
the tumor act as physical barriers limiting the spread of the vector within 
the tumor (de Vrij et al. 2010). To improve on vector distribution, 
multiple injections in different parts of the tumor mass are often applied 
(Calbo et al. 2001; Roig et al. 2004). 
After intraperitoneal administration, the vectors do not interact with the 
components of the vascular system, which reduces some of the hurdles 
of systemic delivery, but the physical barriers to reach the bulk of the 
tumors are increased (Hoffmann and Wildner 2006a).  
In light of the lack of efficacy to reach the bulk of pancreatic tumors by 
the usually applied delivery routes, in this thesis we have studied an 
alternative delivery route to target pancreatic tumors. 
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1.1. Evaluation of the transduction efficiency of 
pancreatic tumors by intraductal administration of 
reporter adenoviruses. 
Intraductal (i.d) or retrograde administration to pancreas is an 
adaptation of the endoscopic retrograde colangio-pancreatography 
(ERCP) technique, used in humans for the evaluation and treatment of 
diseases of the bile duct and pancreas (Dumot 2006). Intraductal 
administration consists on the introduction of a 30G needle into the 
common bile duct through the Vater’s papilla to retrograde deliver virus 
to the pancreas (Figure 1A). Previously to virus administration, the 
common bile duct and the needle are clamped to avoid liver infection 
and regression of the liquid into the duodenum. When the virus is 
administered, it spreads across the pancreas through the branching duct 
system. As a proof of concept, Evans Blue dye was intraductally 
administered to the pancreas. As shown in Figure 1B, the pancreas 
stained blue suggesting that Evans Blue dye reached the whole pancreas. 
 
Figure 1. Intraductal administration into the common bile duct. A) Scheme of 
the surgical technique. Crosses indicate clamping points. Arrows indicate viral 
distribution. B) Pancreas of C57Bl/6 mice after Evans Blue intraductal injection. 
1.1.1. The pancreatic cancer mouse model Ela-myc. 
To evaluate the capacity of adenovirus to reach the pancreas and 
pancreatic tumors upon intraductal delivery, C57Bl/6 wt mice and the 













Figure 2. Pancreas of Ela-myc mice at 11 weeks of age. Representative images 
of wt (A,B) and Ela-myc (C-H) pancreas. Black arrows indicate non-tumoral areas, 
yellow arrows indicate solid regions that show a ductal phenotype, yellow arrow 
head indicates dense stroma, green arrow heads indicate preneoplasic regions 
and green arrows indicate tumoral regions showing an acinar phenotype. 
Original magnification, 2.5x (A, D,E, G), 10x (B, F, H), 40x (insets). 
Transgenic Ela-myc mice of 11 weeks of age exhibited a preneoplasic 








(Figure 2C). Preneoplasic and tumoral pancreas shows a white coloration 
and a grained structure at the macroscopic level (Figure 2C). The 
preneoplasic pancreas is microscopically visualized as disorganized and 
deformed acinus within a well-organized parenchyma (Figure 2G), and 
some areas already exhibit a tumoral acinar phenotype (Figure 2H). At 
this time, non-tumoral areas can be observed surrounding or within the 
preneoplasic areas (Figure 2D, E, black arrows). Solid tumor nodules 
appear lately in tumor development. They present a ductal phenotype 
and a dense stroma (Figure 2F), and preneoplasic/acinar tumoral regions 
can be detected adjacent to them (Figure 2D), constituting the so-called 
mixed acinar/ductal phenotype. When solid nodules appear at early 
times, they are embedded within a healthy parenchyma (Figure 2E). Ela-
myc mice present a survival of 19.6±0.7 weeks.  
1.1.2. Biodistribution study after intraductal delivery of the 
reporter adenovirus AdCMVGFPLuc. 
The reporter adenovirus AdCMVGFPLuc, that expressed the reporter 
genes luciferase and GFP, was intraductally administered into the 
common bile duct of wt C57Bl/6 or transgenic Ela-myc mice. Expression 
of luciferase by bioluminescence analyses was carried out as an indicator 
of viral biodistribution.  
 
Figure 3. Biodistribution study of AdCMVGFPLuc intraductally administered 
into the common bile duct. Representative bioluminescent images of animals 
and isolated organs from wt C57Bl/6 (n=7) and transgenic Ela-myc (n=9) mice i.d 
injected with 5·10
10
 vp of AdCMVGFPLuc. Bioluminescence was measured four 
days later in living animals and in isolated organs (K: kidney, D: diafragm, L: liver, 
St: stomach, Sp: spleen, I: intestine and P: pancreas). 
Five·1010 vp of AdCMVGFPLuc were intraductally delivered to wt and Ela-
myc mice 11 weeks old and four days later, in vivo and ex vivo luciferase 
expression was analyzed by bioluminescent imaging IVIS50 system 
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(Xenogen). As it is observed in Figure 3 luciferase expression was 
restricted to the pancreas both in wt and Ela-myc animals. In a small 
number of mice, punctual luciferase expression was detected in stomach 
or intestine, probably corresponding to pancreas fragments not correctly 
isolated during necropsy. 
1.1.3. Persistence of transgene expression following 
AdCMVGFPLuc intraductal injection. 
Next, we analyzed the persistence of transgene expression in the 
pancreas of wt and Ela-myc mice that received intraductally 1010vp of 
AdCMVGFPLuc. At 4, 7 and 10 days after virus administration animals 
were sacrificed and luciferase expression was quantified in pancreatic 
tissue extracts. 
Maximum transgene expression was obtained at day 4 in both groups 
that decreased at days 7 and 10 (Figure 4). Luciferase activity in Ela-myc 
mice was lower than that of wt mice at all the times analyzed. This could 
probably be explained by the presence of tumoral stroma that hindered 
viral distribution through the neoplasic pancreas. 
 
Figure 4. Time-course study of luciferase expression in the pancreas of wt and 
Ela-myc mice after AdCMVGFPLuc intraductally administered into the common 
bile duct. 10
10
 vp of AdCMVGFPLuc were intraductally administered to wt (n=4 
per day) and Ela-myc (n=5 per day) mice. Animals were sacrificed 4, 7 and 10 
days later, pancreas was removed and luciferase expression was measured in 
tissue extracts. Results are represented as the mean ± SEM and expressed as 

























1.1.4. Comparative analyses of AdCMVGFPLuc 
biodistribution following intraductal or intravenous 
delivery. 
Next we evaluated whether intraductal delivery was providing with any 
advantage to intravascular delivery to target adenovirus to the pancreas 
or pancreatic tumors. To this end, 5·1010 vp of the reporter adenovirus 
AdCMVGFPLuc were intraductally or intravenously administered in 11 
weeks old wt and Ela-myc mice. Four days later, animals were sacrificed 
and luciferase expression was measured in the pancreas and the liver. 
Luciferase expression was mainly observed in the liver after Ad 
intravascular delivery, whereas it was localized in the pancreas after 
intraductal administration (Figure 5A). Interestingly, quantification of 
bioluminescence images showed a 5-40 fold increase in pancreatic 
luciferase expression upon intraductal delivery when compared to 
intravenous delivery. On the contrary, liver transduction was reduced 3 
logs upon i.d administration when compared to i.v administration. To 
confirm these results luciferase expression was quantified in tissue 
extracts from animals intraductally delivered with AdCMVGFPLuc. As 
shown in Figure 5B, transgene expression was significantly higher in the 
pancreas than in the liver of mice i.d injected with Ad. 
These results indicated that intraductal delivery of Ad increased 
pancreatic transduction and reduced liver sequestration when compared 
to intravenous delivery. Thus, the application of intraductal delivery 
provides with pancreatic selectivity. 
1.1.5. AduPARLuc expression analyses after intraductal 
administration. 
To restrict adenoviral activity to pancreatic tumoral cells we decided to 
test the activity of AduPARLuc, a reporter adenovirus with the tumor 
specific promoter uPAR driving the luciferase gene. Previous studies in 
the laboratory had demonstrated that uPAR promoter was highly active 
driving transgene expression and presented good oncoselectivity for 
pancreatic tumors (Huch et al. 2009). 
First, we analyzed uPAR expression in tumor-presenting pancreas of 11 
weeks old Ela-myc mice (Figure 6). Elevated levels of Plaur mRNA were 




Figure 5. Luciferase expression analysis of AdCMVGFPLuc intravenously or 
intraductally administered to wt or Ela-myc mice. A) 5·10
10
 vp of AdCMVGFPLuc 
were intravenously or intraductally administered to wt (n=7, n=7, respectively) 
and Ela-myc mice (n=7, n=9, respectively). Four days later animals were 
sacrificed and liver and pancreas luciferase expression was measured. Top panel: 
Representative bioluminescent images. Bottom panel: Quantification of 
luciferase expression from captured bioluminescence images. Results are 
expressed as photons/s. B) 10
10
 vp of AdCMVGFPLuc were intraductally 
administered to wt (n=4) and Ela-myc mice (n=5), and four days later luciferase 
expression was measured in tissue extracts. Results are expressed in RLU (LU/mg 
of protein). All the results are represented as the mean ± SEM. * p<0.05, ** p<0.01. 
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expression in ductal and acinar cells of preneoplasic areas, and abundant 
staining was also detected in the stromal cells. 
The observation that endogenous expression of the Plaur gene was 
elevated in the pancreas of Ela-myc mice suggested that factors 
regulating the uPAR promoter were active in Ela-myc tumors. This could 
be an indicator that AduPARLuc adenovirus could be highly regulated in 
this context. 
 
Figure 6. uPAR expression in the pancreas of Ela-myc mice. A) RT-PCR of Plaur 
gene (uPAR) and the control 15S gene in the pancreas of Ela-myc and wt mice. B) 
Representatives images of anti-uPAR immunostaining in Ela-myc pancreas. Left 
panel: 20x magnification; Right panel: 40x magnification. 
To test this hypothesis, 1010 vp of AdCMVGFPLuc or AduPARLuc were i.d 
administered to wt mice and luciferase expression was analyzed four 
days later (Figure 7B). AduPARLuc expression was 80 times lower than 
that of AdCMVGFPLuc. This could probably be explained by the low uPAR 
expression observed in the pancreas of wt mice that would correspond 
with a low uPAR promoter activity, contrasting with the highly active 
constitutive promoter CMV. 
To achieve therapeutic success, the adenoviral vector must present 
selectivity for the tumoral tissue while avoiding harming non-tumoral 
cells. To test uPAR promoter oncoselectivity we took advantage of the 
double cassette that expressed the AduPARLuc vector (Figure 7A). We 










Figure 7. AduPARLuc expression after intraductal administration to wt mice. A) 
Scheme of AduPARLuc and AdCMVGFPLuc (AdCMVGFPLuc) viruses. B) 10
10
 vp of 
AdCMVGFPLuc or AduPARLuc were intraductally administered to wt (n=7, n=4, 
respectively), and four days later luciferase expression was measured in tissue 
extracts. Results are represented as the mean ± SEM and expressed as RLU 
(LU/mg). * p<0.05. C) Representative images of anti-GFP and anti-luciferase 
immunostaining in pancreas of wt mice four days after 10
10
 vp of AduPARLuc 





















































the CMV promoter, and the expression of luciferase, controlled by the 
uPAR promoter, in the pancreas of wt mice i.d injected with AduPARLuc. 
Analyses of the same pancreatic regions showed strong GFP 
immunoreactivity but absence of luciferase staining (Figure 7C), 
indicating that although AduPARLuc virus transduced the majority of the 
wt pancreas (as suggested by the strong GFP staining), the transgene 
controlled by the uPAR promoter was not expressed (lack of luciferase 
staining). These results suggested that AduPARLuc transduce normal 
pancreas, but transgene expression driven by the uPAR promoter was 
very low, and undetectable by anti-luc inmunostaining.  
Next, we studied the capability of the AduPARLuc to drive luciferase 
expression in Ela-myc pancreatic tumors when intraductally 
administered. 1010 vp of AduPARLuc were i.d delivered to Ela-myc mice, 
and luciferase expression was analyzed four days later. uPAR promoter 
activity resulted in 10% that of the CMV promoter in the Ela-myc 
pancreas compared to the 1.2% observed in the wt pancreas (Figure 8A). 
Furthermore, as shown in Figure 8B, luciferase expression was detected 
in preneoplasic and tumoral areas with an acinar phenotype (upper 
panel) as well as in the core of solid tumoral masses with ductal 
phenotype and dense stroma (middle and bottom panels).  
In conclusion, the results showed that intraductal delivery of AduPARLuc 
into the common bile duct led to the efficient transduction of Ela-myc 
mice pancreatic tumors. 
1.2. Evaluation of the AduPARTat8TK/GCV therapy to 
treat pancreatic tumors. 
To evaluate the feasibility of intraductal adenoviral delivery to treat Ela-
myc pancreatic tumors we generated the cytotoxic adenovirus 
AduPARTat8TK, in which the cytotoxic gene Tat8TK was regulated by the 
uPAR promoter. First we tested the cytotoxic effect of 
AduPARTat8TK/GCV in primary Emyc tumor cultures.  
Figure 8. Luciferase expression of AduPARLuc in the pancreas of Ela-myc mice 
after intraductal delivery. 10
10
 vp of AdCMVGFPLuc or AduPARLuc were 
intraductally administered to wt (n=7, n=4, respectively) and Ela-myc mice (n=4, 
n=4, respectively), and four days later luciferase expression measured in tissue 




as the ratio x100 between the mean of AduPARLuc expression and the mean of 
AdCMVGFP expression. B) Representative images of luciferase immunostaining 
and hematoxilyn&eosin staining corresponding to the same pancreatic area 


































1.2.1. Generation and molecular characterization of Emyc 
cell lines. 
Eleven pancreatic tumor fragments from six Ela-myc mice of 2.5-4 
months of age were processed to generate primary cultures. From three 
of them we established the independent cell lines: Emyc-1, Emyc-3 and 
Emyc-10, all them deriving from white tumoral areas.  
 
Figure 9. Characterization of Emyc cell lines. Primary cultures were generated 
from pancreatic tumor nodules of Ela-myc mice of 2.5-4 months of age. Primary 
cultures were considered established cell lines from 20 passages. A) 
Representative images of Emyc primary cultures at different passages. B) 
Molecular characterization of Emyc cell lines by RT-PCR analyses. RT-PCR of the 
ductal markers keratin 7 and keratin 19 (K7 and K19), acinar markers elastase 
and trypsin (Ela-myc and Tryp), and c-Myc and Plaur (uPAR) genes in Emyc-1, 
Emyc-3 and Emyc-10 cell lines, and in the controls: pancreas from TgEla-myc 
mice and wt C57Bl/6 mice, and the acinar pancreatic tumoral cell line 266-6. 
Cell line morphology and expression of phenotypic markers were 
analyzed at several passages of the primary culture. Different 
morphologies were found within and through passages (Figure 9A). Initial 
cell population was a mixture of cells, e.g. fibroblasts, polygonal cells, 
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refringent cells, etc. Cultures required about 10 passages to get rid of 
fibroblasts. Around passage 20, a primary culture was considered an 
established cell line (4-5 months after initial plating). 
Cell lines characterization was performed by examining acinar and ductal 
cell-specific markers by RT-PCR analysis. Expression of the oncogenes c-
Myc and uPAR was also analyzed (Figure 9B). RT-PCR analysis revealed 
the expression of ductal markers (Keratin 7 and/or Keratin 19) in all three 
Emyc cell lines. The acinar marker elastase was not detected in any of the 
Emyc cell lines, although some expression of the acinar marker trypsin 
was detected in Emyc-3 and Emyc-10 cells. Interestingly, all Emyc cell 
lines showed stronger uPAR gene expression. 
The stronger expression of Keratin 7 and 19 and lower expression of 
trypsin seemed to indicate that Emyc cell lines exhibited a more 
prominent ductal phenotype. This result is in accordance with the study 
carried out by Biliran et al in which they generated a cell line derived 
from Ela-myc mice and observed expression of acinar and ductal markers 
but prevailed the ductal phenotype (Biliran et al. 2005). 
1.2.2. Susceptibility of Emyc cells to viral transduction and 
response of Emyc cells to uPAR promoter controlled 
adenovirus. 
To test the capacity of AduPAR controlled adenovirus to drive expression 
in the pancreatic cancer Emyc cell line. Emyc, Panc-1 and RWP-1 cultures 
were exposed to 104 vp/cell of AduPARLuc or the control AdCMVGFPLuc 
and GFP and luciferase expression was analyzed three days later. Emyc-1 
cells were susceptible to adenoviral transduction as GFP emission was 
similar to that of RWP-1 cells (high susceptible to adenoviral 
transduction) and highly different from Panc-1 (low adenoviral 
transduction) (Figure 10A). 
All pancreatic cancer cells transduced with the AduPARLuc virus showed 
high levels of luciferase activity, indicating that the uPAR promoter was 
active in all the pancreatic cancer cells, although it was lower than that of 
CMV promoter (Figure 10B). It is not surprising since it has been 
described that tumor specific promoters show lower transcriptional 
activity than that of CMV promoter. Thus, these results indicated that 




Figure 10. AduPARLuc activity in Emyc cell lines. 10.000 cells were seeded in 
triplicate in a 96-well plate. Cells were infected with 10000 vp/cell of 
AdCMVGFPLuc or AduPARLuc, and four hours later medium was changed to 
fresh medium. Transgene expression was measured 3 days later. A) 
Representatives fluorescent images of GFP expression. B) Luciferase expression 
of AdCMVGPLuc and AduPARLuc. Results are represented as the mean ± SEM of 
at least 3 independent experiments and expressed as RLU (LU/µg). * p<0.05. 
1.2.3. Evaluation of the sensitivity of Emyc cells to the 
Tat8TK/GCV system  
- AduPARTat8TK/GCV ID50 value determination.  
Next, we evaluated the response of the Emyc cell lines to the 
Tat8TK/GCV cytotoxic therapy. Six pancreatic cancer cell lines were 
infected with increasing doses of AduPARTat8TK (Figure 11A) and four 
hours after transduction, cells were treated with GCV for 3 days and cell 
viability was then assessed by MTT assay. Dose-response curves were 
obtained (Figure 11B) and vp/cell corresponding to the ID50 values were 
determined (Figure 11C).  
We observed that AduPARTat8TK displayed an important cytotoxic effect 























lowest ID50 values, indicating that Emyc cell lines were highly sensitive to 
the AduPARTat8TK/GCV therapy. 
 
Figure 11. TK/GCV cytotoxic study. A) Schematic representation of 
AduPARTat8TK adenovirus. B) Dose-response curves of pancreatic cancer cells 
transduced with AduPARTAT8TK and treated with GCV. 3.000 cells were seeded 
in triplicate in a 96-well plate and infected with a dose range of 0 to 10
6
 vp/cell. 
Four hours post-infection medium was replaced by complete medium 
supplemented with 100 µg/ml GCV. Viability was measured 3 days later by MTT. 
C) ID50 values±SEM of at least four independent experiments.  
- Study of the bystander effect of Tat8TK/GCV on the Emyc-3 cell line. 
To further analyze the cytotoxicity of the TK/GCV system in Emyc cells, 
we tested for the presence of a bystander effect (BE) in  Emyc cells and 
compared to a battery of cell lines. To this end, PANC-1, RWP1, Emyc-3 
and NP18 pancreatic cancer cells were transduced with the recombinant 
adenoviral vector AdTK at a viral dose corresponding to approximately 
the IC90, and designated as TK
+ cells. Cocultures of 50% TK+ cells and 50% 
TK- cells were established at high confluence and treated with GCV for 3 
days. Cell survival was assessed by MTT assay and the percentage of cell 
viability with respect to PBS-treated cells was calculated. As shown in 
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Figure 12B the percentage of cell survival in the cocultures derived from 
all four pancreatic cancer cell lines was significantly lower than 55%, 
indicating that BE was participating in the TK/GCV cytotoxicity. 
Specifically, coculture of Emyc cells showed very low cell survival values, 
suggesting that BE was a contributing factor to the higher cytotoxicity 
exerted by the TK/GCV system on the Emyc cell lines.  
 
Figure 12. Evaluation of TK/GCV bystander effect in Emyc cells. A) Scheme of 
the experiment performed to study the bystander effect of TK/GCV system on 
cellular models. B) TK/GCV bystander effect. 200.000 cells seeded in a 60 mm 
plates were transduced with AdTK (PANC: 5.000 vp/cell; NP18: 100 vp/cell; 
RWP1 and Emyc-3: 50 vp/cell). The following day, cocultures (50% TK+/50% TK-) 
or 100% TK+ cultures were generated by seeding 5000 cells (RWP1, Emyc-3 and 
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It is well documented that the TK/GCV bystander effect is mediated by 
the transfer of phosphorylated GCV from TK+ cells to neighboring cells 
through gap junctions (Carrió et al. 2001). To corroborate the implication 
of BE on TK/GCV toxicity, we studied the expression of the structural 
proteins connexins constituting the gap junctions; in particular we 
studied Connexin 43 (Cx43) expression, a connexin expressed in the 
pancreas. Immunoblot analysis of confluent cell cultures showed high 
Cx43 expression in NP18 cells, moderate expression in RWP1 and Emyc-3 
cells and no expression in PANC-1 cells (Figure 12C). NP18 and PANC-1 
Cx43 expression levels were in accordance with previous studies 
described in our laboratory (Garcia-Rodriguez et al. 2011). The presence 
of Cx43 in Emyc cells suggest that Cx43 could probably be facilitating 
TK/GCV BE in Emyc cells, although other connexins not analyzed in the 
current study could also be involved. 
1.2.4. Evaluation of AduPARTat8TK/GCV treatment on Ela-
myc pancreatic tumors. 
Next, we studied the antitumoral effect of AduPARTa8TK/GCV therapy on 
pancreatic tumors of Ela-myc mice. First, we evaluated the antitumoral 
effect of the therapy at two different doses of AduPARTat8TK when 
intraductally delivered. Five groups of Ela-myc mice were established 
(PBS, GCV, AduPARTat8TK, AduPARTat8TKLow+GCV and 
AduPARTat8TKHigh+GCV). Ela-myc mice were i.d injected with PBS, 5·10
10 
vp or 1011 vp of AduPARTat8TK. Three days later, a daily dose of 100 
mg/kg of GCV was administered for 6 consecutive days in the control 
group (GCV) and in the AduPARTat8TKLow+GCV and AduPARTat8TKHigh+ 
GCV groups. Six weeks after viral administration animals were sacrificed 
and the pancreatic volume was determined. We evaluated the pancreatic 
volume instead of the tumoral volume because a defined tumoral nodule 
was not always detected at the time of virus administration and, in 
addition, the Ela-myc pancreas was preneoplasic in its totally. 
Non-treated Ela-myc pancreas showed tumor progression with a 
pancreatic volume of 444 mm3 (PBS group in Figure 13B). AduPARTat8TK or 
 
After 72h, cell viability was determined by an MMT assay. Values represent the 
mean ± SEM of 3 independent experiments. C) Connexin 43 expression analyses 
by Western blot. 60µg of total protein extract from confluent cell cultures were 
loaded. Tubulin expression was used as a control. 
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GCV treatments independently administered had no effect on the 
pancreatic volume (423 mm3). On the contrary treatment with both high 
and low viral AduPARTat8TK combined with GCV resulted in a significant 
reduction on the pancreatic volume, with values similar to those of wt 
mice. These results indicated that i.d. adenoviral delivery of 
AduPARTat8TK followed by GCV treatment, significantly reduced Ela-myc 
tumor progression. 
 
Figure 13. Antitumoral effect of AduPARTat8TK/GCV treatment, upon virus 
intraductal delivery, on Ela-myc pancreatic tumors. A) Schematic 




 vp of AduPARTat8TK 
(Low (n=10) and High (n=9), respectively) were intraductally injected to 11 
weeks old Ela-myc mice. Three days later, GCV treatment (100 mg/kg) was i.p 
administered for 6 days. Six weeks after virus administration, animals were 
sacrificed and pancreatic volume was measured. The control groups received 
PBS (n=10), GCV (n=11) or virus at high dose (n=10). B) Pancreatic volume of Ela-
myc mice upon i.d delivery of AduPARTat8TK/GCV therapy. Black line 
corresponds to C57Bl6 (n=8) pancreatic volume (221.3 ± 8.7 mm
3
). *** p<0.005. 
We have previously observed (Figure 5) that adenoviral transduction of 
pancreatic tumors in Ela-myc mice with AdCMVGFPLuc was more 
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delivery. To analyze whether this different transduction effect impacts 
differently on the antitumoral response of a therapeutic virus we 
intraductally or intravenously administered 5·1010 vp of the cytotoxic 
AduPARTat8TK virus, followed by six daily doses of GCV initiated three 
days after virus administration. Pancreatic volume was measured six 
weeks later. As shown in Figure 14, both treated groups showed reduced 
pancreatic volume compared to non-treated mice, suggesting that 
AduPARTat8TK/GCV therapy, administered either i.d or i.v, reduced Ela-
myc tumor progression. Interestingly, intraductal virus delivery reduced 
pancreatic volume to lower values than intravenous delivery. These 
results seemed to indicate that AduPARTat8TK/GCV therapy upon i.d 
delivery was a good candidate therapy to treat Ela-myc pancreatic tumors. 
 
Figure 14. Antitumoral effect of AduPARTat8TK/GCV therapy, upon intraductal 
or intravenous viral administration, on Ela-myc mice. 5·10
10
 vp of 
AduPARTat8TK were intraductally (n=10) or intravenously (n=7) delivered to 11 
weeks old Ela-myc mice. Three days later, GCV treatment (100 mg/kg) was i.p 
administered for 6 days. Six weeks after virus administration, animals were 
sacrificed and pancreatic volume was measured. The control group PBS (n=10) 
intraductally received PBS solution. Black line corresponds to C57Bl6 (n=8) 
pancreatic volume (221.3 ± 8.7 mm
3
). *** p<0.005. 
1.2.5. Toxicity analysis of AduPARTat8TK/GCV therapy.  
After intravascular injection, adenoviruses liver tropism leads to liver 
toxicity caused by an immune response to the viral proteins as well as 
transgene expression. In addition, the pancreas is a delicate organ and 
intraductal injection can lead to pancreatitis. Therefore, we evaluated 
the potential toxicity of AduPARTat8TK/GCV therapy after i.v or i.d viral 






















First, we determined serum biochemical parameters of liver and 
pancreatic function in non-treated Ela-myc mice at different times 
(Figure 15). Pancreatic damage was assessed by measuring amylase, 
lipase and glucose levels, and liver damage was assessed by measuring 
ALT and AST levels. Non-treated Ela-myc mice presented altered 
pancreatic parameters at all the time points analyzed (Figure 15B). 
Specifically, amylase levels were over the reference range in mice at 12 
weeks of age and rapidly increased at later times (17 weeks of age), 
probably related to an exponential growth of the pancreatic tumor. 
Lipase values were in the close vicinity to the lowest reference value and, 
similarly to amylase, rapidly increased at later time points. On the 
contrary, glucose levels were always below the reference range and 
rapidly decreased at later times. These results indicated that Ela-myc 
mice already presented pancreatic damage at 11-12 weeks of age that 
exponentially increased with time. Ela-myc mice also presented elevated 
AST values whereas ALT levels were within the reference suggesting 
minor liver damage associated to the tumor. 
Next, we evaluated serum biochemical parameters of pancreatic function 
in Ela-myc mice intraductally (i.d) or intravenously (i.v) treated with 
5·1010 vp of AduPARTat8TK plus six doses of GCV. Schedule of blood 
sample acquisition is shown in Figure 15A. As shown in Figure 15B, the 
AduPARTat8TK/GCV therapy reduced the levels of the pancreatic 
parameters analyzed at all the time points compared to that of non-
treated mice. Whereas amylase levels were reestablished within the 
reference range aside from the latest time, lipase and glucose levels were 
stabilized below the reference range. These results suggested that 
AduPARTat8TK/GCV therapy ameliorated pancreatic tumor-associated 
toxicity in Ela-myc mice. 
We also evaluated the hepatotoxicity produced by the 
AduPARTat8TK/GCV therapy. Transaminases levels were maintained or 
reduced to the reference range, indicating that AduPARTat8TK/GCV 
therapy produced no hepatotoxicity either upon i.v or i.d administration. 
Probably the use of the uPAR promoter was restricting the hepatotoxicity 
associated to the systemic administration of adenoviruses. 
Therefore, these results indicated that the AduPARTat8TK/GCV therapy 





Figure 15. AduPARTat8TK/GCV toxicity studies in Ela-myc mice. A) Protocol for 
evaluation of pancreatic and liver toxicity of AduPARTat8TK/GCV therapy. Times 
of blood sample acquisition are indicated with red circles. B) Analysis of ALT and 
AST, amylase, lipase and glucose serum levels in treated Ela-myc mice at 4, 11, 
25 and 39 days after virus administration or at their corresponding times in non-
treated Ela-myc mice. AduPARTat8TK/GCV therapies followed the same protocol 
than in Figure 14. Non-treated mice n=4-6, Treated mice n=5 per group. Dash 
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2. ANALYSIS OF THE THERAPEUTIC EFFICAY 
OF AduPARTat8TK/GCV THERAPY 
COMBINED WITH GEMCITABINE TO TREAT 
PANCREATIC CANCER. 
Gemcitabine (GE) is a nucleoside analogue used for the treatment of 
solid cancers, such as pancreatic cancer; in fact it is the first line 
treatment for patients with systemically advanced pancreatic 
adenocarcinoma. Nowadays, a large number of works are trying to 
improve the activity of gemcitabine by its combination with other agents 
(Vonhoff 2006). Some of these regimens, such as gemcitabine plus 
erlotinib (EGFR kinase inhibitor) or gemcitabine plus capecitabine 
(nucleoside analogue), have shown to moderately improve survival over 
the use of gemcitabine alone (Moore et al. 2007; Cunningham et al. 
2009). However, others such as gemcitabine plus bevacizumad (VEGF 
inhibition) plus cetuximab (EGFR inhibition) have shown lack of sufficient 
efficacy (Ko et al. 2011).  
We were interested to study the activity of the combined treatment 
gemcitabine and TK/GCV in the Ela-myc mouse model. Both GE and GCV 
are nucleoside analogues that interfere with DNA replication causing cell 
death by apoptosis (Wong et al. 2009), but GE is also an inhibitor of the 
ribonucleotidase reductase. We hypothesized that GE, through its 
activity as inhibitor of ribonucleotidase reductase, will lead to the 
reduction on the dNTP pool facilitating triphosphorilated-GCV 
incorporation into the DNA and consequently improving TK/GCV 
cytotoxicity. Moreover, Boucher et al demonstrated that GE enhanced 
the GCV-mediated bystander cytotoxicity in vitro and in vivo in s.c colon 
tumors (Boucher and Shewach 2005). 
2.1. Evaluation of the anticancer effect of gemcitabine 
in cellular models and Ela-myc pancreatic tumors.  
First, we determined the response to gemcitabine therapy in vitro and in 
vivo in the Ela-myc model. Emyc-3, NP-18 and RWP-1 pancreatic cancer 
cell lines were exposed to increasing doses of GE (0-105 µM) and three 
days later cell viability was determined by MTT assay. Dose-response 




The results showed that the ID50 value for the Emyc cell lines was 
significantly higher than that of the other pancreatic tumoral cell lines 
analyzed, suggesting that Emyc-3 cells were more resistant to 
gemcitabine cytotoxicity. 
 
Figure 16. Gemcitabine cytotoxic study. A) Dose-response curves to 
gemcitabine (GE) in the pancreatic tumoral cell lines NP18, RWP-1 and Emyc-3. 
3.000 cells were previously seeded in triplicate in a 96-well plate. Cells were 
treated at different GE concentrations. Cell viability was determined by an MTT 
assay 72h later.  Values represent the mean ± SEM of at least 4 independent 
experiments. C) ID50 values of gemcitabine in the different tumoral cell lines. 
 
Figure 17. Antitumoral effect of gemcitabine in Ela-myc mice. Ela-myc mice of 
11 weeks of age were treated with a single dose (160 mg/kg) or four doses of 
gemcitabine (160 mg/kg, once per week), corresponding to GE (n=9) and GE 
weekly (n=9) groups respectively. Non-treated PBS group received saline (n=10). 
Animals were sacrificed and pancreatic volume was measured six weeks after 
initial treatment. Black line corresponds to C57Bl6 (n=8) pancreatic volume 
(221.3 ± 8.7 mm
3

























Next, we tested the antitumoral capacity of gemcitabine on Ela-myc 
pancreatic tumors. Two different gemcitabine treatments were applied 
to Ela-myc mice: animals received a single dose of gemcitabine (GE 
group, 160 mg/kg) or four doses of gemcitabine scheduled once per 
week (GE weekly group). Pancreatic volume was measured six weeks 
after the initial GE dose. As shown in Figure 17, GE weekly treatment 
significantly reduced the pancreatic volume of Ela-myc mice, whereas the 
reduction achieved by a single dose of GE was not statiscally significant. 
These data indicated that a weekly dose of gemcitabine (4 doses in total) 
showed antitumoral capacity. 
2.2. Evaluation of the cytotoxic effects of the 
combination AduPARTat8TK/GCV plus gemcitabine 
in cellular models.  
We evaluated whether the combination of gemcitabine and 
AduPARTat8TK/GCV therapy exerted a synergistic, additive or 
antagonistic effect on the Emyc cellular model. To this end, 
pharmacological interaction between gemcitabine and 
AduPARTat8TK/GCV treatments was assessed by Combination Index 
analysis (CI) in Emyc, NP18 and RWP-1 cell lines. Combination Index 
analysis is one of the most popular methods used to study in vitro drug 
interactions in combination cancer chemotherapy. A CI value <1 indicates 
synergism, =1 additivity and >1 antagonism between the drugs.  
Cells were treated with either GE, AduPARTat8TK/GCV or a combination 
of both, and cell viability was determined by MTT assay three days later. 
Dose-response curves were constructed for each treatment alone or 
combined (Figure 18A) and Hill coefficient and ID50 value were calculated. 
These values were used to calculate the CI values for each Inhibitory 
Fraction (10%-90%) (Figure 18C). Dose-response curves corresponding to 
the combined therapy showed a shift to the left compared to single 
treatments, supposing a reduction in the ID50 value of each drug. 
Interestingly, this effect was higher in the Emyc cell line.  
 
Figure 18. GE and AduPARTat8TK/GCV treatment interaction analysis. A) Dose-
response curves for either gemcitabine (GE), AduPARTAT8TK/GCV or the 




a 96-well plate. For single treatments, cells were transduced with a dose range of 
gemcitabine or AduPARTAT8TK, and four hours post-infection 100 µg/ml GCV was 
added. For the combined treatment cells were transduced with a dose range of 
AduPARTAT8TK (the same than in single treatment) and at 4h medium was 
replaced by fresh medium supplemented with GCV (100 µg/mL) and GE at the 
same dose range than in single treatment. Cell viability was determined by an 
MTT assay 72h later. Values represent the mean ± SEM of at least 4 independent 
experiments. B) Equation of Combination Index value for a specific Inhibitory 
Fraction. C) CI values for the interaction of gemcitabine and AduPARTat8TK/GCV 
treatments are depicted as a function of Inhibitory Fractions. Values represent 
the mean ± SEM of at least 3 independent experiments. 
CI =
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CI analysis revealed CI values lower than 1 for the majority of the 
Inhibitory Fractions in Emyc cells, indicating a synergistic effect of 
gemcitabine cytotoxicity when combined with AduPARTat8TK/GCV. On 
the contrary, CI values for NP18 and RWP-1 cells were higher than 1 or 
lied close to the additivity line, indicating that the combination of both 
treatments induced an antagonistic effect at low Inhibitory Fractions and 
only slightly improved drug cytotoxicity at higher IFs.  
2.3. Evaluation of the antitumoral effect of gemcitabine 
combined with AduPARTat8TK/GCV therapy in Ela-
myc pancreatic tumors.  
Next, we studied whether the synergism between gemcitabine and 
AduPARTat8TK/GCV treatments identified in vitro was also observed in 
vivo. With this objective, two different treatment schedules were applied 
to Ela-myc mice (Figure 19A). Both protocols consisted on the i.d delivery 
of 5·1010 vp of AduPARTat8TK followed by six doses of GCV plus three 
weekly doses of gemcitabine, and the posterior analyses of the 
pancreatic volume six weeks after initial treatment. In the COMB I 
protocol, the first dose of GE was co-administered with the fourth dose 
of GCV; whereas in the COMB II protocol the first dose of GE was 
administered the day previous to virus administration. The two protocols 
differed in the co-administration of both drugs with the objective to 
study possible differences in the outcome of the therapy due to GCV and 
GE interactions.  
As shown in Figure 19B, both combined treatments significantly 
decreased the pancreatic volume of Ela-myc mice similarly to GE weekly 
and AduPARTat8TK/GCV treatments. This result suggested that the 
combined therapy of gemcitabine plus AduPARTat8TK/GCV showed an 
additive effect since no improvement nor diminution of single treatment 
antitumoral capacity was observed when combined. Moreover, no 
statiscally significant differences were found between the combined 
protocols assessed. 
2.4. Toxicity analysis of the combined therapy 
AduPARTat8TK/GCV plus gemcitabine.  
We had previously demonstrated that AduPARTat8TK i.d administered 
and combined with GCV did not produce pancreatic nor liver toxicity. 
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However, previous studies had demonstrated that gemcitabine 
administration led to an increase in the transaminases levels producing 
liver failure in particular cases (Fossella et al. 1997; Robinson et al. 2003). 
Therefore, we evaluated the potential toxicity of AduPARTat8TK/GCV 
therapy when combined with gemcitabine in Ela-myc mice (Figure 20). 
 
Figure 19. Antitumoral effect of gemcitabine and AduPARTat8TK therapy on 
Ela-myc pancreatic tumors. A) Protocol for evaluation of the combined therapy. 
B) Ela-myc mice of 11 weeks of age were treated with the indicated protocols 
and pancreatic volume was determined six weeks after initial treatment. PBS 
non-treated mice received i.d PBS. GE Weekly group (n=9) received four doses of 
gemcitabine (160mg/Kg, once per week). AduPARTat8TK/GCV group (n=10) 
received i.d 5·10
10
vp of AduPARTat8TK and three days later GCV treatment (100 
mg/kg, 6 doses) was initiated (arrows). COMB I (n=7) and COMB II (n=8) groups 
received i.d 5·10
10
vp of AduPARTat8TK plus six doses of GCV (100 mg/kg) 
scheduled as indicated in A). Black line corresponds to C57Bl6 (n=8) pancreatic 
volume (221.3 ± 8.7 mm
3
). * p<0.05. 
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Gemcitabine addition to the AduPARTat8TK/GCV therapy led to an 
increase in the transaminases levels although only AST values were over 
the reference range. Interestingly, lower values were found at day 25 and 
39 after virus administration probably related to the finalization of the 
gemcitabine treatment. GE addition also increased the serum levels of 
amylase and lipase although to a lesser extent than with transaminases 
values.  
These data indicated that the combined therapy of AduPARTat8TK/GCV 
plus gemcitabine ameliorated tumor-associated toxicity but produced 
minor liver damage. 
 
Figure 20. AduPARTat8TK/GCV toxicity studies in Ela-myc mice. A) Protocol for 
evaluation of pancreatic and liver toxicity of AduPARTat8TK/GCV combined 
therapy. Times of blood sample acquisition are indicated with red circles. B) 
Analysis of ALT, AST, amylase and lipase serum levels in treated Ela-myc mice at 4, 
11, 25 and 39 days after virus administration. AduPARTat8TK/GCV therapies 
followed the same protocol than in Figure 19. Treated mice n=5 per group. Dash 
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3. DEVELOPMENT OF A TRANSDUCTIONAL 
TARGETING STRATEGY TO IMPROVE 
ADENOVIRUS INFECTIVITY AND PROVIDE 
WITH PANCREATIC TUMOR SELECTIVITY. 
To confer adenoviral-based therapies with improved antitumoral activity 
we have designed genetically engineered virus with specific fiber 
modifications in order to increase adenoviral tumor cell transduction and 
tumor selectivity.  
Previous studies had demonstrated the capacity of the protein 
transduction domain TAT to successfully transduce living cells when 
fused to several therapeutically active macromolecules (Kashiwagi et al. 
2007; Essafi et al. 2011; Yu et al. 2011). In this thesis, we have genetically 
introduced the 11aa TATPTD into the C-terminal end of the fiber protein of 
AdTAT and AdTATMMP with the objective to improve adenovirus 
infectivity in a CAR independent manner. 
To achieve tumor-selectivity we have benefit of the elevated expression 
of matrix metalloproteases (MMPs) found in primary and metastatic 
tumors (Matsuyama et al. 2002). We have generated the MMP 
activatable adenovirus AdTATMMP which expressed the TATPTD blocked 
by a polyanionic sequence. This blocking sequence was linked to TATPTD 
by an MMP cleavable sequence which would lead to vector tumor 
selectivity by restricting virus activation to MMP2/9 presence. 
To reduce adenovirus liver sequestration we have incorporated the 
YTRGE mutations into the fiber protein of AdTATMMP. These mutations 
have been shown to significantly reduce adenovirus binding to CAR  
receptor and to the blood factors C4BP and FIX, resulting in decreased 
liver transduction and hepatotoxicity in vivo (Shayakhmetov et al. 2005). 
3.1. Characterization of MMP2/9 expression in a 
battery of cell lines. 
First we analyzed the expression of MMP-2 and MMP-9 in a battery of 
cell lines in order to identify cellular models to test the activity of the 
new engineered MMP-activatable adenovirus. MMP2/9 expression was 
analyzed by western blot and gelatin zymography. MMPs are secreted by 
cells as inactive zymogens requiring of its posterior activation. Western 
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blot and zymography techniques detect the different forms of MMP 
generated during its activation: zymogen, pre-active and active forms.  
Confluent cell cultures of PANC-1, RWP-1, Emyc-3, HT1080 and NIH-3T3 
cell lines were grown for 24h in serum free medium. Then, the 
conditioned medium was harvested, concentrated up to 30 µl and the 
same sample was analyzed by WB and zymography (Figure 21). 
Immunoblot analyses revealed elevated MMP9 expression in PANC-1 
cells, and moderate and low expression levels in HT1080 and Emyc-3 cell 
lines, respectively. No MMP9 expression was detected in NIH-3T3 cells. 
By contrast, zymogram analyses detected MMP9 expression in all the 
studied cell lines, although intense bands were shown for active MMP9 
in PANC-1 cells and the zymogen forms in HT1080 and RWP-1 cells. 
 
Figure 21. MMP-9 and MMP-2 expression analysis. A) Western blot analysis of 
MMP-9 and MMP-2 levels in concentrated conditioned media. Control lanes 
correspond to 50 ng of MMP-9 or MMP-2. B) Gelatin zymography analysis of 
MMP-9 and MMP-2 activity levels in concentrated conditioned media. Control 
lane corresponds to 2 ng of MMP-9 and 2ng of MMP-2. Z: zymogen form, P: pre-
active form, A: active form. 
MMP2 expression was detected in all the studied cell lines by WB and 
zymography. High expression levels were observed in HT1080, Emyc-3 
and NIH-3T3 cells. Differences observed in MMP expression between WB 
or zymography analyses may be due to the highest zymography 























3.2. Proof of concept: the MCP peptide. 
To test the feasibility of the engineered system, in which the TAT peptide 
would be initially blocked and only exposed upon MMP activation, the 
Metalloproteinase Cleavable Peptide (MCP) was synthetized by the 
group of Dr. David Andreu (Proteomics and Protein Chemistry Unit, 
Department of Experimental Health Sciences, Universitat Pompeu Fabra). 
MCP peptide consisted on 11 Aa corresponding to TATPTD linked by a 
MMP2/9 target sequence to a polyanionic sequence whith the aim to 
neutralize the polycations of the TAT sequence by forming intramolecular 
hairpins (Figure 22). We used an optimized MMP2/9 cleavable linker that 
was demonstrated to efficiently and specifically recognize MMP-2 and 
MMP-9 proteins (Szecsi et al. 2006). 
 
Figure 22. MCP peptide scheme. 
First, we tested the capacity of the MMP linker to be recognized and 
cleaved by MMPs. The MCP peptide was incubated in the presence of 
recombinant MMP-2 for 4h. At specific time points samples were 
collected and analyzed in an HPLC (Figure 23). Three separated peaks 
were detected in the HPLC chromatograms corresponding to the MCP 
peptide and the products resulted as a consequence of its cleavage: the 
TAT and the polyanionic sequences. At 240 min, only the two peaks 
corresponding to TAT and polyanionic sequences were detected, 
indicating that the MCP peptide was completely cleaved.  
These results indicated that the MMP target sequence of the MCP 
peptide was recognized by recombinant MMP-2, producing MCP peptide 
complete cleavage in 4h.  
Next, we studied whether the MMP cleavable linker was recognized and 
cleaved by endogenous MMPs, and whether the MCP peptide was able 
to introduce a cargo molecule (fluorescein) into cells. To this end, the 
MCP* peptide was generated by linking fluorescein to the TAT domain of 
the MCP peptide. PANC-1 and NIH-3T3 cells were incubated with the 
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Figure 23. MCP cleavage by recombinant MMP-2. 0.5 mM MCP was incubated 
with 2.5 µg recombinant MMP-2 at room temperature for 4h. Samples were 
obtained at 0, 30, 60, 120 and 240 min and were analyzed by HPLC. Each graphic 
















microscope (Figure 24). Fluorescence emission was detected in PANC-1 
cells but not in NIH-3T3 cells indicating that MCP* peptide entered in 
PANC-1 but not in NIH-3T3 cells. Considering the different content of 
MMP in PANC-1 (elevated) and NIH-3T3·cells (low) these results 
suggested that the MCP* peptide was recognized and cleaved by 
endogenous MMPs triggering MMP2/9 specific cell transduction.  
 
Figure 24. Study of MCP cleavage by cells. 10.000 cells were seeded in triplicate 
in a 96-well plate. 16h later, medium was removed and 100 µl of serum free 
medium containing 10 µM MCP*, 10 µM pre-cleaved MCP* or 10 µM MCP* plus 
20 µM GM6001 were added. Three days later, cells were visualized under a 
fluorescence microscope. Pre-cleaved MCP* resulted from the incubation of 
MCP* peptide with 2.5 µg of MMP2 for 9h. Representative fluorescent images 
from one of three independent experiments are shown. 
To further analyze MMP2/9 dependent entrance of the MCP* peptide, 
cells were incubated with pre-cleaved MCP* or with MCP* in the 
presence of the GM6001 MMP inhibitor. Pre-cleaved MCP* entered in 
both PANC-1 and NIH-3T3 cells independently of MMP expression. By 
contrast, MCP* was not able to enter PANC-1 cells in the presence of 
GM6001. These results suggested that MCP* peptide was recognized and 
cleaved by endogenous MMPs and that its transduction capacity was 













3.3. AdTATMMP transduction efficiency in cellular models. 
3.3.1. AdTAT and AdTATMMP generation. 
In light of the obtained results, we generated the reporter adenoviruses 
AdTAT and AdTATMMP (Figure 25A) as explained in section of Materials 
and Methods. We incorporated in our studies the AdYTRGE as a control 
virus of the mutated fiber and AdCMVGFPLuc as control of non-mutated 
fiber. AdCMVGFPLuc, AdYTRGE, AdTAT and AdTATMMP viruses 
expressed the reporter cassette CMVGFPCMVLuc that consisted on the 
GFP and firefly luciferase genes controlled by the CMV promoter (Figure 
25). To verify correct fiber gene expression, HEK293 cells were infected 
with adenoviral vectors, and two days later total DNA was obtained and 
the fiber gene was analyzed by PCR (Figure 25B). Fiber PCR fragments of 
different sizes corresponding to fiber specific mutations were identified. 
Correct fiber sequences were verified by the sequencing of PCR products. 
To confirm that the mutated fibers were correctly incorporated into the 
viral capsid, purified viruses were resolved in an SDS-polyacrylamide gel 
and silver stained. No changes in protein content of the viral capsid were 
observed (Figure 25C).  
These results demonstrated the integrity of the viruses and confirmed 
that the modified fibers were correctly expressed and incorporated into 
the viral capsids of AdYTRGE, AdTAT and AdTATMMP. 
3.3.2. Analysis of AdTATMMP transduction efficiency after 
activation by MMP2/9. 
We evaluated the capacity of AdTATMMP to be activated by MMPs. 
AdTATMMP was incubated with 10 ng/µl of recombinant MMP2 or 
MMP9 at 37 for 2h. HT1080, PANC-1 and NIH-3T3 cells were then 
cultured in the presence of AdTATMMP or the MMP2 and MMP9 pre-
cleaved viruses, and three days later luciferase expression was measured. 
As shown in Figure 26A, MMP2 and MMP9 pre-cleaved AdTATMMP 
exhibited higher luciferase expression than AdTATMMP in all the studied 
cell lines, indicating higher transduction efficiency of AdTATMMP upon 
MMP cleavage. The highest luciferase expression was detected upon 
MMP9 cleavage, probably because the MMP target sequence was better 
recognized by MMP9 than by MMP2 (Liu and Muruve 2003; Greenlee et 
al. 2006). In non-precleaved AdTATMMP experiments HT1080 cells were 
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the most efficiently transduced followed by PANC-1 and NIH-3T3 cells; 
this could be related to the activity of endogenous MMPs. 
 
 
Figure 25. AdTAT and AdTATMMP fiber characterization. A) Schematic 
representation of AdYTRGE, AdTAT and AdTATMMP adenoviruses. B) Fiber 
analyses by PCR. HEK-293 cells were infected with 2µl of purified adenovirus. 
Two days later, cells were harvested and total DNA was obtained and used for 
PCR analyses. C) 10
10
 vp of purified viruses were lysed, resolved in a 10% SDS 
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Figure 26. AdTATMMP infection after MMP2/9 pre-cleavage. A) 10.000 cells 
were seeded in triplicate in a 96-well plate. The next day, AdTATMMP was 
incubated with 10ng/µl MMP9 or MMP2 in FBS-depleted medium at 37C for 2h. 
Cells were infected at 1.000 vp/cell with AdTATMMP or the pre-cleaved 
AdTATMMP and 6h later, virus was removed and cells were further cultured in 
FBS medium. Luciferase expression was measured 3 days later. Results are 
represented as the mean ± SEM of 2 independent experiments. B) The 
experiment was done as in panel A but MMP-9 doses were 10 ng/µl, 1 ng/µl or 
0.1 ng/µl. Results are represented as the mean ± SEM of 3 independent 








































































To further evaluate the MMP–dependent activation, cells were infected 
with AdTATMMP pre-cleaved with three different doses of MMP-9 
(10ng/µl, 1 ng/µl and 0.1 ng/µl), and three days later luciferase 
expression was measured. A dose response effect was observed in all the 
cell lines analyzed being the maximum luciferase activity detected at the 
highest MMP-9 dose used (Figure 26B). 
These results suggested that AdTATMMP was cleaved by MMP2/9 
leading to an increase in the viral transduction capacity of AdTATMMP. 
3.3.3. Evaluation of AdTATMMP transduction efficiency. 
Comparative study with AdTAT, AdYTRGE and 
AdCMVGFPLuc. 
Next, we studied the transduction capacity of AdTATMMP in a battery of 
cell lines that exhibited different MMP9/2 activities and compared to the 
CAR-ablated viruses AdYTRGE and AdTAT and to the CAR-dependent 
AdCMVGFPLuc. Cells were transduced with 1.000 vp/cell of 
AdCMVGFPLuc, AdYTRGE, AdTAT or AdTATMMP in the absence of FBS. 
After 6h the medium was changed for fresh FBS+ medium, and luciferase 
expression was measured three days later.  
A very low transduction capacity was observed for AdYTRGE when 
compared to AdCMVGFPLuc in all the cell lines analyzed in agreement 
with the knowledge that CAR ablation hindered adenoviral infection in 
vitro (Figure 27A). AdTAT and AdTATMMP viruses rescue adenovirus 
transduction capacity. Interestingly, AdTATMMP transduced cells more 
efficiently than AdTAT. A possible explanation could rely on structural 
differences in the modified fibers resulting in conformational changes 
that facilitate TAT domain presentation in AdTATMMP adenovirus. 
However, this remains to be demonstrated. Interestingly, AdTATMMP 
transduction capacity was from 2 to 4-folds higher than AdTAT and 
differences increased in cells that express MMP9/2 (Figure 27B). These 
results indicated that TATPTD insertion restored the transduction capacity 
of a CAR ablated adenovirus and that AdTATMMP presents with 
improved transduction than AdTAT. 
To further analyze the infection capacity of AdTATMMP, we evaluated its 
transduction efficiency in a battery of cell lines with different susceptibility 




Figure 27. Transduction efficiency of AdTATMMP, AdTAT, AdYTRGE and 
AdCMVGFPLuc at 1.000 vp/cell. 10.000 cells were previously seeded in triplicate 
in a 96-well plate. Cells were infected with 1.000 vp/cell of AdCMVGFPLuc, 
AdYTRGE, AdTAT or AdTATMMP in medium FBS-. 6h later, virus was removed 
and FBS+ medium was added. Luciferase expression was measured 3 days later. 
Results are represented as the mean ± SEM of 3 independent experiments. A) 
Luciferase expression relativized to that of AdCMVGFPLuc. * p<0.05. B) 
Luciferase expression of AdTATMMP relativized to that of AdTAT. Cell lines were 








































































































































AdCMVGFPLuc or AdTATMMP at 104 vp/cel and luciferase expression 
was measured three days later (Figure 28). 
Luciferase activity in PANC-1 and NIH-3T3 cells transduced with 
AdTATMMP adenovirus was significantly higher than that achieved with 
AdCMVGFPLuc indicating that transduction with AdTATMMP virus was 
more efficient than with AdCMVGFPLuc. However, similar luciferase 
activity was detected in HT1080 and Emyc-3 cells between the two 
viruses whereas decreased levels were detected in RWP1 cells 
transduced with AdTATMMP.  
These data indicates that AdTATMMP improved adenoviral infection in 
cell lines with low susceptibility to CAR-mediated infection. 
 
Figure 28. Transduction efficiency of AdTATMMP and AdCMVGFPLuc at 10.000 
vp/cell. 10.000 cells were seeded in triplicate in a 96-well plate. Cells were 
infected with 10.000 vp/cell of AdCMVGFPLuc or AdTATMMP in medium FBS-.  
6h later, virus was removed and FBS+ medium was added. Luciferase expression 
was measured 3 days later. Results are represented as the mean ± SEM of 3 
independent experiments. 
3.4. AdTATMMP biodistribution after systemic 
administration to Ela-myc mice. 
The next step was to evaluate AdTATMMP onselectivity in vivo in Ela-myc 
mice. 5·1010 vp of AdYTRGE or AdTATMMP were intravenously 
administered into Ela-myc mice at 11 weeks of age and four days later 
luciferase activity in liver and pancreatic tissue was measured in the 























transduction of 1.4 times respect to AdYTRGE (Figure 29). Interestingly, 
luciferase activity in the pancreas of Ela-myc mice with tumor nodules 
was 7.3 times higher than that of AdYTRGE. Thus, AdTATMMP increased 
tumor/pancreas transduction probably through tumor MMP viral 
activation. 
 
Figure 29. Liver and pancreas AdTATMMP transduction efficiency in Ela-myc 
mice. 5·10
10
 vp of AdYTRGE (n=3) or AdTATMMP (n=4) were intravenously 
administered into Ela-myc mice at 11 weeks of age. Four days later 
bioluminiscence emission of isolated organs was measured. Luciferase 



























4. EVALUATION OF THE EFFICACY OF 
IRREVERSIBLE ELECTROPORATION (IRE) 
TO TREAT PANCREATIC TUMORS. 
It is estimated that from the 85% of patients with unresectable PDAC, 
25% present locally advanced PDAC, and the rest are metastasic (Kern et 
al. 2011). Irreversible electroporation (IRE) has been proposed as a 
method for solid tumor ablation. This technology is based on the 
application of high-voltage pulses with a duration of microseconds to 
milliseconds to induce plasma membrane defects leading to cellular 
death. Interestingly, this method does not affect large blood vessels 
(Rubinsky 2007), which make it suitable for treatment of unresectable 
cancers with a complicated anatomical situation, as in pancreatic cancer 
In this thesis, we decided to evaluate the feasibility of IRE for the 
treatment of PDAC in an orthotopic mouse model. This work was done in 
collaboration with Dr. Luciano Sobrevals. 
4.1. Generation and characterization of BxPC-3-Luc 
orthotopic tumor model. 
To study the therapeutic effect of irreversible electroporation (IRE) on 
pancreatic tumors, we developed a pancreatic cancer model by 
orthotopic implantation of BxPC-3-Luc cells in the body of the mouse 
pancreas (Figure 30A). The expression of luciferase by BxPC-3-Luc cells 
allowed us to follow-up the tumoral growth, as well as the dissemination 
of tumoral cells to other organs, through the use of the in vivo 
bioluminescent system IVIS50. BxPC-3 xenografts were very aggressive 
tumors when implanted orthotopically (Lee et al. 2010a), the tumor 
growth rate was elevated and, in the majority of animals, the tumor 
ended up disseminating through the peritoneal cavity. Histologically, 
BxPC-3 tumors showed the ability to infiltrate the pancreatic parenchyma 
(Figure 30B). 
4.2. Evaluation of IRE treatment on tumor progression 
and mice survival. 
With the objective to follow-up tumor growth, luciferase expression of 
BxPC-3-Luc tumor-bearing mice was monitored once a week until the 
dead of the animal.  Animals were irreversible electroporated (IRE 
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treated group) or sham electroporated (Untreated group) when the 
luciferase counts were within the range of 106-107 photons/s, that 
corresponded to day 32-43 after tumor implantation and to a tumor 
volume of 95.79±29.59. 
 
Figure 30. BxPC-3-Luc orthotopic human tumoral model. A) Representative 
images of tumor aspect (left panel) and luciferase signal (right panel) of 
orthotopic pancreatic BxPC-3-luc tumors. Black arrow indicates tumoral masses 
within the pancreas and white arrow indicates luciferase positive area, 
corresponding to the tumoral masses. B) H&E staining of representative 
orthotopic BxPC-3-Luc tumors. Left and right scale bar: 100 µm and 25 µm, 
respectively. White arrows indicate tumoral cells invading healthy acinar cells. 
IRE treatment consisted on the application of an IRE pulse train to a 
pancreatic tumor situated between the tweezertrodes. The process is 
described in detail in section 5.4 of Materials and Methods. The IRE pulse 
train consisted on 10 sequences of 10 pulses each, separated by 10s each 
sequence. Each pulse was of 2500 V/cm diameter tumor, with duration 
of 100 µs and separated by 1s each pulse. The whole electroporation 




IRE pulse train = 10 x Sequences.       10s between sequences. 
Sequence = 10 pulses x 2500 V/cm.   100µs each pulse and 1s 
between pulses (1Hz). 
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Four days after IRE treatment, the treated group presented significantly 
lower luciferase activity than control mice. For most of the animals 
luciferase values remain low or undetectable for all the period analyzed, 
suggesting a reduced tumor progression or tumor eradication; however 
in a small subset of mice, 30 days post-IRE treatment luciferase activity 
increased, indicative of tumor regrowth ( Figure 31).  
 
Figure 31. IRE treatment effect on tumor progression. BxPC-3-Luc orthotopic 
tumors were generated in nude mice. When the luciferase counts were within 




 photons/s, animals were irreversible electroporated. A) 
Representative images of bioluminescent emission from untreated or IRE-
treated BxPC-3-Luc tumor-bearing mice, at different time points. B) Luciferase 
quantification of bioluminescent emission images from untreated (n=7) and IRE-
treated (n=12) BxPC-3-Luc tumor-bearing mice, before (pre-IRE) and after 4, 14 
and 20 days of IRE treatment. Results are expressed as photons per second. 
Values are represented as mean ± SEM. *p < 0.01 
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IRE treatment prolonged mouse survival and increased the median 
survival time from 42 days in untreated mice, up to 88 days in the IRE-
treated group (Figure 32). At the end of the experiment 25% of mice 
presented complete tumor eradication.  
 
Figure 32. Survival analysis of BxPC-3-Luc tumor bearing mice after IRE 
treatment. BxPC-3-Luc orthotopic tumors were generated in nude mice and 





 photons/s. Kaplan-Meier analyses survival curve (log-rank test, p<0.01). 
Untreated group n=15, IRE treated group n=18. Crosses indicate censored mice. 
4.3. Evaluation of the pancreatic pathological 
alterations produced by IRE treatment. 
Next, we analyzed the pathological alterations produced in the pancreas 
by irreversible electroporation. For this, we assessed gross morphology, 
histological analysis and immunohistochemical studies in the pancreas of 
treated animals at days 1, 7 and 14 post-IRE, as well as in non-treated 
animals.  
4.3.1. Gross morphology and histological analysis. 
With the objective to analyze the effect of IRE treatment on tumor/tissue 
morphology, pancreas/tumors from untreated and IRE-treated mice 
were obtained at 1, 7 and 14 days after electroporation. Tumors of 
untreated animals were visualized as a mass of white bright color. In 
contrast, treated tumors at days 1 and 7 post-IRE revealed an intense 
brown area covering the tumor, suggestive of blood accumulation. At day 
14 post-IRE a yellow mass of strong intensity in the periphery was 
Untreated
IRE treated















observed defining a well-demarcated tumor, indicative of necrosis 
(Figure 33A).  
 
Figure 33. IRE treatment effect on tumor morphology. BxPC-3-Luc orthotopic 
tumors were generated in nude mice and IRE treated when the luciferase counts 




 photons/s. Animals were sacrificed at the 
indicated time points, and the pancreas was obtained. A) Representative tumors 
from untreated (n=2) and IRE-treated mice, showing the macroscopic effect of 
electroporation at day 1 (n=2), 7 (n=4) and 14 (n=4). B) H&E staining of BxPC-3-
Luc tumors untreated and IRE-treated at 1, 7 and 14 days. Black arrows indicate 
hemorrhagic reaction, green arrow indicates islands of tumoral cells immersed 
into necrotic tissue and yellow arrows point at lymphocytic infiltrates. Scale bar 
400 µm (top panel) and 50 µm (bottom panel). 
Histological tissue examination after IRE treatment (Figure 33B) revealed 
an extensive necrotic area, evident since day 1. At day 1 post-IRE a large 
number of red blood cells were visualized suggesting vascular disruption 
as a consequence of the procedure. At day 7 post-IRE extensive areas of 
necrotized tissue were observed, as well as the presence of lymphocytic 
infiltrates and histiocytes, that was much more remarkable at day 14.  
B
IRE treatedUntreated
d1            d7            d14
A
Day 1 Day 7 Day 14Untreated
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In some animals residual viable tumoral cells were present within the 
electroporated tumor, and curiously, at day 14 post-IRE, small non-
electroporated nodules were also found distant to the electroporated 
tumor suggesting that at the moment of IRE procedure these nodules 
were not detected. These nodules could be a factor implicated on the 
tumor regrowth detected in some animals despite a good response to 
IRE treatment.  
Regions of non-viable epithelium of the pancreatic parenchyma were 
also observed in some animals, probably due to the inclusion of a portion 
of normal pancreas between the plate electrodes during the IRE 
procedure.  
4.3.2. Analysis of tumor cell viability in IRE treated mice. 
We next analyzed the effect of IRE treatment on tumoral cell 
proliferation by staining with Ki67, a well-known marker of cell 
proliferation, in sectioned pancreas. Strong immunoreactivity was 
observed in untreated tumors, indicative of active proliferating tumors. 
In contrast, most of the treated tumors analyzed were Ki67 negative at all 
the time-points. In particular, some remnant proliferating cells positive 
for Ki67 were identified within or at tumor periphery, especially at day 1 
post-IRE, probably indicating an incomplete IRE effect (Figure 34).  
 
Figure 34. IRE treatment effect on proliferation and apoptosis. BxPC-3-Luc 
orthotopic tumors were generated in nude mice and IRE treated when the 




 photons/s. Animals were 
sacrificed at the indicated time points, and the pancreas was obtained and 
embedded in paraffin. Immunohistochemical analysis in untreated and IRE-
treated mice at days 1 (n=2), 7 (n=4) and 14 (n=4) after treatment was 
performed. Representative images of anti-Ki67 and anti-active caspase-3 
immunostaining are shown. Scale bar: 100 µm. 












To study whether IRE treated tumors suffer from apoptotic cell death, we 
analyzed the presence of activated caspase-3. No caspase-3 positive cells 
in any of the analyzed tumors were detected indicating that IRE was not 
activating apoptotic cell death. However, some isolated caspase-3 
positive cells could be identified in untreated tumors, corresponding to 
normal tumor development (Figure 34, bottom panel). At day 14 some 
polymorphonuclears cells in the tumor burden were also positive for 
caspase-3. 
4.3.3. Analysis of tumor vascular architecture in IRE treated 
mice. 
We also analyzed the effect of IRE treatment on tumor vascular 
architecture. Immunostaining against the endothelial cell marker CD-31 
was performed. Anti-CD31 staining nicely showed microvessel-density in 
the BxPC-3Luc xenograft model. Disruption of the small vascular 
architecture was clearly observed since day 1 post-IRE and was present 
at all time-points post-IRE treatment (Figure 35). At day 14, images seem 
to indicate that there was a vascular regrowth.  
 
Figure 35. IRE treatment effect on tumor vasculature. BxPC-3-Luc orthotopic 
tumors were generated in nude mice. When the luciferase counts were within 




 photons/s, animals were irreversible electroporated. 
Animals were sacrificed at the indicated time points, and the pancreas was 
obtained and included in OCT. Representative images of anti-CD31 
immunohistochemical analysis in untreated and IRE-treated mice at days 1 
(n=2), 7 (n=4) and 14 (n=4) after treatment are shown. Top panel scale bar: 400 
µm; bottom panel scale bar: 100 µm. 
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4.4. Evaluation of IRE procedure-associated toxicity. 
We next evaluated the safety of the IRE procedure by analyzing serum 
biochemical parameters of liver and pancreatic function at 1h, 6h, 24h, 7 
days and 14 days after IRE procedure. Liver damage was assessed by 
measuring serum AST and ALT levels at different time-points after IRE 
application. As shown in Figure 36A a peak in serum levels of liver 
transaminases was detected at 6h. However, at one day post-treatment 
ALT values were already within the normal range and AST levels were 
almost completely recovered. At days 7 and 14 post-IRE ALT and AST 
values were both within the reference range.  
Pancreatic function was assessed by measuring serum amylase and lipase 
levels (Figure 36B), as well as serum glucose levels (Figure 36C). A 
transient increase in both amylase and lipase enzymes was detected at 
6h post-IRE that completely normalized at 24h. Normal values were also 
detected at days 7 and 14 post-IRE treatment.   
A 2-fold increase in the glucose levels was detected in the first hour post-
IRE, followed by a slight hypoglycemia at 6h that resolved at 24h. The 
transient increase in the glucose levels in the first hour could be an 
indication of the glucose release from dying tumor cells. Normal glucose 
values were maintained at 7 and 14 days post-treatment.  
These data indicated that IRE pancreatic tumor treatment generated 





Figure 36. Liver and pancreatic function studies in IRE treated mice. Analysis of 
ALT and AST (A), amylase and lipase (B) and glucose (C) serum levels in IRE-
treated mice before (n=18) and after 1h (n=6), 6h (n=6), 24h (n=7), 7 d (n=12) 
and 14 d(n=9) IRE treatment. Graphic insets correspond to the first 24h after 
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“Es mejor debatir una cuestión sin resolverla, que resolver una 










Pancreatic cancer is one of the most devastating malignancies with a 5-
year survival rate lower than 5%. Pancreatic cancer (PC) is classified in 3 
clinically important categories: i) localized cancer, ii) locally invasive 
disease, and iii) unresectable PC. The criteria for unresectability of PC 
include tumor vascular involvement (celiac axis or superior mesenteric 
artery) and the presence of distant metastasis (Edge et al. 2010). The 5-
year survival directly correlates to the stage at diagnosis (Table 13) since 
surgical treatment is the only potential cure of PC. Due to the absence of 
early diagnosis and its highly invasive and metastatic features, only 10-
15% of patients with pancreatic cancer are candidates for surgical 
resection. However, even after resection, the 5 year survival rate is only 
20% or less as PC has a high loco-regional recurrence rate and a tendency 
towards early liver metastasis, requiring the employment of adjuvant 
therapy in combination with surgical resection (Fatima et al. 2010). 
Unresectable and metastatic patients are treated with chemo and 
radiotherapy (Sharma et al. 2011); however, PC shows strong resistance 
to the currently available chemotherapy and/or radiotherapy protocols. 
In the recent years clinical trials with FOLFIRINOX (oxaliplatin, irinotecan, 
leucoviron and 5-FU) or with the combined treatment (gemcitabine, 
capecitabine, bevazicumab and erlotinib) have shown a small 
improvement on survival (from a median survival of 6.9 months with 
standard therapy to 10.5 and 11.1 respectively) in patients with 
advanced disease. This still represents very limited success for treatment, 
thus, novel therapeutic modalities are urgently needed. 
Stage at diagnosis Stage 
distribution (%) 
5 year relative 
survival (%) 
Localized (confirmed to primary site) 8 22.5 
Regional (spread to regional LNs) 26 8.8 
Distant (cancer had metastasized) 53 1.9 
Unknown (unstaged) 14 5 
Table 13. Stage distribution of pancreatic cancer and 5-year relative survival by 
stage at diagnosis for 1999-2006. LNs : lymphatic nodules. 
Gene therapy is a potential and promising therapeutic modality for the 
treatment of cancer. Effective treatments must be capable of efficiently 
target tumoral nodules destroying tumoral cells without harming non-
tumoral cells, and without being inactivated by components of the blood 
stream nor rapidly sequestered into non-target tissues. Tumor anatomy 
represents a challenge to gain access to tumoral cells, especially in 
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pancreatic tumors, where the dense stroma and the poor tumor 
vascularization limited the arrival of viruses to the bulk of the tumor. One 
of the objectives of this thesis has been the improvement of adenoviral 
gene delivery to pancreatic tumors by exploring a novel delivery route 
and by enhancing tumor transduction through a retargeting strategy. 
The success of a gene therapy-based tumoral treatment not only relies 
on the viral transduction efficiency of the tumor, but also on the capacity 
of the therapeutic agent to destroy tumoral cells. Hence, a second 
objective of this thesis has been the evaluation of the therapeutic 
efficacy of the antitumoral AduPARTat8TK/GCV gene therapy and its 
combination with the chemotherapeutic gemcitabine. 
Following the general objective of this thesis of developing novel 
antitumoral strategies for the treatment of pancreatic cancer, we have 
evaluated the antitumoral efficacy of the novel non-thermal ablative 
technique irreversible electroporation. 
 
1. STRATEGIES TO IMPROVE ADENOVIRAL 
TUMOR TARGETING. 
1.1. Intraductal injection into the common bile duct as 
a novel delivery route to target pancreatic tumors. 
The success of gene therapy relies, among others, on the delivery route 
of vector administration since therapeutic efficiency has been clearly 
associated with the ability of the viral agent to spread throughout the 
tumor (Heise et al. 1999). The location and stage of the tumor will 
influence the choice of the optimal route of administration. Systemic 
delivery by intravenous administration is specially indicated for 
pancreatic tumors with distant metastasis; whereas intratumoral 
injection is a locoregional route to target primary tumors. However, all 
routes face with difficulties to achieve optimal delivery.  
Direct injection of anticancer therapies into the pancreas, although 
tested, are limited by the relative inaccessibility of the organ and the 
potential for causing pancreatitis. CT-guided injection of the replicative 
adenovirus ONXY-015 in a Phase I trial demonstrated the safety and 
feasibility of the adapted technique (Mulvihill et al. 2001); however, CT-
guided injection was cumbersome and it was difficult to perform 
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repeated intratumoral injections during a given treatment session. EUS-
guided injection of ONYX-015 (Hecht et al. 2003) and TNFarade, a 
replication-deficient adenovirus carrying the TNF- gene (Chang et al. 
2008; Chang and Irisawa 2009) have shown encouraging results in clinical 
trials; unfortunately, this technique has also presented several 
complications from the injection procedure such as infection, perforation 
of the duodenum or the stomach, risk of pancreatitis and the potential 
for malignant seeding (Seo 2010). Then, nowadays clinical trials on top of 
evaluating the safety and the efficacy of therapeutic agents, they also 
analyze for the safety and efficacy of novel delivery routes to treat 
pancreatic tumors. 
Systemic administration of adenoviral vectors is limited by the 
sequestration of adenovirus by the liver (Lieber et al. 1997; Di Paolo et al. 
2009) which produces hepatotoxicity and reduces the amount of 
therapeutic vector targeting the tumor. Moreover, the preexistence of 
neutralizing antibodies can lead to the clearance of the viral vector 
(Harvey et al. 1999). In addition a great obstacle to the clinical 
application is the innate immune response towards the vector that 
occurs upon adenovirus administration that depends entirely on virus 
capsid interaction with host cells (Liu and Muruve 2003). Such response 
has been observed both after intravenous delivery and upon direct 
injection of adenovirus into the pancreas (McClane et al. 1997). 
ERCP is an imaging technique used in human for the diagnoses of bile 
and pancreatic duct diseases and in some cases for the diagnoses of 
pancreatic neoplasms. Intraductal injection is an adaptation of the ERCP 
technique and has been used for the delivery of compounds to the 
pancreas of animal models, to generate rat models of pancreatitis after 
administration of sodium taurocholate, or to generate animal models of 
pancreatic cancer after administration of tumoral cells or carcinogen 
agents (Kamano et al. 1991; Jonsson and Ohlsson 1995; Folch et al. 2000; 
Tsuji et al. 2006; Gea-Sorli and Closa 2009). The technique has also been 
used for the treatment of diabetes after adenovirus or adenoassociated 
virus administration to mouse models (Tokui et al. 2006; Jimenez et al. 
2011). In this thesis, we have evaluated the effectiveness of the 
intraductal injection method for the delivery of adenovirus to target 
pancreatic tumors. We have shown that adenoviral delivery through the 
common bile duct restricted transgene expression to pancreas and, when 
compared to systemic administration, intraductal injection increased 
pancreatic viral transduction with significantly reduced liver infection. 
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Importantly, adenoviruses efficiently reached the bulk of pancreatic 
tumors in Ela-myc mice upon intraductal delivery. 
Our data showed that by adenoviral intraductal administration transgene 
expression from the adenoviral vector was detected in the whole 
pancreas probably because adenoviruses distribute through the 
pancreatic branching duct system to the whole organ. To restrict viral 
antitumor activity to cancerous cells we have used the uPAR promoter 
controlling transgene expression. Previous studies had demonstrated 
that the PLAUR gene (uPAR) was overexpressed in pancreatic tumors and 
PLAUR gene amplification was a highly significant adverse prognostic 
marker (Hildenbrand et al. 2009). Moreover, uPAR-based adenoviruses 
present with oncoselectivity for pancreatic tumors (Huch et al. 2009). In 
the pre-neoplasic Ela-myc pancreas we have shown that uPAR mRNA 
expression was upregulated compared to wt pancreas, similarly to what 
has been shown in high-grade PanIN lesions of clinical samples 
(Hildenbrand et al. 2009). These data suggest that the factors driving 
uPAR transcription may be highly active in the tumoral context. Indeed, 
we have observed that the AduPARLuc reporter adenovirus showed 80 
times lower luciferase activity than AdCMVGFPLuc in wt mice whereas 
this reduction was only of 10 times in the Ela-myc tumoral model. This 
difference in luciferase activity was probably caused by the elevated 
expression of uPAR in the Ela-myc pancreas that led to the activation of 
the uPAR promoter in the adenoviral context. This oncoselectivity was 
further confirmed by the elevated and broadly distributed expression of 
GFP, driven by the CMV promoter in the pancreas of wt mice contrasted 
with the lack of luciferase expression, controlled by the uPAR promoter. 
On the contrary, in Ela-myc mice luciferase expression was detected in 
the core of solid pancreatic tumors demonstrating that AduPARLuc 
targeted the bulk of pancreatic nodules upon i.d administration. 
The interest of the intraductal delivery as a target route against 
pancreatic tumors was demonstrated by showing the antitumoral 
efficacy of the cytotoxic adenovirus AduPARTat8TK/GCV. The antitumoral 
capacity of Tat8TK-based adenovirus for the treatment of pancreatic 
subcutaneous tumors upon intratumoral injection has been previously 
demonstrated by our group (Cascante et al. 2007; Garcia-Rodriguez et al. 
2011). Interestingly, the i.d. delivery of AduPARTat8TK showed major 
reduction on the tumoral growth of Ela-myc pancreatic tumors than the 
intravascular delivery. These results were in line with the data from the 
reporter experiments where we demonstrated that AdCMVGFPLuc 
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adenovirus targeted Ela-myc tumors more efficiently upon intraductal 
injection.  
Importantly, no pancreatic toxicity was observed upon intraductal 
administration of AduPARLuc to Ela-myc mice demonstrating that the 
intraductal injection into the common bile duct was a safe delivery route 
for the administration of adenoviruses to the pancreas. Moreover, the 
lack of hepatotoxicity found upon AduPARLuc systemic administration 
confirmed the specificity of the uPAR promoter for tumoral tissue and 
demonstrated the safety of the AduPARTat8TK/GCV therapy. 
An interesting aspect of this route of administration is the potential 
feasibility of being applied for repeated adenoviral administrations. It has 
been reported that intraductal delivery of adenovirus into the common 
bile duct (two and three times) led to successful re-expression of the 
transgene into the liver despite the existence of neutralizing antibodies in 
serum. Interestingly, no neutralizing antibodies were present in the duct 
(Tominaga et al. 2004). This technique was similar to the one employed 
in the present work, but differed in the clamping of the bile duct. The 
absence of bile duct clamping would allow for adenovirus reaching the 
liver. Thus, intraductal administration seems to be a good option to 
overcome an important limitation of the adenoviral vectors, the inability 
of vector re-administration. Neutralizing antibodies have also been 
detected following direct injection of adenoviral vectors into the 
pancreas what induced a systemic response that prevented local direct 
re-administration of the vector (McClane et al. 1997). Noticeable, the 
mechanisms that triggered a systemic immune response upon direct Ad 
injection were not activated upon intraductal injection. Therefore, it 
would be interesting to evaluate the feasibility of AduPARTat8TK/GCV 
intraductal re-administration and its therapeutic effect on Ela-myc 
pancreatic tumors.  
Altogether, our results indicate that intraductal administration of 
adenovirus into the common bile duct efficiently targeted pancreatic 
tissue. Moreover, AduPARTat8TK/GCV therapy is capable of great activity 
and selectivity for pancreatic tumors, reducing the tumoral growth of Ela-
myc tumors with no toxicity and ameliorating tumor-associated toxicity. 
The intraductal administration delivery route of cytotoxic adenovirus to 
pancreatic tumors would mostly applied for the treatment of localized 
tumors or locally invasive pancreatic tumors. Nevertheless, because the 
application of this technique in the absence of bile duct clamping has 
been shown to allow for the virus to reach the liver, it could be 
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speculated that in such conditions small pancreatic liver metastasis could 
be targeted with an appropriate adenovirus through this route. This 
remains to be demonstrated; however, if so, it will enlarge the potential 
application of the intraductal delivery route. 
1.2. Infectivity and selectivity of the metalloprotease 
activatable adenovirus AdTATMMP.  
Human adenovirus serotype 5 has been widely exploited as a gene 
delivery vector owing to its superior gene delivery efficacy, minor 
pathological effects on humans and easy manipulation in vitro. However, 
they present inefficient transduction of cancerous tissue due to low 
levels of CAR expression, and the innate hepatotropism and toxicity of 
Ad5 in vivo following intravenous delivery (Lieber et al. 1997; Hamdan et 
al. 2011). Thus, Ad vectors which combine liver detargeting with high 
efficiency CAR-independent gene delivery to cancer-specific receptors 
would improve the adenoviral tumor delivery and, consequently, their 
antitumoral capacity. In this thesis we have generated the MMP 
activatable adenovirus AdTATMMP. On one hand, AdTATMMP virus 
carried the previously described YTRGE mutations to provide with liver 
detargeting by eliminating the binding to coagulation FIX and the 
complement factor C4BP (Shayakhmetov et al. 2005). The virus was also 
mutated in its motif for CAR receptor binding recognition leading to an 
adenovirus with a CAR-independent cell entry. On the other hand, 
AdTATMMP virus expressed the protein transduction domain TAT into 
the fiber protein to mediate viral infection. To provide the virus with 
tumor selectivity, we have blocked the TATPTD with a polyanionic tail 
linked by a MMP cleavable linker. 
AdTATMMP virus showed to be activatable by metalloproteases. 
Incubation of the virus in the presence of recombinant MMP2 or MMP9 
demonstrated that AdTATMMP was able to transduce cells in a dose-
response manner being more efficient at the highest concentration of 
MMP9 tested. Interestingly, cell lines with higher content of MMP2/9 
also were more susceptible to AdTATMMP transduction. This MMP-
activation could provide to the virus with oncoselectivity, suggesting that 
in environments with high MMP activity, such are the pancreatic tumors 
(Jimenez et al. 2000; Giannopoulos et al. 2008), the virus could be 
activated. This selectivity has also been observed for other virus such are 
Retrovirus, Sendai virus and Measles virus which had been successfully 
engineered to be activated by MMPs and had demonstrated to 
DISCUSSION 
 145 
selectively transduce MMP-rich cells and subcutaneous tumor models 
after intratumoral administration (Schneider et al. 2003; Kinoh et al. 
2004; Springfeld et al. 2006; Szecsi et al. 2006; Duerner et al. 2008). 
However, all these viruses were enveloped virus and, upon activation, 
viral entrance was mediated by the env proteins. 
AdTATMMP is a CAR-ablated virus, thus, the entrance to the cell was 
engineered to be through the TAT domain with the aim to improve CAR-
mediated tumor transduction. The TATPTD incorporation into the C-ter of 
the YTRGE fiber protein was probably mediating viral entry because both 
AdTAT and AdTATMMP adenoviruses restored viral transduction 
capacity. As a cell penetrating peptide, TATPTD is capable to translocate 
across the plasma membrane of mammalian cells and mediate the 
intracellular delivery of heterologous proteins fused to them after their 
systemic delivery (Schwarze et al. 1999; Beerens et al. 2003; Orii et al. 
2005). TATPTD had already been used to facilitate virus infection; in 
particular, bi-specific adaptor proteins consisting of TATPTD fused to the 
extracellular domain of CAR were used to coat Ad vectors, which resulted 
in enhanced gene delivery (Kuhnel et al. 2004). However, genetic fusion 
of TATPTD to the fiber protein possesses major advantages such as the 
stable interaction between Ad5 and TATPTD, and the possibility of retarget 
replicative adenovirus. During the development of this thesis Han et al 
and Kurachi et al developed adenoviruses that incorporated the TATPTD 
domain into the HI-loop or the 3’ end of the fiber gene (Han et al. 2007; 
Kurachi et al. 2007). They demonstrated that the recombinant vectors 
combined cell entry mediated by CAR with that mediated by TAT. TAT-
modified viruses resulted in improved gene delivery efficacy in cellular 
models as well as in subcutaneous tumor models after Ad intratumoral 
administration. No biodistribution differences were found between 
systemic administration of TAT-modified or non-modified adenoviruses. 
By contrast, in this thesis we have evaluated the transduction capacity of 
a CAR-ablated TAT-modified adenovirus when introduced at the 3’ end of 
the fiber protein. The resolution of the crystal structure of the Ad5 knob 
domain by X-ray crystallography has identified the HI loop region as a 
region suitable for peptide incorporation (Xia et al. 1995), and to date 
this site has been shown to tolerate the insertion of ligands up to 83 
amino acids with negligible effects on structural integrity (Belousova et 
al. 2002). The 3’ end of the fiber gene has also been used for peptide 
incorporation. Indeed, the suitable location for peptide incorporation 
seemed to be dependent on the peptide itself. RGD motif insertion 
improved adenoviral transduction more efficiently when incorporated at 
the HI-loop whereas polylysine (pK7) insertion improved transduction 
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efficiency when incorporated at the C-terminus (Koizumi et al. 2003). 
Kurachi et al incorporated TATPTD both at the HI-loop and at C-terminus 
of the fiber knob and reported better transduction efficiency in HI-loop 
modified vectors. But Han et al cloned the TATPTD at the C-terminus of 
the fiber protein and also observed enhanced transduction capacity. In 
the case of AdTATMMP, we were forced to introduce the TAT-MMP 
linker-blockage peptide at the C-terminus of the fiber protein since the 
blocking domain had to be released after cleavage by MMPs.  
Transduction experiments in this study indicated that AdTATMMP 
exhibited enhanced transduction capacity compared to that of AdTAT. 
Although there is not a clear explanation for that it could be speculated 
that the TAT peptide acquired a conformation in the YTRGE-TATMMP 
fiber that facilitated its interaction with the cell membrane more 
efficiently that in the YTRGE-TAT fiber. We hypothesize that YTRGE 
mutations hindered TATPTD exposure since it was predicted that YTRGE 
mutations changed the overall conformation of the knob domain and 
created sterical hindrances preventing interaction with ligands 
(Shayakhmetov et al. 2005). On the contrary, the presence of the 
blocking domain in the YTRGE-TATMMP fiber could facilitate the correct 
folding and exposure of TATPTD after its cleavage by MMPs.  
The systemic administration of the MMP-activatable retrovirus in mice 
with s.c tumors showed an improved ratio tumor/bone marrow, but the 
retargeted vector was less potent than the control retrovirus (Duerner et 
al. 2008). Interestingly, AdTATMMP was 7.3 folds more potent than its 
control virus AdYTRGE to target pancreatic tumors when administered 
intravenously. On the other hand, only a 1.4-fold increase in liver 
transduction was observed suggesting that AdTATMMP vector exhibited 
selectivity for tumoral tissue.  
Despite containing the YTRGE mutations both AdYTRGE and AdTATMMP 
significantly transduced hepatic cells when administered systemically. Its 
transduction capacity was much lower than that from the AdCMVGFPLuc 
adenovirus, carrying a non-modified fiber. Luciferase counts in the liver 
after AdYTRGE or AdTATMMP intravenous administration were about 2-
logs less than those from AdCMVGFPLuc. Thus YTRGE mutation 
contributed to minimize liver transduction but there was not a complete 
liver detargeting effect. This is not surprising because during the 
development of this thesis, Kalyyuzhniy et al and Waddington et al 
demonstrated that hexon protein is a major mediator of liver 
transduction by interaction with coagulation factor X (Kalyuzhniy et al. 
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2008; Waddington et al. 2008). Indeed, hexon hypervariable region five 
(HVR5) substitution or pseudotyping with serotype 3 hexon protein 
dramatically reduced liver transduction and associated toxicity (Vigant et 
al. 2008; Short et al. 2010). Therefore, the introduction of hexon 
modifications to AdTATMMP virus would be a possible strategy to reduce 
to a greater extent liver transduction and increase the tumor/liver ratio.  
 
2. EFFECTS OF THE COMBINED TREATMENT 
AduPARTat8TK/GCV GENE THERAPY AND 
GEMCITABINE. 
The pathogenesis of pancreatic cancer is complex and single therapies 
are unlikely to achieve a cure. The chemotherapeutic gemcitabine (GE) is 
the first line treatment for pancreatic cancer; however, the survival 
benefit for advanced pancreatic cancer remains limited. Nowadays many 
studies are evaluating the therapeutic efficacy of combined therapies 
such as gemcitabine plus a gene therapy agent. Previous studies reported 
a synergistic effect between gemcitabine and GCV; in particular, it was 
described that gemcitabine enhanced the bystander effect of GCV in vitro 
and in vivo (Boucher and Shewach 2005).  
In this work we have observed a synergistic effect between GE and 
AduPARTat8TK/GCV in vitro that was remarkable in the Emyc cell line. To 
understand the basis of this synergism we have to pay attention to the 
mechanism of action of GE and GCV. Both drugs are nucleoside 
analogues that incorporate into the DNA during its synthesis, blocking 
chain elongation and finally causing cell death by apoptosis. In addition, 
GE is an inhibitor of the ribonucleotide reductase, through this activity 
GE reduces dNTPs pool, increasing in this way the ratio 
triphosphorilated-GE (dFdCTP)/dCTP (its nucleoside analogue) and, 
consequently, enhancing gemcitabine (dFdCTP) incorporation into the 
DNA. Therefore, GE can synergize with GCV reducing the endogenous 
dGTP pool (GCV nucleoside analogue) and consequently facilitating the 
incorporation of GCV-TP into the DNA. On the contrary, GE can 
antagonize with GCV by inhibiting DNA syntheses and then hindering TP-
GCV incorporation into the DNA. The outcome of the combined therapy 
will depend on which of these two additional mechanisms would prevail. 
Unfortunately, we could not appreciate any synergism when both 
therapies were applied in vivo in the Ela-myc mice in any of the two 
DISCUSSION  
 148 
protocols applied. The two protocols differentiate in the order of 
application of GE, AduPARTat8TK and GCV. The initial idea was that by 
giving GE first, this would reduce the dNTP pool, what will potentially 
enhance the posterior incorporation of GCV into the DNA. Moreover, the 
administration of GE first could also affect the uPAR promoter activity 
influencing the cytotoxicity of the TK/GCV. It is known that GE treatment 
can modify the expression pattern of some genes showing for example 
enhanced expression of transcription factors such as Wilms’ tumor 
(Takahara et al. 2011), a positive regulator of the uPAR promoter (Dra. 
Maria Victoria Maliandi, personal communication). Hence, we cannot 
rule out that gemcitabine treatment could modulate uPAR promoter 
activity influencing on the output of the TK/GCV therapy with 
consequences in the combined treatment. It will be interesting to study 
whether this translates in an activation of the promoter, similar to what 
has been proposed for the CMV promoter (Onimaru et al. 2010) or on 
the contrary it limits its activity. Although the upregulation of the uPAR 
positive regulator Wilm’s tumor might suggest an activated uPAR 
mediated transcription, we could not discard the induction of other 
mediators that could negatively regulate the uPAR promoter. 
The results of the in vivo combined therapy have to be also 
contextualized to the characteristics of the mouse model utilized. As we 
observed in the Emyc cultures these tumor cells are much more resistant 
to gemcitabine than any of the human derived cancer cells tested in the 
study (with an ID50 160 to 80 times higher). Thus, in an in vivo situation 
the option that tumor cells would be receiving sufficient amount of GE 
inducing an effect that could synergize with activated GCV metabolites 
could be suboptimal. However, the fact that Ela-myc mice have an intact 
immune system could provide with potent biological activity to 
gemcitabine. It is well known that GE presents with immunostimulatory 
functions by the alteration of the local immunosuppressive 
microenvironment of the tumor. It has been described that GE releases 
tumoral antigens inducing an antitumor response (Suzuki et al. 2005), 
prevents tumor-induced systemic immunosuppressive cells (Gallina et al. 
2006; Curiel 2008) and can augment trafficking and activation of immune 
cells in tumor sites (Pardoll 2003).  
The immune system has a dual role in the outcome of an adenoviral 
therapy. On one hand, replication-deficient adenoviruses induce a rapid 
inflammatory response that define dose limiting toxicity (Lieber et al. 
1997) and T cell mediated killing of infected cells can reduce transgene 
expression (Dai et al. 1995). On the other hand, AduPARTat8TK/GCV 
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combined therapy could have an immunostimulatory role by eliciting an 
antitumor immune response. Several studies have demonstrated that 
cell killing via suicide gene therapy can stimulate the immune system and 
generate antitumor immunity (Vile et al. 1997; Shibata et al. 2008; Neves 
et al. 2009). Interestingly, the stimulation of an antitumor immune 
response following adenoviral suicide therapy was demonstrated in 
patients with prostate cancer in which an increased frequency of T cells 
recognizing prostate-specific antigens (PSA) or prostate-specific 
membrane antigen (PSMA) was observed after intratumoral suicide 
therapy (Onion et al. 2009). Importantly, it has been proposed that 
chemotherapy delivered after viral immunogene therapy (AdTK+GCV) 
augmented antitumor efficacy via multiple immune-mediated 
mechanisms (Fridlender et al. 2010). The authors proposed a primed-
boost vaccine effect in which AdTK+GCV could “primed” an initial strong 
antitumor immune response, and sequential courses of chemotherapy 
would act as “boost” by the release of immunostimulatory tumor 
antigens. In our studies (COMB I protocol), AduPARTat8TK /GCV followed 
by gemcitabine was administered so that this priming-boost effect could 
be happening in such combined protocol.  
It is worth to note that in our experiments single therapies of GE and 
AduPARTat8TK already showed a good response and reduced the 
pancreatic volume of Ela-myc mice to an average similar to that of wt 
mice. To observe for a synergistic effect we might test for doses leading 
to partial responses in the individualized treatments. In addition, a third 
combined protocol in which GE and the first dose of GCV were co-
administered could be of interest to test. In fact, with this co-
administration protocol Boucher et al described synergism between GE 
and GCV in subcutaneous tumors (Boucher and Shewach 2005); 
however, these experiments were carried out in nude mice, thus eluding 
what can be an important contributor, the immune response effect. 
Toxicity studies of the combined treatment revealed some liver damage 
that resolved at the end of gemcitabine treatment. In fact, the elevation 
of hepatic transaminases has already been reported as a secondary 
effect of gemcitabine, especially when used in combination with other 
chemotherapeutics (Fossella et al. 1997). On the contrary, the combined 
treatment did not produce pancreatic toxicity but ameliorated the 
pancreatic tumor-associated toxicity. 
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3. ANTICANCER EFFECTS OF IRREVERSIBLE 
ELECTROPORATION ON PANCREATIC 
TUMORS. 
Irreversible electroporation is an emerging technology for non-thermal 
tumor ablation. In this study we have investigated the efficacy of 
irreversible electroporation to achieve antitumoral effects in a pancreatic 
cancer mouse model. We have demonstrated efficacy of IRE by showing 
potent reduction in tumor growth from day 4 post-IRE with increased 
mice survival and complete tumor regression in the 25% of animals at 90 
days post-treatment. Moreover, we have shown a rapid recovery of 
pancreatic function from an initial damage probably associated to IRE in 
non-tumoral areas. 
These data have been achieved in a preclinical orthotopic model based 
on the pancreatic inoculation of the BxPC-3 pancreatic cancer cell line 
modified to express the luciferase gene. Several works have already 
demonstrated the use of bioluminescence to measure tumor biometrics 
after antitumor therapy in orthotopic pancreatic xenografts and highlight 
the utility of the technology to monitor tumor response in longitudinal 
studies (Kim et al. 2009; Lee et al. 2010a; McNally et al. 2010). It is worth 
mentioning that the BxPC-3 xenografts is a highly aggressive tumor 
model when implanted orthotopically (Lee et al. 2010a). Importantly, we 
have observed a very early response to IRE treatment, already detected 
at one day post-treatment. However, in certain tumors limited viable 
cells were detected within the ablated area as well as secondary tumors 
were lately localized in the pancreas distant to the primary 
electroporated tumor in particular animals. These remaining proliferating 
cells could be the responsible of the tumor regrowth shown in some 
animals. A second round on the application of the procedure could help 
to act against secondary nodules detected in later examinations. 
We have shown that IRE procedure produced a disruption of the 
microvascular architecture with a rapid release of red blood cells and the 
appearance of a bloody tumor in accordance with other studies (Al-
Sakere et al. 2007; Tracy et al. 2011). At days 7 and 14 post-IRE necrosis 
was much more evident than at day 1 and inflammatory cell reaction was 
observed. It has been proposed that the IRE pulses induced vascular 
congestion, which should also cause tissue hypoxia and may further 
contribute to tumor cell death. Disaggregation of the membranes starts a 
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couple of hours after the pulse delivery and is completed at 24 h when 
necrosis can be already detected (Al-Sakere et al. 2007).  
Efficacy of IRE treatment has also been recently reported in a rat model 
of hepatocellular carcinoma with a necrotic response similar to the one 
we have observed (Guo et al. 2010). By contrast, the authors also 
reported extensive caspase-3 activation, suggesting an apoptotic cell 
death at one day post-IRE that was no longer visible later on. Similarly, a 
recent study in normal pig pancreas has reported an increase in the 
apoptotic index after IRE procedure determined by a TUNEL assay (Bower 
et al. 2011). In our model we did not detect caspase-3 activation in the 
tumor cells at any of the periods analyzed which is in agreement with 
other studies performed on renal tissue, lung tissue and fibrosarcoma 
subcutaneous tumors which reported cell death caused by necrosis (Al-
Sakere et al. 2007; Deodhar et al. 2011; Tracy et al. 2011). Some of these 
studies described an increase in the number of nuclei stained by TUNEL 
reaction at 1 h after treatment that was no longer detected at later 
times. The authors argumented that TUNEL staining was not indicative of 
apoptosis since irreversible electroporation could affect the nuclear 
envelope, exposing the DNA to extracellular nucleases generating double 
strand breaks that are the seeding point for the TUNEL assay. In fact, 
there is a debate about the cause of cell death induced by IRE procedure. 
This is not surprising since studies were performed in different tumor 
models with different susceptibility to apoptotic cell death. Nevertheless, 
we cannot discard that the IRE protocol that we applied presents with 
different kinetics on the response to cell death as we have used different 
type of electrodes and applied a pulse train with different number and 
frequency of pulses. Thus caspase-3 activation could be an earlier event 
that escaped from our analysis. 
The IRE procedure that we used in addition to ablate the tumor area 
produced some damage to the adjacent parenchyma, also showing small 
necrotic areas. Nevertheless the effects on pancreas and liver 
functionality were only transiently affected. Most damage occurred in 
the first to 6h and at one day post-IRE, despite necrosis in small 
pancreatic areas, enzyme serum levels were normalized. Thus no major 
adverse effects were observed in treated mice proving for the low 
toxicity of the procedure. Our data is in agreement with a recent study in 
which IRE was applied to the pancreas of swine pigs and only transient 
increases in pancreatic enzymes were observed (Bower et al. 2011). In 
that study, as in ours, all animals tolerated the procedure without 
immediate complications and no associated cardiac dysrhythmias. 
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Other ablative techniques such as radiofrequency RFA are currently 
performed for locally advanced pancreatic neoplasms in a combined 
therapeutic plan. Improvement in the quality of life due to the 
achievement of pain relief has been reported (Wu, J. Surgical Oncology 
2006; Girelli Br. J. Surg. 2010), nevertheless significant results on 
increased survival are still missing (D’Onofrio. Word J. Gastroenterol. 
2010). However these techniques are based on the use of thermal energy 
that damages structures such as blood vessels, bile ducts, and nerves 
entailing a relevant limitation to the pancreas which lies immediately 
adjacent to the superior mesenteric artery, portal vein, and common bile 
duct (Bower et al. 2011). In fact many cases of hemorrhages have been 
reported after the RFA procedure and that makes it a very difficult 
technique to be implemented in current practice. By contrast, 
irreversible electroporation is a non-thermal technique that it has been 
shown to preserve the vital structures within the IRE-ablated zone such 
are gross blood vessels, ducts and nerves (Maor and Rubinsky 2010; Li et 
al. 2011), what makes it suitable for pancreatic cancer treatment. 
Although additional studies are required, the work presented in this 
thesis shows the potential of IRE in the treatment of non-metastatic 
pancreatic tumors and it can be considered as an alternative approach to 
RFA. Some of the relevant advantages of IRE are that it is a very rapid 
procedure and could potentially be applied to treat different nodules 
located in separated areas by a unique surgical procedure. Moreover the 
low toxic effects of the therapy could encourage the application of more 
than one round of IRE treatment in the subset of tumors that may 

































I. Adenoviruses intraductally injected through the common bile duct 
efficiently target pancreatic tumors in the Ela-myc mouse model. 
II. AduPARTat8TK intraductally delivered into the common bile duct, 
followed by GCV treatment, triggers pancreatic tumor regression in 
Ela-myc mice. Increased antitumoral effect is achieved by 
AduPARTat8TK intraductal delivery compared to intravenous 
administration. 
III. AduPARTat8TK/GCV gene therapy ameliorates pancreatic function 
and hepatic tumor-associated toxicity in Ela-myc mice. 
IV. The combined therapy AduPARTat8TK/GCV plus gemcitabine shows 
synergistic effects in pancreatic cancer cell lines. The two combined 
regimens tested in vivo did not augment the antitumor effect of 
individual therapies.  
V. AdTATMMP fiber-modified adenovirus is activable by MMP-2 and 
MMP-9 and shows in vitro enhanced transduction efficiency in MMP 
rich cells. AdTATMMP rescues the infectivity of the CAR-ablated 
AdYTRGE.  
VI. AdTATMMP systemically delivered to Ela-myc mice increased 
pancreatic tumor transduction in 7.3 times respect to AdYTRGE. 
VII. Irreversible electroporation reduces BxPC-3-Luc orthotopic tumor 
growth, increases mice survival and leads to complete tumor 
regression in 25% of the animals at 90 days post treatment. 
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Pancreatic Ductal Adenocarcinoma (PDAC) therapies show limited 
success. Irreversible electroporation (IRE) is an innovative loco-regional 
therapy in which highvoltage pulses are applied to induce plasma 
membrane defects leading to cellular death. In the present study we 
evaluated the feasibility of IRE against PDAC. IRE treatment exhibited 
significant antitumor effects and prolonged survival in mice with 
orthotopic xenografts. Extensive tumor necrosis, reduced tumor cell 
proliferation and disruption of microvessels were observed at different 
days post-IRE. Animals had transient increases in transaminases, amylase 
and lipase enzymes that normalized at 24h post-IRE. These results 
suggest that IRE could be an effective treatment for locally advanced 
pancreatic tumors. 
 
 
